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Cancer-induced bone pain is reported to be one of the most detrimental aspects of the
disease, often broadly categorized into two separate pain phenomena. Patients experience
ongoing pain, a dull achy persistent background pain that worsens as disease progresses which
is currently treated with around the clock mu opioid receptor (MOR) agonists such as morphine.
Patients also report transient episodes of severe pain that is spontaneous but often triggered by
movement that “breaks through” around the clock medication. Breakthrough pain is treated
with additional rapid onset MOR agonists that are hindered by dose-limiting side effects and
often misalign with treatment for patients. The failure of current medications to effectively treat
patients and undesirable side effects of MOR agonists highlights the need to develop novel
treatments. We examined the hypothesis that ongoing pain and breakthrough pain are
mitigated by unique populations of sensory afferents.
Utilizing a rat model of cancer-induced bone pain (CIBP) that implants MATBIII
adenocarcinoma cells into the tibia of Fischer rats, we demonstrate that IB4-binding fibers play a
critical role in transducing breakthrough pain, whereas TRPV1 expressing fibers do not.
Limitations of the chemo-ablative approach used to target these neurons directed work to a

mouse model of CIBP that relies on implantation of Lewis lung carcinoma cells into the femur of
C57BL/6 mice. Utilizing Nav1.8-Cre and MrgD-Cre-ERT2 mouse lines, targeted expression of the
light sensitive proton pump ArchT allowed for the inhibition of neurons in animals with CIBP.
Using conditioned place preference to pain relief, we demonstrate that inhibition of Nav1.8
fibers relieves ongoing pain, and silencing MrgD fibers in tumor-bearing animals results in
conditioned place preference. We also describe a potential approach to measure breakthrough
pain in the mouse, but did not characterize it. This work provides evidence to target these
populations of sensory neurons to develop treatments in an effort to reduce and treat cancerinduced ongoing and breakthrough pain. The implication of non-peptidergic neurons to convey
components of cancer-induced bone pain is a novel finding and distinguishes them for a unique
role in CIBP from other work in the pain field.
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CHAPTER 1
INTRODUCTION TO CANCER-INDUCED BONE PAIN
1. Introduction
1.1. Preface, Etiology of Cancer-Induced Bone Pain
It is well known and established that common cancers such as breast, prostate and lung
have a propensity to metastasize to the bone (Coleman 2006, Lozano-Ondoua, Symons-Liguori
et al. 2013, Kane, Hoskin et al. 2015). It is estimated that nearly 70% of patients that die as a
result of their cancer have bone metastasis, with the most common sites of cancer metastasis
being the vertebrae, pelvis long bones and ribs (Kane, Hoskin et al. 2015). Estimates place the
incidence of patients suffering from cancer or a history of cancer in America at 14.5 million in
2015 and nearly 32.6 million worldwide in 2012 (Smith and Saiki 2015). Reports also suggest
that nearly all patients with myeloma, more than half with metastatic breast and prostate
cancer and a third of patients with lung cancer develop metastasis to the bone (Gul, Sendur et
al. 2016).
Upon metastasis these lines of cancer often have differential effects on the bone
following their establishment and development of unique tumor microenvironments (Mantyh
2014, Mantyh 2014). The origin of these tumors induces varying, but characterized effects on
the bone. For example, metastases of lung origin lean towards bone degradation or osteolytic
lesions, breast cancer metastases typically induce a range of maladaptive bone remodeling that
results in osteolytic lesions as well as maladaptive osteoblastic lesions (Mantyh 2006)).
Metastases of prostate origin typically have maladaptive bone deposition and remodeling, or
osteoblastic lesions (Mantyh 2006). The maladaptive bone remodeling that occurs in patients is
often, but not always accompanied by pain that originates from the sites of metastasis and bone
1

remodeling (Mantyh 2014, Mantyh 2014, Kane, Hoskin et al. 2015). Nearly two-thirds of patients
with metastasis have been reported to experience severe pain (Mantyh 2006). While more
broadly, 34% of patients who are hospitalized with cancer and 45% of patients enrolled in inhome care report pain (Scarpi, Calistri et al. 2014). In fact, pain originating from a site of tumor
growth or metastasis is typically one of the first symptoms that draws patients to the clinic and
nearly half of patients with cancer report moderate to severe pain (Halvorson, Kubota et al.
2005, Kane, Hoskin et al. 2015, Paice 2018).
Pain is often reported by patients to be one of the worst or most feared consequences
of these ailments (Paice 2018, Paice 2018). Despite improvements in pain management and
improved understanding of CIBP, patients continue to suffer from inadequate pain management
(Paice 2018, Paice 2018). From the perspective of the field as well as patients, this is worsened
by the increased survival time of patients, due to improvements in cancer treatments, patients
live longer with these maladaptive bone pathologies (Lozano-Ondoua, Hanlon et al. 2013,
Lozano-Ondoua, Symons-Liguori et al. 2013, Kane, Hoskin et al. 2015, Paice 2018, Paice 2018).
Patients’ reports typically describe two separate pain phenotypes, that as the disease
progresses are both treated with the same class of analgesics. The first and more prominent
pain phenotype is a dull-achy type of pain from the site of remodeling/metastasis that is
constant and worsens as the disease progresses and/or time goes on. Due to the description of
the pain and its nature, this is referred to as ongoing pain.
This is treated in accordance with the World Health Organization’s “Ladder” of analgesia
that begins with non-steroidal anti-inflammatory drugs (NSAIDs) to treat the pain patients
experience. This is escalated in response to the worsening of pain reported by the patient, to
adding adjuvant treatments in addition to NSAIDs, followed by “weak” opioids such as tramadol,
codeine and buprenorphine, but ultimately escalates to around the clock mu opioid receptor
2

(MOR) agonists such as morphine (Sabino and Mantyh 2005, Mantyh 2006, Kane, Hoskin et al.
2015). The last step on the ladder allows for additional administration of adjuvant drugs to
manage fear and anxiety, however this may introduce complications with chronic opioid
regiments (Bruera and Paice 2015, Kane, Hoskin et al. 2015) .
This escalation occurs in an attempt to mitigate background pain to a level that can
allow patients to still retain a positive quality of life. However, some patients’ doses are
escalated to a point where the treatments (high doses of MOR agonists) detrimentally affect the
patient’s quality of life themselves. Proper management of this requires a skilled and vigilant
team of medical professionals to adequately titrate and prescribe analgesics (Bruera and Paice
2015). In addition to this, patients often have to be prescribed additional compensatory
compounds, such as laxatives early in analgesic prescription to manage the more prominent
side-effects of opioid therapy such as constipation (Bruera and Paice 2015). Treating patients
afflicted with CIBP can be difficult even after following well described practices, requiring
multiple visits to titrate dosing as well as identifying tolerable MOR agonist agents (Bruera and
Paice 2015, Smith and Saiki 2015). Another challenge is adequate education of clinicians in
successful pain management. Reports suggest that clinicians in the most optimal position to
manage a patient’s pain, receive inadequate training to do so (Smith and Saiki 2015). Even while
practices exist and continue to improve, estimates still place nearly 50% of patients with under
managed pain (Smith and Saiki 2015). Development of tolerance to MOR agonists that patients
likely develop also leads to escalation of doses of treatments. While not directly assessing the
outcomes in patients with CIBP, there is mounting evidence that MOR agonists themselves do
not effectively treat vary forms of chronic pain (Morrone, Scuteri et al. 2017). Following in the
footsteps of the larger pain research community, these limitations of MOR agonists drives those
of us working to find better treatments for advanced and difficult pain types, and to question if
3

it is responsible to continue to rely so heavily on treatment of pain with chronic regiments of
MOR agonists. This is further complicated at this point in time by the opioid overuse epidemic,
which correlative studies suggests has directly affected patients suffering from CIBP, resulting in
decreased prescriptions for patients who have no alternative to manage their pain (Paice 2018).
Some clinical reports argue that treatment of ongoing pain with MOR agonists are
sufficient and ample at reducing pain and improving quality of life, while it Is widely accepted
that a better alternative is necessary for patients (Mantyh 2006, Schmidt 2015, Mercadante and
Bruera 2016). Best clinical practice aims to treat each individual patient while maintaining open
dialogue to allow changes in treatment dependent on the needs of the individual (Bruera and
Paice 2015). One practice used in the clinic known as “opioid switching”, a practice that nearly
80% of patients will require, involves the rotation or switching between different MOR agonists
to achieve therapeutic levels of pain relief while minimizing side-effects (Bruera and Paice 2015,
Mercadante and Bruera 2016). Some work suggests that this practice can reduce, but not
eliminate adverse side effects in as many as 50-90% of patients (Mercadante and Bruera 2016).
This is not completely understood, and attempts to underpin a genetic correlation have
provided no target single nucleotide polymorphisms supporting a cause for the exacerbated
pain from CIBP, or the need to switch certain individuals from one MOR agonist to another
(Scarpi, Calistri et al. 2014). This leads to a best practice of tailoring dosing regiments and
therapies to fit the needs of the individual rather than treating patients as a whole, another
detail highlighting why CIBP is “one of the most difficult chronic pains to treat” (Mantyh 2014,
Mantyh 2014). These limitations of the current approach to treating patients with CIBP highlight
why research continues to attempt to find alternatives to MOR agonists to treat intense pain.
In addition, and perhaps alternatively to MOR agonists, patients are treated with
radiotherapy, and agents that actively block cancer-induced bone remodeling to stay ongoing
4

pain from sites of pathological bone remodeling, which have varying degrees of success (Kane,
Hoskin et al. 2015). Bisphosphonates have been demonstrated to bind to bone and actively
block osteoclast induced bone destruction through osteoclast induced cell death (Drake, Clarke
et al. 2008, Mantyh 2014, Mantyh 2014). Osteoprotegerin (OPG) and denosumab both target
and block the receptor activator of nuclear factor kappa B (RANK) and RANK-ligand (RANKL)
pathway that induces osteoclast activation. This approach has been demonstrated to effectively
block pathological osteoclast induced bone-remodeling, which by blocking bone remodeling
resolves some aspects of pain from sites of metastasis, but these treatments have restrictive
side-effects of their own (Mantyh 2014, Mantyh 2014, Gul, Sendur et al. 2016).
Studies indicate that these compounds reduce skeletal pain and delay skeletal related
events such as hypercalcemia and fracture, some of the factors that are believed to induce pain
from the bone, but have room for improvement (Coleman 2008, Mantyh 2014, Mantyh 2014).
While effective at reducing pathological bone resorption in a number of skeletal diseases,
bisphosphonates have been associated with several undesirable side-effects that can lead to
discontinued use. The first being gastrointestinal disturbance including erosive esophagitis if
taken improperly, and potentially nausea, dyspepsia, abdominal pain and gastritis (Kennel and
Drake 2009). Initial exposure to bisphosphonates may also induce temporary fever, however
this occurrence reduces after multiple exposures and is believed to be temporary (Kennel and
Drake 2009). Severe suppression of bone turn over and the requirement for adequate vitamin D
and calcium supplementation are also considerations for patients undergoing chronic
bisphosphonate therapy (Kennel and Drake 2009). Lastly and perhaps most apparent are the
associated risks of renal dysfunction and osteonecrosis of the jaw, resulting in special
considerations to be taken if use in patients is required (Coleman 2008, Kennel and Drake 2009).
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While preclinical evidence of Anti-nerve growth factor (NGF) antibodies provide
evidence that the treatment blocks measures of ongoing bone pain in both models of CIBP and
osteoporosis, they fail to stop bone remodeling (Halvorson, Kubota et al. 2005, JimenezAndrade, Bloom et al. 2010, Bloom, Jimenez-Andrade et al. 2011, Suzuki, Millecamps et al.
2018). At least one clinical trial investigating the effects of anti-NGF monoclonal antibody
suggest positive effects on CIBP, as well as other studies suggesting the same in osteoarthritis
and lower back pain (Sopata, Katz et al. 2015, Chang, Hsu et al. 2016). Several studies that
included anti-NGF treatment suggested a connection between long term use of anti-NGF
treatment, with or without NSAID co-administration, and rapid joint destruction, resulting in a
temporary hold on clinical studies utilizing this approach (Chang, Hsu et al. 2016). However, this
ban has since been lifted due to the potential for benefit in the clinical population with
considerations and radiologic intervention, but no clinically/FDA approved anti-NGF agent is
currently available (Chang, Hsu et al. 2016).
In addition to ongoing pain, many patients with skeletal metastasis experience pain that
“breaks through” around the clock medication, typically opioids, managing their ongoing pain.
Due to its etiology this pain phenomenon is referred to as “breakthrough pain” (BTP). Estimates
put the percentages of patients who experience BTP while already experiencing ongoing pain at
40-80%, however confounds in reports exist as to whether or not proper definition of BTP has
been used in some studies examining the pain type (Mercadante 2015). While BTP can occur
spontaneously, it is much more often triggered, and likely more readily documented, in
response to movement. Unavoidable movements such as getting out of bed in the morning or
performing necessary tasks often can be enough to trigger a BTP episode.

Equally as

detrimental but likely more stressful, unexpected and involuntary movements such as coughing
or sneezing can result in initiation of a BTP experience (Mercadante 2015). It is reported that
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these BTP experiences can occur as many as 4 times a day, rate as high as 7.4/10 on the pain
intensity scale and last 30-60 minutes (Mercadante 2015, Mercadante 2018). Due to the
unpredictable nature of BTP, patients often have to choose between pursuing activities, (i.e.
maintaining a positive quality of life) or avoiding activities that might produce pain (Mercadante
2015).
It is in part due to the unexpected nature of this pain type and the need to take
analgesic regiments in response to the start of the pain, that current treatments fall on the
patient to dose in response to sensation of pain. If you can imagine, this is not an ideal method
of effectively treating intense pain and improving the quality of life of patients. Due to the
pharmacokinetics of treatment methods (dosing in response to pain initiation), this often results
in patients missing the window to adequately treat their most severe pain (Kane, Hoskin et al.
2015). By clinical definition BTP must be a pain experience that breaks through onboard opioid
treatments, originally described in 1990 (Portenoy and Hagen 1990, Mercadante 2015).
Although this is the well-accepted clinical and preclinical definition, until recently many clinical
based reports have not accurately adhered to this criteria, making the description of and
evaluation of treatment of BTP in past reports to some extent murky (Mercadante 2015). Recent
reports address and acknowledge this limitation and highlight the need for more stringent
inclusion/exclusion criteria in clinical reports (Mercadante 2011, Mercadante 2015). Previous
treatments of BTP involved dosing oral morphine at levels proportional to those being used to
manage patients’ ongoing background pain, with little to no scientific evidence to support this
approach (Mercadante 2011, Mercadante 2015). While intravenous morphine with doses of
between 6 and 12 mg, (also proportional to daily regiments of background medication)
demonstrate rapid pain relief, it is confounded by the propensity of cognitive failure and
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feasibility of intravenous delivery, which most patients cannot comply with (Mercadante 2011,
Mercadante 2012, Sousa, de Santana Neto et al. 2014, Mercadante 2015).
Due to the relatively slow pharmacokinetics of oral morphine treatment, analgesic
application has shifted towards more rapid MOR agonist formulations (Mercadante 2015). The
current mainstay to treat BTP is with rapid onset opioids, with varying methods of delivery,
which have reportedly better outcomes for patients, however efficacy of these require ideal
patient responsiveness (Mercadante 2015). Transmucosal fentanyl and lozenges, lollipops and
other means to rapidly and dose-dependently deliver additional MOR agonists are available to
patients (Mercadante 2015). A recent report attempted to compare new analgesics used to
treat BTP to the traditional oral morphine, finding that reported and well conducted clinical
experiments suggest that out of the available treatments, the most effective agents are fentanyl
products, although admitting oral morphine has its place for treatment of predictive episodic
BTP (Mercadante 2018).
Relying on additional MOR agonists to treat BTP is limited in a number of ways. The first
hurdle in treatment likely lies with the nature of dosing in response to the sensation of pain, as
previously mentioned, which can result in patients misaligning therapy with their pain
experience (Kane, Hoskin et al. 2015). In this sense, a medication with alternative mechanisms
of action to MOR agonists that would allow for around the clock dosing would be ideal.
Alternative mechanisms to MOR agonists are needed as evidence reports that even at high
doses of MOR agonists, patients with advanced disease and pain, continue to experience BTP,
demonstrating that MOR agonists fail to effectively treat BTP (Bennett 2010, Havelin, Imbert et
al. 2017). One possible explanation to this is that the sensory fibers transducing BTP may be
mechanistically or inherently different from those that respond to MOR agonists and
successfully manage ongoing pain (Havelin, Imbert et al. 2017). Due to the regiments patients
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are already on, there is the realistic limitation of dosing to effect due to the adverse and
potentially life threatening side effects of MOR agonists. Side effects such as nausea,
constipation, somnolence, dizziness and risk of falls, mental confusion and potential respiratory
depression, all limit the improvement of quality of life these patients experience despite any
benefits to pain relief they may experience (Bruera and Paice 2015, Kane, Hoskin et al. 2015,
Mercadante 2015).
A non-opioid option with opioid sparing effects would greatly benefit the quality of life
of these patients. These limitations and current failures of treatments demonstrate that at the
level of the patient we have not developed a treatment that sufficiently manages CIBP or a
treatment that simultaneously allows them to return to the quality of life they desire. To
develop such a class or agent of analgesics, the field has relied heavily on animal models of CIBP
that allow us to isolate the site where CIBP is generated and therefore study the effects of
tumor modulation of local tissue and neuroanatomical changes induced by this chronic pain in a
controlled manner.

1.2. Contributions of Preclinical Models to the Neurobiology of Bone Pain
The section below is work that is published as a review article in Osteoporosis Reports
(Havelin and King 2018). It has been slightly modified for this dissertation.

1.2.1. Introduction
Ultimately a most optimal treatment may be a dual acting therapy that has alternate
molecular targets that treat pain while also slowing the growth of cancer. Preclinical studies
over the past 20 years have implicated a number of molecular targets, as well as some agents to
target them, however few if any of these have made it to the clinic to positively impact patient’s
9

quality of life. These will be discussed in Chapter 1.3 after a brief explanation of preclinical
models and pain signaling to emphasize contributions preclinical models have made to our
understanding of mechanisms driving CIBP.
Bone and joint pain can occur in response to numerous conditions including trauma,
infection, inflammation, autoimmune disease, genetic driven disease states, joint and bone
pathology associated with aging, and cancer. Bone and joint associated pain can be acute (e.g.
due to trauma), recurring, or chronic in nature. Indeed, musculoskeletal pain such as
osteoarthritis is the most common form of chronic pain and disability worldwide. It is important
to recognize that bone and joint pain is very complex, with multiple types of pain as well as
multiple etiologies that may require different treatment strategies for complete pain
management. Some patients also report development of persistent background pain and/or
breakthrough pain episodes that are resistant to currently available medications (Hawker,
Stewart et al. 2008, Paice and Ferrell 2011, Hawker and Stanaitis 2014, Mercadante 2015). This
indicates a requirement for development of therapies targeting multiple mechanisms underlying
the various aspects of bone and joint pain for more comprehensive pain management for these
patients. Development of such therapeutic options requires better understanding of
mechanisms underlying the multiple aspects of bone and joint pain needed for better care for
these patients.

1.2.2. Overview of the Pain Pathway
Signals from events that may damage tissue (e.g. twisted joint, stressful impact) or from
actual damaged tissue activate specialized sensory neurons known as nociceptors. Both bone
and joint tissue are innervated by these specialized neurons which allow for the transduction of
painful stimuli to aid in preventing further damage to tissue and repeating potentially tissue
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damaging behaviors (Jimenez-Andrade, Mantyh et al. 2010, Alliston, Hernandez et al. 2017,
Eitner, Hofmann et al. 2017, Ivanusic 2017). Multiple classes of nociceptors have been studied to
date, differentiated by their cell body and axon size, their myelination patterns,
electrophysiological characteristics such as conduction velocity and response thresholds, and
the characteristics of stimuli that they respond to (Schaible and Schmidt 1983, Schaible and
Schmidt 1983, Cavanaugh, Lee et al. 2009, Woller, Eddinger et al. 2018). Evidence that different
classes of sensory neurons contain observable differences in cytochemical markers as well as
terminate in different anatomical locations with the spinal cord dorsal horn have existed since
the 1980’s and 1970s (Hunt and Rossi 1985). Interestingly, the observations that peptide rich
and peptide lacking c-fibers have slightly different innervation patterns in the periphery, and the
theory that these nociceptors may indeed transmit unique nociceptive signals is not new (Hunt
and Rossi 1985). Critical evaluation of these two fiber types by Molliver and colleagues
demonstrated unique neurochemical markers between the populations as well as termination
patters in the spinal cord dorsal horn (Molliver, Radeke et al. 1995). Elegant work by Molliver
and colleagues demonstrated that throughout development expression patterns of TrkA, the
receptor for NGF, is downregulated to a smaller population of neurons that go on to express
classic markers of peptidergic fibers (i.e. calcitonin gene-related peptide, [CGRP]) (Molliver,
Radeke et al. 1995, Molliver, Wright et al. 1997). Neurons in the dorsal root ganglia that
downregulate TrkA begin to express c-Ret, a receptor for glial cell line-derived neurotrophic
factor (GDNF) (Molliver, Wright et al. 1997). Additionally, this work demonstrated that while
TrkA expressing neurons require NGF for continued survival, c-Ret expressing cells require
GDNF, and the two cell populations do not survive in the presence of the others neurotrophic
factor (Molliver, Wright et al. 1997). Reports have also suggested that following dissection and
growth in-vitro and injury the non-peptidergic population of cells potentially undergo a
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phenotypic switch or regression (Wang, Molliver et al. 2011). In-vitro the non-peptidergic cells
once again require NGF to survive, and in-vivo following injury they begin to express the
transient receptor potential vanilliod 1 (TRPV1) protein, a classical marker of the peptidergic
population (Wang, Molliver et al. 2011). Table 1.1 contains some common nomenclature that is
used somewhat interchangeably when discussing these two fiber types.

These classic observations have been repeated, supported and expanded upon through
the use of modern tools. Recent RNA sequencing data indicate that multiple classes of
nociceptors exist (Usoskin, Furlan et al. 2015). Distinct RNA transcription profiles and protein
expression in conjunction with behavioral experiments demonstrate specific nociceptive
responses from nociceptor populations that have distinct molecular characteristics (Zylka, Rice
et al. 2005, Cavanaugh, Lee et al. 2009, Scherrer, Imamachi et al. 2009, King, Qu et al. 2011,
Okun, DeFelice et al. 2011, Barabas, Kossyreva et al. 2012, Usoskin, Furlan et al. 2015, Havelin,
Imbert et al. 2017). Studies such as these demonstrate that different fiber populations not only
exist but convey distinct sensory information depending on modality (thermal, chemical,
mechanical) as well as areas of innervation (cutaneous vs deep tissue) as outlined in the labeled
line hypothesis of sensory processing (Cavanaugh, Lee et al. 2009, Scherrer, Imamachi et al.
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2009, King, Qu et al. 2011, Okun, DeFelice et al. 2011, Barabas, Kossyreva et al. 2012, Havelin,
Imbert et al. 2017).
Sensory fibers mediating pain and itch project to the spinal cord, where projections
terminate in the superficial lamina of the dorsal horn, lamina I and II (Link, Pulliam et al. , Ma
2010, Abraira and Ginty 2013, Bourane, Duan et al. 2015, Duan, Cheng et al. 2017, Todd 2017).
Upon activation by noxious stimulation, terminal endings of the nociceptors release small
molecule (eg. glutamate) and peptidergic (e.g. substance P, CGRP) neurotransmitters into the
synaptic cleft. Of interest to our work, the two major populations of nociceptors often referred
to as the “non-peptidergic” and “peptidergic” have been demonstrated to use these signals.
These neurotransmitters act on receptors located on interneurons within the spinal cord as well
as projection neurons that project along specialized tracts (e.g. the anterolateral tract) to
various regions of the brain such as the thalamus, periaqueductal grey, lateral parabrachial area
and regions within the medullary reticular formation (Link, Pulliam et al. , Ma 2010, Abraira and
Ginty 2013, Bourane, Duan et al. 2015, Duan, Cheng et al. 2017, Todd 2017). There has been a
great deal of progress in gaining a better understanding of the circuitry mediating nociception
within the spinal cord (Link, Pulliam et al. , Ma 2010, Abraira and Ginty 2013, Bourane, Duan et
al. 2015, Duan, Cheng et al. 2017, Todd 2017).
While some of the second order neurons within superficial dorsal horn of the spinal cord
project signals directly to the brain, not all neurons are involved in directly transmitting
information to the brain (Todd 2017). Additionally, within lamina I-II, roughly 90-95% neurons in
lamina I and nearly all neurons in lamina II are characterized as interneurons (Todd 2017).
Interneurons that modulate pain signals intuitively consist of both inhibitory neurons that
release gamma-aminonutyric acid (GABA) and glycine, and excitatory interneurons that are
predominately glutamatergic (Todd 2017).

Various studies examining the role of these
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interneurons indicate that they play a key role in processing the incoming signal, with several
interneuronal populations responding to multiple modalities of input (e.g. chemical, mechanical,
thermal, touch, itch) (Abraira and Ginty 2013, Duan, Cheng et al. 2014, Bonin, Wang et al. 2016,
Koch, Acton et al. 2018). Although studies have begun to explore the role of subpopulations of
spinal inhibitory and excitatory interneurons in mediating pain, itch and mechanical allodynia, a
full understanding of the complex interactions and circuitry is not complete (Koch, Acton et al.
2018). Little is known regarding processing of sensory information from deep tissues such as the
joint and the bones. It is very likely that gaining a better understanding of the processing and
integration of signals within the spinal cord will be essential in developing improved treatments
that address the multiple components of bone and joint pain such as movement-associated
pain, breakthrough pain, and persistent background aches and pains.
Of importance, multiple regions within the brain including cortical regions (e.g. anterior
cingulate cortex, somatosensory cortex, prefrontal cortex, insula, parietal lobe), the
diencephalon (thalamus), and the limbic regions (e.g. amygdala) are implicated in processing the
incoming signal and contribute to the perception of pain (Tracey 2017). Notably, these different
brain regions may contribute to different components of the complex sensation of pain that
includes both sensory and emotional components (Navratilova, Atcherley et al. 2015,
Navratilova, Morimura et al. 2016). Clinical and preclinical studies are making important gains in
our understanding of how these different brain regions contribute to the affective (unpleasant)
and sensory (intensity, location) aspects of pain (Porreca and Navratilova 2017). How these and
other regions interact and how they may be altered in the conditions of chronic pain (e.g.
arthritis, low back pain) are under investigation (Kuner and Flor 2016, Davis and Seminowicz
2017). Moreover, key changes in brain volume, functional connections, and processing are
observed using imaging studies (Mansour, Farmer et al. 2014, Smith, López-Solà et al.). In
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patients with chronic back pain, studies have reported diminished cortical grey matter and
impaired emotional decision-making (Apkarian, Sosa et al. 2004). These observations are
mimicked in a preclinical model of nerve injury in which chronic pain disrupts normal function
and anatomy of the prefrontal cortex, partially reversed by different molecules with analgesic
properties (Shiers, Pradhan et al. 2018). This observation has been expanded to other chronic
pain states including chronic osteoarthritis (Mansour, Farmer et al. 2014, Smith, López-Solà et
al. 2017).

1.2.3. Initiation of Pain Signals from the Bone and Joint:
Early studies in the cat demonstrated that the knee joint is innervated by sympathetic
fibers as well as sensory afferent fibers, primarily fine myelinated A-delta fibers and
unmyelinated (slow conducting C-fibers) sensory afferent neurons (Langford and Schmidt 1983).
Both A-delta and C-fibers demonstrated responses to mechanical stimulation at higher
thresholds compared to other tissues such as skin, with some fibers that respond only to
stimulation in the noxious range (Schaible and Schmidt 1983). Electrophysiological studies
characterizing movement-induced activation of sensory fibers innervating the joint further
classified these fibers into 4 subtypes: fibers activated by non-noxious movement; fibers
activated both by non-noxious and noxious movement; fibers activated only by noxious
movement, and fibers that failed to respond to movement (Schaible and Schmidt 1983).
These data led to the conclusion that the sensory afferent fibers innervating the joint
contribute to deep pressure sensation and nociception, and likely signal that the joint is about to
leave the normal working range (Schaible and Schmidt 1983). Subsequent electrophysiological
characterization of the A-delta and C-fibers innervating the knee joint in the setting of acute
inflammation revealed altered firing properties in the context of injury. Fiber populations from
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inflamed knee joints demonstrated increased activity in the absence of any stimulation or joint
movement (spontaneous activity). In addition, they demonstrated lower response thresholds to
mechanical stimulation (hypersensitivity), and increased activity in response to mechanical
stimulation from probing the joint with calibrated von Frey filaments and to joint movement
(Coggeshall, Hong et al. 1983, Grigg, Schaible et al. 1986, Schaible, Schmidt et al. 1987). In
addition, silent sensory fibers that normally do not demonstrate activity during non-noxious
movement of the joint, became active following exposure to knee joint injection of
kaolin/carrageenan, a model of acute experimental arthritis in the cat (Schaible and Schmidt
1985). Findings such as these have highlighted the potential of sensory neurons to undergo
maladaptive change in their response to both natural and artificial stimuli.
Little was known about the protein expression patterns and identity/anatomy of the
sensory nerves involved in transducing pain from the bone in naïve animals let alone disease
treated animals (i.e. nociceptive, autonomic, large diameter, etc.). Several studies examining
innervation of the bone using a combination of IHC and transgenic animals indicate that bone as
well as the surrounding periosteum is well innervated by small-diameter peptidergic C-fibers, Adelta fibers, and sympathetic fibers (Mach, Rogers et al. 2002, Jimenez-Andrade, Mantyh et al.
2010, Guedon, Longo et al. 2016). Several reports suggest key differences in patterns of
innervation of the bone and other deep tissue compared to skin. Initial work using staining
methods (Mach, Rogers et al. 2002) was replicated utilizing a transgenic animal that selectively
expressed eGFP under control of the mas-related G-coupled protein sub family D expressing
(MrgD) promoter developed by Zylka et al. 2005, that serves as a marker for non-peptidergic
nociceptors (Zylka, Rice et al. 2005). Analysis of tissue from these animals demonstrated a lack
of eGFP+ fiber innervation to the bone and periosteum thus a lack of MrgD+ or nonpeptidergic
nociceptors, but dense innervation within skin of the same animals (Mach, Rogers et al. 2002,
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Jimenez-Andrade, Mantyh et al. 2010). Studies that directly compared innervation of skin and
bone using these mice demonstrated that whereas skin is innervated by both peptidergic
(CGRP+) and non-peptidergic populations of C-fibers, bone shows evidence of innervation by
peptidergic and sympathetic, but not non-peptidergic C-fibers (Mach, Rogers et al. 2002,
Jimenez-Andrade, Mantyh et al. 2010). Jimenez-andrade et. al 2010 also demonstrated lack of
purinergic receptor P2X3 (P2X3) IHC staining in the bone and periosteum, another marker of the
stereotypical non-peptidergic nociceptor population (Jimenez-Andrade, Mantyh et al. 2010).
Additional recent immunohistochemical evidence in the rat has also demonstrated TRPV1
expressing fibers in marrow, which can be sensitized by application of capsaicin (Morgan,
Nencini et al. 2019). This has led to the proposal that bone and joints are not innervated by the
non-peptidergic population of C-fibers in mice (Mantyh 2014). However, evidence regarding the
presence of non-peptidergic C-fibers innervating the bone has been reported in rat studies using
retrograde tracers injected into the intramedullary space of the bone (Ivanusic 2007, Kaan, Yip
et al. 2010, Ivanusic 2017).
Such discrepant findings suggest the possibility that there may be a subpopulation of
non-peptidergic fibers that innervate the bone that have not been directly assessed in previous
studies. Alternative explanations include the possibility of differences in the methods used to
examine innervation. The processes of decalcification of the bone may have altered binding sites
for markers of non-peptidergic fibers such as isolectin B4 (IB4) or P2X3 diminishing potential
visualization of fibers innervating the bone and leading to false negative findings (JimenezAndrade, Mantyh et al. 2010). However, IB4 binding has been reported in muscle that had been
processed for decalcification in the same manner as bone that did not show these markers of
non-peptidergic fibers (Jimenez-Andrade, Mantyh et al. 2010). In addition, MrgD expressing and
IB4 binding fibers were not observed in periosteum whole mount tissue that did not undergo
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decalcification whereas in side by side control tissue, both were expressed in the skin (JimenezAndrade, Mantyh et al. 2010). These observations indicate that the decalcification process does
not explain the absence of these markers of non-peptidergic fibers within the bone.
Alternatively, as bone is a site of perfusion, it is possible that injection of the retrograde tracers
may have leaked to other sites resulting in false positive findings. It is also of importance to note
the difficulty to process calcified tissue, especially following the establishment and degradation
of tissue due to cancer. Let alone locate fibers of small to medium diameter neurons when
processing slices of this tissue. Methods continue to improve to allow such analysis, including
here at the University of New England’s histology core.
Finally, it is possible that there are species differences in innervation or population
(peptidergic vs non-peptidergic) separation and identity that causes these discrepant findings.
Indeed, differences between rats and mice related to expression of these specific molecular
markers of neuronal subtypes have been reported (Price and Flores 2007). In the mouse these
populations have been demonstrated to be mostly non-overlapping in the DRG (Molliver and
Snider 1997, Molliver, Wright et al. 1997, Cavanaugh, Lee et al. 2009, Scherrer, Imamachi et al.
2009, Thakur, Rahman et al. 2012, Usoskin, Furlan et al. 2015), whereas in the rat these
populations show a ~45% overlap in expression in the DRG, and these expression profiles vary
between DRG and trigeminal ganglia (Price and Flores 2007). In addition to these differences
between rats and mice, distribution of these fiber populations have been reported to differ
across different strains of mice (Laedermann, Pertin et al. 2014). Future studies examining
potential differences in innervation of bone and joint across multiple species is warranted to
better understand whether patterns of innervation of bone is conserved.
In addition to these populations of nociceptors, some recent studies have implicated
low threshold mechanoreceptors (C-LTMRs) in mediating mechanical pain to normally non18

noxious stimuli in conditions of injury and chronic pain (Rutlin, Ho et al. 2014, Zimmerman, Bai
et al. 2014, Abraira, Kuehn et al. 2017). The C-LTMRs have been most studied within the skin.
Whether this population innervates bone or joint or mediates pain associated with trauma or
pathology that generates chronic pain is unknown and difficult to assess due to the nature of
joint and bone tissue accessibility. Improved understanding of subpopulations innervating the
bone and surrounding tissues as well as how they may contribute to diverse aspects of bone and
joint pain are needed to develop a more comprehensive understanding of mechanisms
underlying the multiple components of bone and joint pain.

1.2.4. Site of Injury or Pathology:
Inflammation. Tissue damage leads to an innate immune response that results in release
of molecules including chemokines, cytokines, and growth factors from local tissue (e.g.
fibroblasts, chondrocytes), blood, and local and migrating inflammatory cells (Mantyh 2014,
Krustev, Rioux et al. 2015, Jeon, David et al. 2018, Syx, Tran et al. 2018). These factors may
promote disease progression and pathology in disease states such as arthritis or cancer-induced
bone pain. Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha),
Interleukin 6 (IL-6) and IL1-beta have been implicated in bone resorption by increasing
osteoclast activity (Braun and Schett 2012). In addition, these cytokines produce peripheral
sensitization of nociceptive fibers, resulting in decreased thresholds for activation and amplified
signaling (Cook, Christensen et al. 2018). Growth factors NGF, vascular endothelial growth factor
(VEGF) and insulin-like growth factor (IGF) are also implicated in development of bone or joint
pathology in disease states such as arthritis and cancer-induced bone pain. VEGF has been
implicated in angiogenesis associated with arthritis and skeletal metastases (Felson 2005,
Mantyh 2014).
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NGF has been implicated in peripheral sensitization through mechanisms such as
upregulation of key channels such as sodium channels and transducers that regulate neural
activity and by phosphorylation of transducers such as TRPV1 within neurons leading to
enhanced activity and increased neuronal excitability (Chang, Hsu et al. 2016, Denk, Bennett et
al. 2017). In addition, NGF has been shown to mediate pathological sprouting of nociceptive and
sympathetic fibers within the bone and joint across various rodent models of bone and joint
pain including cancer-induced bone pain (Jimenez-Andrade, Bloom et al. 2010), arthritis
(Jimenez-Andrade, Mantyh et al. 2012) and fracture (Jimenez-Andrade, Martin et al. 2007,
Chartier, Thompson et al. 2014). Building upon these preclinical studies, therapies such as antiTNF-alpha, anti-IL6 and anti-NGF antibodies are in clinical use or in clinical trials for pain
associated with bone or joint pathology has not been investigated. However, the role of many of
these inflammatory signaling molecules has not been assessed in models of ongoing pain
assessment or, primarily due to a lack of models, BTP.
Neuropathic Pain. In addition to the development of inflammation, neuropathic changes
have also been reported in animal models of bone and joint pain (Thakur, Rahman et al. 2012,
Falk, Bannister et al. 2014, Falk and Dickenson 2014, Mantyh 2014, Thakur, Dickenson et al.
2014). Studies in rat and mouse models of cancer-induced bone pain and chemical-induced
osteoarthritis joint pain have demonstrated expression of activated transcription factor 3
(ATF3), a neural marker of nerve damage, in cell bodies within the dorsal root ganglion
innervating the bone or joint (Peters, Ghilardi et al. 2005, Sabino and Mantyh 2005, Csont,
Bereczki et al. 2007, Thakur, Rahman et al. 2012). Pathological changes to sensory and
sympathetic nerve fibers within the bone and joint have been demonstrated across models of
cancer bone pain, arthritis pain, and fracture pain (Jimenez-Andrade, Martin et al. 2007,
Jimenez-Andrade, Bloom et al. 2010, Jimenez-Andrade, Mantyh et al. 2012, Chartier, Thompson
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et al. 2014). These studies describe development of neuromas and disorganized structures of
fibers similar to those reported following traumatic nerve injury in patients and animal models
of nerve-injury induced neuropathic pain. Finally, pharmacological studies in animal models of
bone and joint pain have demonstrated that knee joint arthritis pain and cancer bone pain
associated with markers of nerve damage are resistant to pain alleviating effects of antiinflammatory drugs such as NSAIDs (e.g. ketorolac, diclofenac) (Okun, Liu et al. 2012, Thakur,
Dickenson et al. 2014, Remeniuk, Sukhtankar et al. 2015).
In contrast, these pain states were found to be responsive to drugs typically used to
treat neuropathic pain within the clinical setting, duloxetine, pregabalin and gabapentin
(Thakur, Dickenson et al. 2014, Havelin, Imbert et al. 2016). Importantly, these studies
demonstrate that anti-inflammatory drugs may be effective in some aspects of pain whereas
they are ineffective on others, results echoed by clinical observations of the need to elevate
patients with CIBP to analgesics using molecular targets that differ from inflammatory
mediators. In a rat model of advanced osteoarthritis in which both evoked measures of joint
pain and non-evoked ongoing pain are observed, the NSAID diclofenac effectively blocked
weight asymmetry whereas it failed to block persistent ongoing joint pain (Okun, Liu et al. 2012)
whereas duloxetine blocks both evoked and ongoing joint pain (Havelin, Imbert et al. 2016).
Similarly, in a rat model of CIBP, diclofenac was demonstrated to effectively block tactile
hypersensitivity, a measure of referred evoked pain, but not ongoing pain (Remeniuk,
Sukhtankar et al. 2015). Specific to peripheral neurons, treatment with anti-NGF antibody
relieved many of the measurable pain behaviors in mice with CIBP where as anti-P2X3
antibodies only reversed referred tactile hypersensitivity (Guedon, Longo et al. 2016). Such
observations indicate that there are mechanistic differences between different clinically
important aspects of bone and joint pain. Such complexity highlights the need for more
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comprehensive analysis of the multiple aspects of bone or joint pain when examining potential
molecular mechanisms of pathological chronic pain and for effectiveness of potential
therapeutic targets.

1.2.5. Sensitization
Many animal and clinical studies have demonstrated that sensitization of peripheral and
central neurons develops in the context of chronic bone or joint pain (Falk and Dickenson 2014,
Arendt-Nielsen, Egsgaard et al. 2015, Eitner, Hofmann et al. 2017). The international association
for the study of pain (IASP) defines sensitization as “Increased responsiveness of nociceptive
neurons to their normal input, and/or recruitment of a response to normally subthreshold
inputs”. They note that sensitization may include a decrease in activation threshold, increase in
suprathreshold responses, spontaneous discharges of neurons, and increases in receptive field
of neurons. They further clarify that sensitization is a neurophysiological term and can only be
applied when both input and output of the neural system being studied (e.g. peripheral input,
spinal signaling) are known. It is emphasized that clinically, sensitization may only be inferred
indirectly from observations such as exacerbated pain from a known painful response
(hyperalgesia) or a painful response from a previously non-painful stimulus (allodynia).
Temporal summation is also used within the clinical literature as a sign of sensitization (ArendtNielsen, Egsgaard et al. 2015). Sensitization can be measured in the periphery, termed
peripheral sensitization defined by IASP as “Increased responsiveness and reduced threshold of
nociceptive neurons in the periphery to the stimulation of their receptive fields”. Sensitization
can also be measured at sites within the central nervous system such as the spinal cord, termed
central sensitization defined by IASP as “Increased responsiveness of nociceptive neurons in the
central nervous system to their normal or subthreshold afferent input.”
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This has been described in patients with moderate to severe knee osteoarthritis
(Arendt-Nielsen, Egsgaard et al. 2015). Further, in patients with knee osteoarthritis associated
with spread of allodynia and temporal summation, functional magnetic resonance imaging
demonstrated that whereas direct painful stimulation at the osteoarthritic site did not
distinguish between sensitized and non-sensitized patients, stimulation at an area of spreading
sensitization resulted in increased signals within brain regions associated with pain processing
(Pujol, Martinez-Vilavella et al. 2017). Stimulation of an area associated with spreading
sensitization also produced activation of brain regions not associated with pain processing,
extending to the auditory, visual, and ventral sensorimotor cortices (Pujol, Martinez-Vilavella et
al. 2017). Such studies will be critical in gaining a better understanding of changes associated
with development of central sensitization that contribute to worsening of pain and to
medication resistant pain states associated with bone and joint pain.
There are many well written overviews of mechanisms contributing to development of
peripheral sensitization (Schaible 2018, Syx, Tran et al. 2018) and central sensitization (Woolf
2011, Falk, Bannister et al. 2014, Falk and Dickenson 2014, Schaible 2018). Much has been
learned about the impact of many of the factors that are released by local tissues, such as
adenosine triphosphate (ATP), adenosine diphosphate (ADP), endothelins, bradykinin, and
growth factors (Jimenez-Andrade, Bloom et al. 2010, Mantyh 2014, Schaible 2018, Syx, Tran et
al. 2018, Woller, Eddinger et al. 2018). These factors have been shown to act both directly on
neurons to activate them and to alter the properties of the neurons. These actions including
lowering of activation thresholds and increased in responses are key characteristics of
peripheral sensitization (Jimenez-Andrade, Mantyh et al. 2010, Syx, Tran et al. 2018, Woller,
Eddinger et al. 2018). Several factors including proinflammatory cytokines (e.g. IL-1 beta, TNF
alpha, IL-6) have been shown to be catabolic and may enhance bone resorption promoting
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underlying pathology (Lee, Ellman et al. 2013). Mechanisms underlying peripheral sensitization
include translation and trafficking of transducer channels as well as phosphorylation of
transducer channels such as TRPV1 resulting in altered activation thresholds and increased
transfer of cations allowing for enhanced depolarization of the neurons and amplified signaling
(Jimenez-Andrade, Mantyh et al. 2010, Syx, Tran et al. 2018, Woller, Eddinger et al. 2018).
Similarly, increased translation and trafficking of sodium channels resulting in amplified action
potentials and increased numbers and phosphorylation of calcium channels result in enhanced
neurotransmitter release from afferent terminals within the spinal cord (Devor 2006, Bao 2015).
In addition, pathophysiological changes in neurons such as pathological sprouting and formation
of neuromas may contribute to ectopic discharge and amplified signaling from the bone or joint
(Jimenez-Andrade, Mantyh et al. 2010).
Ongoing afferent input has been suggested to result in spinal sensitization (Devor 2009,
Latremoliere and Woolf 2009, Woolf 2011). Various studies in animal models of cancer-induced
bone pain and osteoarthritis have demonstrated development of central sensitization including
lowered thresholds for activation, amplification of signal, and widening of the receptor field
(Thakur, Rahman et al. 2012, Thakur, Dickenson et al. 2014), as well as activation of spinal
neurons in response to normally non-noxious stimuli such as movement of the tumor bearing
hind limb (Schwei, Honore et al. 1999) or arthritic joint (Havelin, Imbert et al. 2016). Various
mechanisms have been implicated in mediating spinal sensitization, including activation of glia,
upregulation and excitatory signaling by dynorphin, and diminished tonic inhibition by
GABAergic interneurons (Coull, Beggs et al. 2005, De Koninck 2007, Lai, Luo et al. 2008, Gao and
Ji 2010, Trang, Beggs et al. 2011, Beggs and Salter 2013, Clark, Old et al. 2013, Ji, Berta et al.
2013, Mapplebeck, Beggs et al. 2016). Several studies have demonstrated a role for spinal
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microglia and elevated pro-inflammatory cytokines in mediating cancer-induced bone pain
(Zhou, Liu et al. 2016) and in animal models of osteoarthritis (Tran, Miller et al. 2017).
In addition to release of pro-inflammatory cytokines, spinal microglia mediated release
of the brain derived growth factor (BDNF) has been implicated in mediating spinal changes
resulting in disinhibition and spinal sensitization (Coull, Beggs et al. 2005, Trang, Beggs et al.
2011, Beggs and Salter 2013). These changes have been described in animal models of nerve
injury as well as opioid-induced hypersensitivity. Release of BDNF is proposed to increase
chloride channels (KCCL) leading to disruption of the gradient balance of chloride ions (Trang,
Beggs et al. 2011, Beggs and Salter 2013). This is proposed to result in GABA activation of
normally inhibitory channels become excitatory, thereby facilitating sensitization and
hyperexcitability (Coull, Beggs et al. 2005, De Koninck 2007, Prescott, Ma et al. 2014, Bonin,
Wang et al. 2016). Whether such changes are implicated in chronic bone and joint pain has not
been well studied. The role of these changes in mediating evoked hypersensitivities compared
to persistent ongoing pain has not been systematically studied. Upregulation of dynorphin has
also been implicated in spinal sensitization in preclinical models of nerve injury-induced pain
through activation of non-opioid receptors such as the bradykinin receptor (Lai, Luo et al. 2008).
Upregulation of dynorphin has been reported in a mouse model of cancer-induced bone pain
(Schwei, Honore et al. 1999). However, further investigation regarding the role of spinal
dynorphin in mediating chronic bone or joint pain has not been investigated.

1.2.6. Descending Pain Modulation
Another important aspect of pain processing is the ability for the brain to modulate pain
signals through descending pain pathways that can amplify (descending pain facilitatory
pathways) or diminish (descending pain inhibitory pathways) the pain signal (reviewed by
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(Suzuki, Rahman et al. 2004, Ossipov, Dussor et al. 2010)). Key sites implicated in descending
pain modulation include the anterior cingulate cortex, the periaqueductal grey, and the
rostroventromedial medulla (RVM) (Suzuki, Rahman et al. 2004, Ossipov, Dussor et al. 2010). In
the uninjured/non-pain state, pain can be modulated in response to physical or psychological
stress. Much has been learned about how stress can activate these descending pain modulatory
pathways to dampen pain or induce analgesia through endogenous opioid and cannabinoid
signaling within the brain (Ossipov, Dussor et al. 2010). Following injury, a time-dependent
increase in net descending pain facilitation occurs, wherein descending facilitatory pathways
promote enhanced spinal cord activity to noxious and non-noxious stimuli (Ossipov, Dussor et
al. 2010, Falk, Bannister et al. 2014) as well as behavioral responses showing enhanced
responsiveness to noxious and non-noxious stimuli modeling hyperalgesia and allodynia,
respectively (Burgess, Gardell et al. 2002, Qu, King et al. 2011, King, Qu et al. 2012, Havelin,
Imbert et al. 2016, Bannister, Qu et al. 2017).

1.2.7. Conclusion
Much has been learned regarding biological mechanisms contributing to bone and joint
pain. The continued improvement and development of animal models that more accurately
represent the human condition will continue to advance the field and allow basic researchers to
identify translational proteomic, cellular and systems to better treat pain. In addition, the
relatively recent advent of specific genetic tools including transgenic animals with alterations to
“pain-specific” genes (i.e. knock-ins and knock-outs), reporter genes, and development of virally
deliverable tools to induce genetic alterations allow dissection and analysis of molecular targets
and microcircuitry underlying specific and distinct aspects of chronic pain. Optogenetic and
chemogenetic tools offer increased ability for spatial and temporal precision of the investigation
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of key cell subtypes and circuits within the CNS. Fluorescent proteins that serve as a surrogate
for neuronal firing/activity such as GCaMP6 and the continued incorporation of light sensitive
ion channels and pumps that allow for selective activation or inhibition of cells are immensely
powerful tools working their way to the forefront of the pain field. In addition, improvements in
imaging techniques both at the site of pathology (Felson 2005) and brain imaging assessing brain
activity and changes in processing in chronic pain patients will guide future studies on molecular
and circuit changes that are associated with chronic pain.
Such analyses will open new potential targets as genomic and proteomic analyses reveal
novel targets at the site of pathology or the neural circuitry driving chronic pain. In addition,
brain imaging will allow for potential insights into development of comorbidities associated with
chronic pain such as development of depression, anxiety and altered cognitive processing
(Borsook, Hargreaves et al. 2011, Parks, Geha et al. 2011, Tetreault, Mansour et al. 2016, Bajic,
Craig et al. 2017, Colon, Bittner et al. 2017, Peng, Steele et al. 2018). Beyond the development
of exciting new tools there remain complexities that go beyond the scope of this review of work,
such as integral contributions by the immune system and the endocrine system. Continued and
growing analysis of genetic susceptibility to increased or decreased pain sensitivity, and
epigenetic modifications that result from chronic pain will guide our understanding of the
predisposition of different races/ethnicities/sexes to chronic pain and the potential
effectiveness or insensitivity to specific pain treatments.

1.3. Preclinical Models of Cancer-Induced Bone Pain
Several variations of animal models exist to examine CIBP in preclinical studies. Much of
the initial work done to examine the mechanisms underlying CIBP was performed in a murine
model that utilizes an injection of a primary tumor line into the femur, and to date most
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published work still uses this approach. The first published piece of working using this approach
was performed by Clohisy et al. 1995, where injection of the 2472 sarcoma cells into the femur
of osteoclast deficient mice resulted in the upregulation of macrophage colony-stimulating
factor and a pathological increase in osteoclast activity and morphology that coincided with
osteolysis (Clohisy, Ogilvie et al. 1995). It is important to note that unless using
immunocompromised animals it is necessary to use syngeneic cell lines with the species and
strain of animal being used. Work immediately following this expanded on this observation
looking at the differences between the 2472 sarcoma cell line and G3.26 melanoma cell line
(Clohisy, Ogilvie et al. 1996). Investigation here demonstrated that whereas the sarcoma cell line
induced osteoclast pathology and bone destruction, the melanoma line grew but failed to alter
osteoclast numbers or structure and no change in bone remodeling was reported (Clohisy,
Ogilvie et al. 1996). Further support that this approach resulted in maladaptive bone remodeling
resulted when a human breast cancer cell line MDA-MB-45s, induced an increase in the number
and size of osteoclasts in a mouse model of cancer-induced bone loss, as well as induced
osteoclasts to increase bone resorption (Clohisy, Palkert et al. 1996). In general, these bodies of
work demonstrated bone remodeling that mimicked in the clinical observations, leading to this
approach to be heavily utilized to study CIBP.
Following the initial establishment of this approach, work by Dr. Patrick Mantyh adapted
this with the intent to examine mechanisms underlying CIBP. His work examined alterations to
the peripheral and central nervous system and corresponding emergence of behaviors that are
still used as measures of pain. This work and previous work by Clohisy and colleagues
demonstrated pain measures were induced by tumor growth within the bone as they are only
observed in the mice that received cells implanted, and upon improvement of the surgical
implantation of cells, sealed directly into the femur (Schwei, Honore et al. 1999). Schwei et al.
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1999 was the first paper published in the series of work by Dr. Mantyh and established this
approach as a clinically relevant method to evaluate CIBP. An initial clinically relevant
observation being that this approach resulted in tumor induced drastic bone remodeling and
prolonged growth resulted in invasion of the tumor into the periosteum of the femur,
observations that had not been documented in the previous work by Clohisy and colleagues
(Schwei, Honore et al. 1999).
This was furthered by a direct comparison between pain models within Dr. Mantyh’s lab
in the subsequent publication of Honore et al 2000 suggesting that difficulty in treating CIBP
might be due to its apparent “unique” neurochemical footprint, a combination of oxidative
stress within the spinal cord, increased expression of dynorphin within the spinal cord, and
increased glial cell hypertrophy (Honore, Rogers et al. 2000). In an effort to compare the efficacy
of morphine in treating CIBP vs inflammatory pain this group also demonstrated that
comparable to observations in the clinic, higher doses of morphine are required to temper pain
measurements in this model of CIBP (Luger, Sabino et al. 2002). This work was soon echoed by
Wacnik et al. 2003 who also demonstrated that in advanced CIBP, the required doses of
morphine were nearly 2.5 times as high (measured be ED50) when compared to a model of
carrageenan induced muscular pain to reverse movement-related hyperalgesia as measured by
grip strength (Wacnik, Kehl et al. 2003). These works notably only observed acute effects of
morphine at potentially behavior altering doses (30 mg/kg and ED50 23.9 mg/kg Luger et al.
2002 and Wacnik et al. 2003 respectively) and didn’t compare efficacy of morphine in a chronic
regiment to observe the effects of morphine tolerance development or whether an increase in
dosing would be necessary to manage pain as the cancer progressed.
Work by King et al. 2007 demonstrated that mini-pump implantation to deliver varying
doses of morphine not only failed to attenuate CIBP behaviors 3-5 days after implant, but
29

exacerbated measures of pain. Alarmingly this work also demonstrated that this regiment of
morphine also induced an increase in tumor-induced bone destruction after as short a time as 35 days of chronic morphine exposure, and this effect was blocked by naloxone indicating these
observations to be opioid receptor mediated (King, Vardanyan et al. 2007). These are two of the
fundamental challenges within the clinic when treating CIBP in patients, as patients are on
regiments of increasing opioids for long durations of time (Luger, Sabino et al. 2002).
Interestingly Peters et al. 2005 demonstrated that chronic administration of gabapentin, also
attenuated flinching as a measure of ongoing pain, as well as palpation induced increase in
flinching, a proposed behavioral measure of pain exacerbated by movement of the cancerafflicted limb (Peters, Ghilardi et al. 2005). These observations demonstrate that not only does
CIBP have a unique neurochemical footprint, but an interesting response to various
pharmacological agents, implicating the potential for multiple mechanisms driving this pain
state.
A similar rat model exists to study CIBP, where the major difference (excluding cancer
cell line utilized) is that primary tumor cells are sealed and restricted to the tibia rather than the
femur. The first report of this approach was in 2002 by Medhurst and colleagues using the
MRMT-1 rat mammary gland carcinoma cells. They reported tumor-induced bone destruction
indicated by both radiographic analysis and microcomputed tomography (Medhurst, Walker et
al. 2002). These observations are not only similar to results in the mouse model, but more
importantly. similar to clinical observations of osteolytic bone loss in many breast cancer
patients with skeletal metastasis (Mantyh 2002, Mantyh, Clohisy et al. 2002). A corresponding
decrease in mechanical thresholds, a relative decrease in wheel running, altered weight bearing
away from the cancer afflicted limb and increased glial fibrillary acidic protein (GFAP) staining
ipsilateral to the cancer-afflicted limb in the dorsal horn was reported (Medhurst, Walker et al.
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2002). This initial characterization established a model that allowed future analysis and use of
rats that would allow additional techniques that could not be achieved in the mouse due to
technical challenges, such as electrophysiological recordings in awake animals, and behavioral
assays that may be more reliable in the rat.
Recent novel methods used to measure ongoing pain in models has allowed us to assess
the role of pain in a non-evoked way (King, Vera-Portocarrero et al. 2009, Navratilova and
Porreca 2014). Within the rat model of CIBP, Remenuik et al. 2015 demonstrated that peripheral
blockade of sensory fibers (by lidocaine) to the cancer-afflicted tibia in rats resulted in
conditioned place preference (CPP) to the lidocaine paired chamber indicating pain relief along
with an increase in dopamine release in the nucleus accumbens indicating that relief of CIBP as
other pain states is rewarding (Remeniuk, Sukhtankar et al. 2015). These two observations not
only demonstrate that generation and likely maintenance of ongoing pain from the cancer
afflicted limb in rats requires sensory neuron activity, but holds measures that blockade of the
pain signal has a rewarding behavioral effect and a physiological response in the reward centers
of the brain. These two measures went further to demonstrate that while administration of a
systemic NSAID reverses tactile hypersensitivity, it fails to induce CPP to pain relief or dopamine
release in the nucleus accumbens (Remeniuk, Sukhtankar et al. 2015). However, systemic
morphine successfully blocks peripheral nerve block induced CPP and dopamine release in the
nucleus accumbens, suggesting that morphine successfully manages ongoing pain and tactile
hypersensitivity, recapitulating clinical reports that NSAIDs fail to manage advanced CIBP
whereas opioids have some effect (Bruera and Paice 2015, Kane, Hoskin et al. 2015).
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1.4. Known Mechanisms Driving Cancer-Induced Bone Pain
The following is meant to expand on the previous section and discuss with slightly more
detail some of the key findings in preclinical models of CIBP that led to the specific direction of
the work included in this dissertation.
Evidence from the earliest bodies of work investigating these preclinical models of CIBP
have uncovered many important factors involved in CIBP. As mentioned previously Schwei et. Al
1999, described evidence that implied the neurochemical changes observed in their mouse
model to be “unique” from other models of pain, or perhaps more of a hybrid signature when
compared to previous results from inflammatory and neuropathic pain models (Schwei, Honore
et al. 1999). Non-noxious stimulation that consisted of a 2-minute hind limb movement, induced
c-fos expression and neurokinin-1 receptor (NK-1) internalization in the superficial dorsal horn
of the spinal cord ipsilateral to the implantation of the tumor, as well as deep lamina c-fos
expression (Schwei, Honore et al. 1999). Beyond this these animals displayed increased GFAP
staining ipsilateral to the tumor, and dynorphin and c-fos expression in deep lamina of the spinal
cord dorsal horn. These findings were replicated in a follow up publication from Honore et al.
2000 that directly compared neurochemical changes between models of inflammation and
neuropathic pain (Honore, Rogers et al. 2000).
Honore et al. 2000 and Luger et al. 2001 demonstrated that both the bone destruction
and neurochemical changes induced by the tumor were blocked by OPG, an effective osteoclast
“decoy” that inhibits osteoclast function as previously mentioned through the RANK-RANKL
activation pathway (Honore, Rogers et al. 2000, Luger, Honore et al. 2001). These observations
paired well with previous results from Clohisy and colleagues that demonstrated OPG effectively
reduces the number of osteoclasts at the site of an osteolytic tumor, effectively blocking them
from degrading bone. This effectively demonstrated that osteoclasts are required for bone
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degradation, and bone degradation plays a key role in the generation of pain from the bone,
connecting this preclinical model to the clinic (Clohisy and Ramnaraine 1998, Clohisy,
Ramnaraine et al. 2000). This highlighted the role for osteoclasts direct involvement in
degrading the bone and emphasized the role for bone destruction and osteoclasts in driving
neurochemical changes and pain in this model. Investigation of different cell lines and their
potential impact on CIBP behavior and osteoclast reprogramming by Sabino et al. 2003 (Sabino,
Luger et al. 2003) demonstrated that in immunocompromised mice the injection of sarcoma,
melanoma and colon cancer cell lines resulted in different patterns of pathology (Sabino, Luger
et al. 2003).
Perhaps most remarkably with respect to bone remodeling, a similar observation was
recorded to Clohisy and colleagues’ earlier work with a melanoma cell line (G3.26 derived from
C57BL6 mouse) in this model and approach (Clohisy, Ogilvie et al. 1996). The previously
categorized sarcoma line (2472) replicated findings of the generation of unevoked
flinching/guarding behaviors and an increase in pain behaviors during forced ambulation on a
rotarod apparatus and palpation-evoked guarding. Whereas melanoma (B16-F10 derived from
C57/bl6) and colon (NCI derived from Balb/c mice) cell lines failed to induce unevoked guarding
behaviors and have differential effects on ambulation and palpation-evoked behaviors (Sabino,
Luger et al. 2003). Beyond this, normally non-noxious palpation of the hind limb of animals
injected with all cell lines demonstrated increased c-fos expression in the deep lamina of the
spinal cord, but only sarcoma and melanoma cell lines, not colon, induced pathological c-fos
expression in the superficial lamina of the spinal cord dorsal horn. Demonstrating a unique
pattern of sensitization that correlated to palpation-induced guarding of the hind limb.
Interestingly, GFAP expression was also demonstrated to be upregulated in animals injected
with the sarcoma and colon cell lines (but not melanoma), reflecting cancer-induced alteration
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of ambulatory pain scores (Sabino, Luger et al. 2003). Evidence such as this demonstrates that
the effects of different primary tumors within the bone can have unique neurochemical as well
as behavioral changes, further exemplifying the heterogeneity of CIBP (Sabino, Luger et al.
2003).
Little was known about the actual identity or anatomy of the sensory nerves involved in
transducing pain from the femur in naïve animals let alone disease treated animals (i.e.
nociceptive, autonomic, large diameter, etc.). Early work in the mouse utilizing
immunohistochemical (IHC) staining demonstrated that innervation in naïve bone as well as the
periosteum was primarily CGRP and tyrosine hydroxylase (TH) positive with additional staining
suggesting the presence of A-delta fibers (Mach, Rogers et al. 2002). These observations were
accompanied by a notable lack of IB4-binding fibers (Mach, Rogers et al. 2002). This work was
replicated utilizing a transgenic animal that selectively expressed eGFP under control of the
MrgD promoter originally developed to visualize non-peptidergic nociceptors without the need
for staining and the caveats introduced by different methodological approaches (Zylka, Rice et
al. 2005). Analysis of tissue from these animals demonstrated a lack of eGFP+ fiber innervation
to the bone, thus a lack of MrgD+ or non-peptidergic nociceptors in the bone, but dense
innervation within skin of the same animals (Jimenez-Andrade, Mantyh et al. 2010). However,
dense innervation of CGRP+ fibers was observed within the bone and periosteum, again
consistent with previous experiments identifying peptidergic nociceptors in the periosteum and
bone (Jimenez-Andrade, Mantyh et al. 2010). This study also demonstrated lack of P2X3 IHC
staining in the bone and periosteum in mice, another marker of the stereotypical nonpeptidergic nociceptor population.
This lent further evidence to the ideology in mice the innervation of the bone and
periosteum is primarily peptidergic, CGRP+ fibers, and that these native populations undergo
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sprouting that may be contributing directly to ongoing and spontaneous pain originating from
this site. Counter intuitively, additional investigation within this model demonstrated that while
in the early stages of cancer cell growth within the bone pathological sprouting is observed,
denervation occurs in the distal end of the femur at late stages of disease progression, perhaps
highlighting a role for active damage to neurons within the bone and periosteum, and a role for
neuronal damage to contribute to the pain generated from the cancer-afflicted hind limb
(Peters, Ghilardi et al. 2005). Of note the peptidergic population of nociceptors also reliably
express the TRPV1, and one body of work in the dog demonstrated ablation of TRPV1 fibers
improved several outcomes in companion dogs affected by bone cancer and CIBP (Brown,
Agnello et al. 2015).
Work that immediately followed this sought to observe fiber anatomy following the
implantation of cancer cells into the femur. Jimenez et al 2010, demonstrated that not only was
pathological sprouting observed following cancer cell implantation but that the fibers
undergoing pathological sprouting were primarily CGRP+, TrkA+ and neurofilament protein 200
(NF-200+) (Jimenez-Andrade, Bloom et al. 2010). As mentioned previously, this pathological
sprouting was blunted by administration of an NGF-sequestering antibody, and observed pain
behaviors also decreased, however bone pathology remained unaffected by the NGF-antibody.
Bloom et al. 2011 demonstrated similar sprouting in TrkA+ fibers in the periosteum, a location
close proximity to the tumor cells, stromal cells and bone remodeling, this too was blocked by
the NGF sequestering antibody (Bloom, Jimenez-Andrade et al. 2011). These findings were
supported by additional results in experiments that utilized a TrkA receptor antagonist, further
highlighting the role for NGF-induced changes in peripheral nerve structure and CIBP (Ghilardi,
Freeman et al. 2011). It is not clear whether blockade of bone remodeling by OPG blocks
pathological sprouting of fibers. Both of these key bodies of work demonstrated a role for
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neuronal plasticity induced by the presence of NGF following bone remodeling and tumor
growth.
In an attempt to compare effects of mitigating pain on the peptidergic and nonpeptidergic populations work was performed in both the mouse and the rat. As previously
mentioned work in the rat utilizing retrograde labeling from the tibia implicated the possibility
that some fibers innervating the bone were in fact non-peptidergic (Ivanusic 2009). Work from
Mantyh’s group demonstrated the two fiber types likely have differential roles in CIBP by
performing a side by side comparison using an NGF-sequestering antibody and an antibody
targeting the P2X3 protein in the mouse (Guedon, Longo et al. 2016). As previously observed the
NGF-antibody blocked/reversed pain behaviors both in the skin and measures of pain from the
bone in the mouse model of CIBP, whereas the P2X3 antibody only blocked the tactile
hypersensitivity that reliably develops in these models of CIBP (Guedon, Longo et al. 2016).
Perhaps in line with the differing observations of fiber type innervation of the bone in the rat,
Kaan et al. 2010 used a P2X2/P2X3 antagonist and demonstrated that while bone pathology was
unaltered by drug treatment, mechanical allodynia and phosphorylated extracellular receptor
kinase (pERK) expression in DRG were reversed (Kaan, Yip et al. 2010). Wu et al 2012 also
demonstrated that antagonism of the P2X3 receptor transiently blocked cancer-induced tactile
hypersensitivity (Wu, Xu et al. 2012).
While this work was informative to the peripheral identity of cell types innervating the
femur, and the potential for altering each fiber types transduction of pain, observation of the
cellular bodies of these neurons within the DRG of animals has added some specifics to the story
of CIBP. Peters et al 2005 investigated the anatomical location of cells that may be undergoing
damage following cancer cell implantation. While compared to sham treated animals, cancer
cell implantation resulted in an upregulation of the neuronal damage marker ATF3 in L1, L2 and
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L3 DRG, with a distinct lack of ATF3 expression in other DRG (Peters, Ghilardi et al. 2005). This
work was run in comparison to femoral nerve transection, which displayed similar patterns in
DRG of ATF3 expression, and sciatic nerve transection which displayed a shifted pattern of ATF3
expression towards the L3-L5 DRG (Peters, Ghilardi et al. 2005). Intuitively implicating the role of
innervation from the femoral nerve, which contains fibers from cell bodies within L2 DRG.
Additionally, marked galanin expression and immune cell activation/migration was observed in
the L2 DRG of cancer treated animals when compared to sham (Peters, Ghilardi et al. 2005).
Sevcki et al 2004, demonstrated an interesting link between bone destruction and the
development of ATF3 expression, demonstrating that bisphosphonate blockade of bone
destruction results in a decrease in cell bodies within the DRG expressing ATF3 (Sevcik, Luger et
al. 2004). Interestingly work by King et al. 2007 demonstrated an upregulation of ATF3 in L4 DRG
compared to shams, demonstrating that establishment and growth of the cells within the femur
reliably induce neuronal damage in sensory neurons and this coincides with c-fos expression in
the L4 spinal cord segment by Sabino et al 2003 (Sabino, Luger et al. 2003, King, Vardanyan et al.
2007). Notably ATF3 expression was exacerbated by exposure to chronic mini-pump delivered
morphine, an observation that coincided with enhanced bone destruction as previously
mentioned (King, Vardanyan et al. 2007). Ivanusic et al. 2009 who performed a characterization
of retrograde labeling to identify the DRG(s) in which the cell bodies innervating the tibia in the
rat, reported that the tibia and periosteum contain terminals of cells primarily within the L2-L5
DRG. This report also contained information that the diameter of these cells ranged from small
(likely C-fibers) to larger (A-delta) cell bodies, with more positive cells being small diameter
neurons (Ivanusic 2009). In addition to this, tumor growth and perhaps CIBP as a result,
increases the presence of CGRP RNA and protein in the DRG of mice (King, Vardanyan et al.
2007, Isono, Suzuki et al. 2011). An effect exacerbated in the presence of chronic morphine, and
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diminished by the lack of activated prostaglandin E2 (PGE2) (King, Vardanyan et al. 2007, Isono,
Suzuki et al. 2011).
This addition to the literature gave the anatomical location of sensory nerves
innervating the femur in these mice and tibia of the rat, as well as likely the identity of the cells
generating and maintaining pain signals, an important contribution to future work that
would/will allow for targeted proteomic and genomic investigation of sensory neurons following
cellular implant.
Evidence that tumor cells alter cellular signaling of osteoclasts and immune cells has
also been demonstrated in both the mouse and rat model of CIBP. Work as early as Clohisy et al.
1995 has demonstrated the likelihood of tumor cells inducing cellular changes within close
proximity to their growth. Remeniuk et al. 2018 demonstrated that in animals that received
tumor implant, markedly increased levels of interleukin-6 were found in bone exudate and
plasma, an observation closely following measures of clinical patients with metastatic breast
cancer (Remeniuk, King et al. 2018). The authors of this paper found that acute administration
of an IL-6 antagonist temporarily reversed tactile hypersensitivity, while having no effect on
ongoing pain measured by CPP to pain relief. However, chronic administration of the IL-6
antagonist beginning at the time of tumor implantation resulted in blockade of the development
of tactile hypersensitivity, ongoing pain as well as bone remodeling, a most promising result
with clinical translation indeed. Isono et al. 2011 demonstrated that microsomal prostaglandin E
synthase-1 (mPGES-1) knock out mice, that lack the ability to activate PGE2 showed diminished
pain behaviors along with tumor growth potentially due to a lack of RANKL activation,
implicating a role of cancer-induced activation of the gene in order to produce certain aspects of
CIBP (Isono, Suzuki et al. 2011).
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Electrophysiological recordings from spinal cord dorsal horn neurons in cancer cell
injected rats has demonstrated that as pain behaviors develop and bone destruction occurs,
central sensitization occurs, however it did so in a manner unique from previously observed
neuropathy models (Urch, Donovan-Rodriguez et al. 2003). CIBP caused hyperexcitability in wide
dynamic range cells in the spinal cord in response to a number of nociceptive stimuli, changes
that remained even when a chronic morphine regiment was given to rats (Urch, DonovanRodriguez et al. 2003, Urch, Donovan-Rodriguez et al. 2005). Interestingly the hyperexcitablity of
dorsal horn neurons evoked by A-delta and C-fibers in the periphery in the rat was blocked by
administration of the P2X3 antagonist, an interesting contradiction to the observed role in mice
for the non-peptidergic fibers (Kaan, Yip et al. 2010). The reactivity and sensitization that is
recorded from superficial dorsal horn neurons not only agrees with the known innervation
patterns of the spinal cord from previously reported evidence, but coincides with retrograde
labeling from the tibia. Both Kaan et al. 2010 and Ivanusic 2009 report the identity of cell bodies
within DRG that innervate the tibia in the rat, and demonstrate co-labeling for stereotypical
nociceptive markers, eg. SP, CGRP and notably IB4, in contrast to results noted in the mouse
(Ivanusic 2009, Kaan, Yip et al. 2010) .
These examples and efficacy of approaches varies between measurable pain behaviors,
i.e. certain approaches treat tactile hypersensitivity but fail to manage supposed measures of
ongoing pain, and vice versa. Acute administration of a p38-MAPK inhibitor reversed cancerinduced increases in flinching and decreased cancer-induced hind limb guarding, but failed to
ameliorate cancer-induced tactile hypersensitivity (Sukhtankar, Okun et al. 2011). Chronic
administration of the kappa opioid receptor (KOR) agonist U50-488 has similar effects, where
U50-488 reversed these measures although to a lesser extent (Edwards, Havelin et al. 2018).
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While these additions to the body of literature surrounding CIBP have been informative,
few have resulted in the development of novel improvements in the clinic. One potential
limitation of the translation of these findings are the methods used to evaluate their efficacy.
While behaviors such as shifted weight bearing, evoked tactile hypersensitivity, increased
flinching/guarding and impaired limb use have been the mainstay for nearly 20 years of CIBP
preclinical work, it is not necessarily clear that reversal of these behaviors is truly due relief of
ongoing pain. A dramatic implication of work published by King et al. 2009, where the authors
demonstrated compounds that alleviate tactile hypersensitivity in preclinical models do not
necessarily always alleviate ongoing pain, similar to observations form the clinic (King, VeraPortocarrero et al. 2009). While some work is likely more convincing than others, e.g. blockade
of neuronal sprouting by NGF-antibodies that may have clinical efficacy, and blockade of
osteoclast induced bone remodeling which does show clinical efficacy, other approaches may be
more limited in their translatability. Recently the development and successful implementation
of CPP to ongoing pain relief in models of CIBP has provided a novel and non-evoked measure of
pain relief that may serve for screening of more effective therapeutics (Remeniuk, Sukhtankar et
al. 2015, Remeniuk, King et al. 2018). This, in addition to the lack of a model of BTP that truly
involves a non-painful stimulus are truly two hindrances to the field. In the case of BTP, this has
been a detriment to the field in the development and screening of novel analgesics to treat BTP,
as little is known about the underlying neurophysiology of BTP. In the following I share the
results of our group in developing a novel model of BTP in a rat model of CIBP along with a
unique role for the non-peptidergic IB4-binding fibers in being critical to BTP. Following this, due
to limitations of the techniques used in our rat work, we sought to expand and clarify the role of
unique populations of sensory fibers in ongoing pain and BTP in the mouse using an optogenetic
approach that would allow us to transiently silence peripheral fibers rather than ablate them.
40

CHAPTER 2
MEDIATION OF MOVEMENT-INDUCED BREAKTHROUGH CANCER PAIN BY IB4-BINDING
NOCICEPTORS IN RATS

The section below is work that is published as a primary research article in The Journal
of Neuroscience (Havelin, Imbert et al. 2017). It has been slightly modified for this dissertation.

2.1. Abstract
Cancer-induced bone pain (CIBP) is characterized by moderate to severe ongoing pain
that commonly requires the use of opiates. Even when ongoing pain is well controlled, patients
can suffer breakthrough pain (BTP), episodic severe pain that “breaks through” the medication.
We developed a novel model of cancer-induced BTP using female rats with mammary
adenocarcinoma cells sealed within the tibia. We previously demonstrated that rats with bone
cancer learn to prefer a context paired with saphenous nerve block to elicit pain relief (i.e.,
conditioned place preference, CPP), revealing the presence of ongoing pain. Treatment with
systemic morphine abolished CPP to saphenous nerve block demonstrating control of ongoing
pain. Here, we show that pairing BTP induced by experimenter-induced movement of the
tumor-bearing hind limb with a context produces conditioned place aversion (CPA) in rats
treated with morphine to control ongoing pain, consistent with clinical observation of BTP.
Preventing movement-induced afferent input by saphenous nerve block prior to, but not after,
hind limb movement blocked movement-induced BTP. Ablation of isolectin B4 (IB4) binding, but
not TRPV1+, sensory afferents eliminated movement-induced BTP suggesting that input from IB4
binding fibers mediates BTP. Identification of potential molecular targets specific to this
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population of fibers may allow for development of peripherally restricted analgesics that control
BTP and improve quality of life in patients with skeletal metastases.

2.2. Introduction
Pain is the most feared consequence of cancer (Breivik, Cherny et al. 2009, Paice and
Ferrell 2011). Metastatic bone pain is characterized by moderate-to-severe persistent ongoing
pain associated with tumor growth, nerve destruction and bone remodeling. As many as 40-80%
of these patients also experience breakthrough pain (BTP), transient episodes of severe to
excruciating pain occurring in the presence of medication controlling background cancer pain
(Portenoy and Hagen 1989, Portenoy and Hagen 1990, Mercadante 2015). BTP is frequently
reported for 15-30 min following voluntary or involuntary movements, such as changing
position or coughing, with as many as 4-6 episodes reported within a day dramatically reducing
patients’ quality of life (Haugen, Hjermstad et al. 2010, Mercadante 2015). Treatment of BTP
typically requires rapid onset opioids that while often effective, are confounded by uncertainty
of dosing requirements for safe and effective treatment of individual patients (Mercadante
2011, Mercadante 2015). Further complicating treatment, BTP takes place on a background of
medication, primarily opioid, controlled ongoing pain. Increasing the opioid dose results in a
high likelihood of adverse side effects, further diminishing these patients’ quality of life
(Mercadante 2015). The discovery of safe and effective medications to treat BTP is an urgent
unmet medical need.
The observation that BTP occurs in the setting of opioid medication that sufficiently
controls ongoing pain suggests that these pain states are mechanistically distinct (Bennett
2010). Analgesic actions of drugs such as morphine occur at mu opioid receptors (MOR) that are
located within the periphery, spinal cord and brain. One possibility is that movement may
42

recruit additional fibers that are not blocked by peripheral MOR agonists at doses that block
persistent background pain. In the setting of pain-induced central sensitization, such signals may
elicit excruciating BTP (Mantyh 2013, Falk and Dickenson 2014, Mantyh 2014), that requires
fast-acting opioids that likely exert their effects at supraspinal sites.
While recent RNAseq studies have described as many as 11 subpopulations of sensory
fibers (Usoskin, Furlan et al. 2015), two broad classes of fibers that have been widely
characterized are TRPV1 expressing fibers IB4 binding neurons (Molliver and Snider 1997, Snider
and McMahon 1998, Basbaum, Bautista et al. 2009, Wang and Zylka 2009). Previous studies
have demonstrated that long-lasting desensitization of TRPV1 expressing sensory fibers
produces insensitivity to thermal stimulation and ongoing pain, without altering tactile
hypersensitivity, in models of neuropathic and inflammation-induced pain (Yaksh, Farb et al.
1979, Ossipov, Bian et al. 1999, Okun, DeFelice et al. 2011). Others have demonstrated that
ablation of MrgD expressing or IB4 binding fibers blocks tactile hypersensitivity without altering
thermal responses (Joseph, Chen et al. 2008, Cavanaugh, Lee et al. 2009, Ye, Dang et al. 2012).
Given the mechanical component of movement-evoked BTP, we tested the hypothesis that
blocking nociceptive input from IB4 binding fibers will block movement-evoked BTP whereas
blocking nociceptive input from TRPV1 expressing fibers will not block movement-evoked BTP.
Evaluation of BTP and cancer-induced ongoing pain has been limited by the lack of
available preclinical models. We recently reported capturing ongoing cancer pain through a
learning paradigm assessing motivation to seek a context associated with pain relief (Remeniuk,
Sukhtankar et al. 2015). Here, we developed a novel measure of BTP by assessing the motivation
to avoid a context associated (conditioned place avoidance, CPA) with pain following movement
of the tumor-bearing hind limb. Critically, this model assessed CPA in rats with morphinecontrolled ongoing bone cancer pain, simulating movement triggered BTP in patients.
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2.3. Materials and methods
2.3.1. Animal Care
Female and male Fischer F344/NhSD (Harlan Laboratories Inc, Indianapolis, IN, USA)
weighing 125-150g were chosen based on their histocompatibility with the MAT BIII tumor line.
The rats were maintained on a 12-hour light/dark cycle with food and water available ad libitum.
All experiments were performed in accordance with the policies and recommendations of the
International Association for the Study of Pain, National Institutes of Health, and the
Institutional Animal Care and Use Committee of the University of Arizona and University of New
England.

2.3.2. Cell Line Maintenance
The Fischer rat mammary adenocarcinoma cell line 13762 MAT BIII (ATCC, CRL 1666,
RRID:CVCL_3475, Manassas, VA) was maintained in McCoy’s media with L-Glutamine (CellGro,
Manassas,

VA)

with

10%

fetal

bovine

serum

(ATCC,

Manassas,

VA)

and

1%

penicillin/streptomycin at 37°C in a 5% CO2 atmosphere. Prior to surgical implantation, cells
were washed with phosphate-buffered saline and detached with 0.05% trypsin-EDTA (CellGro,
Manassas, VA). The cells were spun at 2300 rpm for 3 minutes and re-suspended at a
concentration of 2 x 105 cells/ µL in McCoy’s serum free media.

2.3.3. Surgical Procedures and Drug Treatment
Intratibial Surgery and Cancer Implantation. This surgical procedure was performed
according to previously published methods (Remeniuk, Sukhtankar et al. 2015). Briefly, rats
were anaesthetized under gas anesthesia (2% isoflurane O2 mixture). The right hind limb of the
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rat was shaved and disinfected with 70% ethanol and betadine. The animal was placed on its
back and a 1 cm incision was made horizontally across the femoral-tibial region to expose the
patellar tendon, and surrounding skin retracted to expose the proximal end of the tibia. A small
hole was drilled between the lateral and medial condyles into the intramedullary canal followed
by insertion of a 5 cm, 28-gauge guide cannula (Plastics One) attached to Tygon tubing (ColePalmer) to a 25 µL syringe (Hamilton, Reno, NV), with location verified by x-ray imaging
(Faxitron, Tucson, AZ). Injection of 5 µL of MAT BIII cells, or cell free McCoy’s serum free media
(vehicle), was followed by sealing the drilled hole with bone cement (Stryker Orthopaedics,
Simplex P Bone Cement, Mahwah, NJ). The area was flushed with sterile saline and the knee
joint was reinforced with a vicryl 5-0 suture (Ethicon, Cornelia, GA) placed across the drilled
area. Each rat received 1 mg/ml of gentamicin sulfate (Sparhawk Laboratories Inc, Lenexa, KS)
via subcutaneous (s.c.) injection and was allowed to recover from anesthesia prior to return to
the housing colony. Animals did not receive treatment with analgesics following tumor
implantation as treatment with NSAIDs, specifically COX inhibitors, as well as morphine have
been demonstrated to impact aspects of disease progression including tumor growth and
tumor-induced bone remodeling (Sabino, Ghilardi et al. 2002, Sabino, Ghilardi et al. 2002, King,
Vardanyan et al. 2007). For ethical considerations, all experiments were terminated within 14
days of tumor inoculation into the tibia. A total of 83 tumor-bearing rats and 50 sham rats were
used across all studies.
Morphine Pellet Implantation. Effects of morphine on tumor-induced bone pain were
assessed by insertion of morphine or placebo pellets 11 days post-intratibial surgery and
behavioral testing 20-24 hours post-pellet implantation, 12 days post intratibial surgery.
Morphine sulfate (75 mg) or placebo pellets, generously provided by the National Institute on
Drug Abuse (NIDA) Drug Supply Program, were inserted (s.c.) under gas anesthesia (2%
45

isoflurane O2 mixture) on the side contralateral to tibia surgery of the rat in front of the pelvic
region. The region was shaved and disinfected with 70% ethanol and betadine. A 1 cm incision
was made into the skin, and a pocket created with forceps in between the skin and muscle. A
single pellet was inserted into the pocket region, and the incision closed using a surgical wound
clip. Rats received 1 mg/mL (s.c.) of gentamicin sulfate (Sparhawk Laboratories Inc, Lenexa, KS)
and were allowed to recover from anesthesia prior to return to the housing colony. For CPP and
CPA experiments, pellets were implanted immediately following assessment of baseline (preconditioning) time spent in the conditioning chambers.
Intrathecal Catheterization and Spinal Drug Delivery. Rats underwent surgical
implantation of an intrathecal catheter for drug administration at the level of the lumbar spinal
cord a minimum of 7 days prior to intra-tibial surgeries to allow sufficient recovery time from
the intrathecal surgeries. Intrathecal catheters were surgically implanted as previously described
(Yaksh and Rudy 1976, Yaksh, Farb et al. 1979, King, Qu et al. 2011). Rats were anesthetized
under gas anesthesia (2% isoflurane O2 mixture) while secured in a stereotaxic frame (Stoelting,
Wood Dale, IL). The atlanto-occipital membrane was exposed, punctured, and a section of
polyethylene-10 tubing (PE-10) 6.5 cm in length was passed caudally from the cisterna magna to
the lumbar enlargement for a single spinal administration of the appropriate drug or vehicle. To
determine the effect of eliminating input from TRPV1 expressing fibers, rats received spinal
administration of capsaicin (20 µg/10 µl 10% Tween, 10% Ethanol, 80% saline) followed by 10 µl
saline flush or equivolume vehicle (10% Tween, 10% Ethanol, 80% saline) vehicle followed by 10
µl saline flush. To determine the effect of eliminating input from IB4-binding fibers, separate
groups of rats received spinal administration of IB4-Saporin (IB4-SAP, Advanced Targeting
Systems, 3.2 µg /20 µl saline) or the control, blank-SAP (Advanced Targeting Systems, 3.2 µg /20
µl saline) followed by a 10 µl flush of saline. Movement of an air bubble placed between drug
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solution and saline was used to monitor progress of the injection. Immediately following
injection, catheters were slowly removed from the spinal cord and the wound closed. Any
animals displaying motor impairment or paralysis during recovery (<10% total rats) were
immediately euthanized. Animals were routinely checked throughout the experiment to
monitor health. Following behavioral testing, rats were euthanized and tissue collected for
immunohistochemical verification of elimination of TRPV1 or IB4 immunofluorescence in the
spinal dorsal horn of capsaicin or IB4-SAP treated rats, respectively.
Immunofluorescent Analysis of Effect of Spinal Capsaicin or IB4-SAP on TRPV1, SP, CGRP
and IB4 Immunofluorescence in the Spinal Dorsal Horn. To verify that these treatments produced
selective ablations of targeted nociceptor terminals, tissue was collected for immunofluorescent
staining and semi-quantitative image analysis D21 post intrathecal administration of IB4saporin, blank-SAP, capsaicin, or the vehicle for capsaicin. Rats were deeply anesthetized with
Beuthanasia-D (Henry Schein Animal Health, Dublin, OH) and underwent intracardiac perfusion
through the left ventricle with PBS containing heparin (100 U/mL) followed by 4% PFA
containing PBS, pH 7.4. The L3-L4 spinal cord segments were immediately dissected out and
post-fixed in 10% formalin overnight. The spinal cord was then moved into a 30% sucrose
solution at 4oC for 12 to 24 hours for cryoprotection. Spinal cords were embedded in OCT (VWR,
Radnor, PA) and frozen on dry ice for sectioning. Sections were cut on a cryostat (Leica, Wetzlar,
Germany) at 30 microns, collected onto positively charged slides (Azer Scientific, Morgantown,
PA), and allowed to dry before storage at -80oC. Sections were rinsed 3 times with PBS
containing 0.05% Tween (PBST) to remove OCT, then non-specific binding proteins were blocked
by 30 min incubation with 5% normal donkey serum (EMD Millipore, Billerica, MA) and 1%
bovine serum albumin (Amresco, Solon, OH) in PBST. This blocking solution was also the
antibody diluent. Primary antibodies and Alexa 488-conjugated IB4 were incubated overnight at
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4°C as follows: IB4-AF488 1:500 (Molecular Probes Cat# I21411 also I21411 RRID:AB_2314662);
goat anti-TRPV1 1:100 (AF3066, R&D Systems, Minneapolis, MN); rabbit anti-Substance P 1:500
(ImmunoStar Cat# 20064 RRID:AB_572266, Hudson, WI); rabbit anti-CGRP 1:2000 (ImmunoStar
Cat# 24112 RRID:AB_572217). The TRPV1 antibody was validated in rat DRG tissue by
competition experiments with the TRPV1 antigen peptide that completely abolished binding of
the TRPV1 antibody as well as verifying that the antibody detected a protein of the appropriate
molecular weight in western blots (Isensee, Wenzel et al. 2014). Both the CGRP and SP
antibodies are widely used and cited in the literature, with 504 citations for the SP antibody and
110 citations for the CGRP antibody verifying that these antibodies are widely used in peerreviewed journals (https://www.citeab.com/), proposed as the most reliable way to identify a
suitable antibody (Helsby, Leader et al. 2014). Sections were rinsed 3 times with PBST and
incubated in the dark for 1 hour at RT with appropriate cross-adsorbed secondary antibodies:
Donkey anti-goat Alexa Fluor 568 1:1000 (A-11057, Life Technologies, Carlsbad, CA); donkey
anti-rabbit Alexa Fluor 568 1:1000 (ab175692, Abcam, Cambridge, MA); donkey anti-goat Alexa
Fluor 488 1:1000 (ab150133, Abcam). Sections were rinsed with PBS 3 times and mounted with
DAPI-containing Fluoroshield (ab104139, Abcam). Primary and/or secondary antibody omission
controls under identical staining conditions resulted in no fluorescent signal.
Images were acquired using a Leica TCS SP5 confocal laser scanning microscope using a
20x/0.7 NA plan apo objective lens. Excitation light was generated at 488 nm by an argon gas
laser or 561 nm by a diode pumped solid state laser through a double dichroic beam splitter,
and emission was detected sequentially via photomultiplier tubes to avoid cross-talk between
fluorophores. Z-stack images were collected with a 0.71 um step size, and maximum projections
generated for subsequent analysis. All z-stack images within each staining condition were
acquired in a single session using the same laser intensity settings. Images were analyzed using
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FIJI image analysis software (Schindelin, Arganda-Carreras et al. 2012). Confocal z-stack images
captured using the Leica confocal software were opened using the Bioformats plug-in. Images
were rotated on the X/Y axis so that the dorsal portion of the spinal dorsal horn is located at the
top of the image and a Z projection image was created using maximum intensity for 2D
visualization of the stack. The split channels function was used to create red (TRPV1, SP or
CGRP) or green (IB4) fluorescent images. Regions of interest (ROI) were selected from a file and
arranged to calculate ratios of the mean grey value of pixels within the ROI for 1) an area of
lamina 1 and the same area in the deep dorsal horn (L1/L1con) and 2) an area of lamina 2 and
the same area in the deep dorsal horn (L2/L2con) (See Fig 4). This allowed for an internal
reference to normalize intensity ratings for comparison across sections. The number of sections
analyzed for TRPV1 analyses are reported in table 1. These numbers include sections from
TRPV1/IB4, SP/IB4 and CGRP/IB4 co-stains as there were no significant differences in intensity
ratings for IB4-fluorescence across these three immunofluorescent conditions. Average intensity
ratios across sections were used to calculate means and SEM across samples from individual
animals. Ratios were calculated across spinal dorsal horn images from 3 control rats, 4 capsaicin
treated rats for SP and CGRP, 3 for TRPV1 and 2 IB4-SAP treated rats.
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Table 2.1. Numbers of Sections Analyzed for Staining Intensity

Sample 1

Sample 2

Sample 3

TRPV1
Control
IB4-SAP
Capsaicin

8
6
11

14
9
12

15

SP
Control
IB4-SAP
Capsaicin

13
9
9

15
9
12

15

CGRP
Control
IB4-SAP
Capsaicin

12
10
7

13
13
13

16

IB4
Control
IB4-SAP
Capsaicin

35
15
27

41
31
36

Sample 4

17

17

18

17

18

40
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2.3.4. Behavioral Measures
Behavioral Measure of tactile hypersensitivity. Rats were placed into elevated chambers
with a wire mesh floor and allowed to acclimate for 30 min. Paw withdrawal thresholds were
determined in response to probing with calibrated von Frey filaments with spaced increments
ranging from 0.5 to 15 g. Each filament was applied to the middle of the plantar surface of the
paw using the "up and down" method and analyzed using a Dixon nonparametric test (Chaplan,
Bach et al. 1994).
Behavioral measure of impaired limb use. Limb use was assessed as previously described
(Luger, Honore et al. 2001). The animal was placed in an empty pan and observed while walking.
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Usage of the treated limb was rated on the following scale: 0=complete lack of use, 1=partial
non-use, 2=limping and guarding, 3=limping and 4=normal walking.
Behavioral measure of BTP using CPA. Analysis of movement-induced BTP was
performed using CPA to a chamber associated with movement triggered BTP. Within the clinical
setting, voluntary or involuntary movement has been reported to trigger episodes of BTP lasting
approximately 30 min following the movement (Haugen, Hjermstad et al. 2010, Mercadante
2015). Therefore, we hypothesized that placing the rat into the chamber following a 2-min
period of movement of the tumor-bearing hind limb would produce a transient period of BTP
and that association of the BTP with the novel context produces motivation to avoid the
chamber on test day resulting in CPA. CPA was assessed in a three-chamber apparatus with
chambers distinguishable by visual, tactile and odor cues. One pairing chamber within the
apparatus had striped walls, a smooth floor, and pink-lemonade chap stick (Lipsmackers) applied
to the ceiling. The other pairing chamber within the apparatus had uniformly gray walls, a rough
floor, and vanilla chap stick (Lipsmackers) applied to the ceiling. The neutral chamber had white
walls, a smooth floor, no chap stick, and a LED light (Sylvanna, LED/DOTS/BLACK/1X12/BL) on
the ceiling to diminish time spent in the middle chamber and encourage exploration of the
pairing chambers. The boxes were cleaned (Sparkleen, Fisherbrand) between each baseline,
conditioning, and testing session. Each rat underwent baseline, conditioning and testing in the
same CPP apparatus.
Both tumor-bearing and sham control rats underwent a one-day pre-conditioning period
(D11 post-surgery) where they were placed in the three-chamber apparatus with open access to
all chambers for 15 min. Behavior was video recorded and time spent in each chamber
determined by video tracking software (Anymaze, Stoelting, Wood Dale, IL). Any rats spending
less than 180 seconds in a single chamber were removed from the study (<25% total animals
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tested). On conditioning day (D12), rats were paired with an enclosed chamber (striped or grey)
for 30 min with no treatment to minimize potential-accidental movement of the tumor-bearing
hind limb. Four hours later, rats underwent 2 minutes of movement to the cancer-bearing limb
and were placed in the opposite chamber. This treatment was previously demonstrated to
induce spinal FOS and NK-1 receptor internalization in tumor bearing mice but not sham treated
mice (Schwei, Honore et al. 1999). Hind limb movements were completed in a separate room
from the conditioning chambers to prevent other rats from being unnecessarily exposed to signs
of distress from the rats during the hind limb movement. Both sham and tumor-bearing rats
vocalized during the treatment. On the test day (D13), rats were once again placed in the threechamber apparatus with open access to all chambers. Behavior was video recorded and time
spent in each of the pairing chambers was determined by Anymaze video tracking software.
Difference scores were calculated as the preconditioning baseline (BL) scores subtracted from
test scores (test - BL). A negative score indicates aversion, and a positive score indicates
preference.
Morphine’s effects on BTP. To determine whether movement-induced CPA breaks
through ongoing morphine treatment that controls ongoing pain (Remeniuk, Sukhtankar et al.
2015), the ability of morphine infusion across 20-24 hours to block movement-induced CPA was
determined. On day 11 following injection of cancer cells into the tibia, rats underwent baseline
analysis of time spent in each of the conditioning chambers as described above followed by
implantation of extended release morphine or placebo pellets. Pellets were surgically implanted
(s.c.) on the lower back 1 inch above the pelvic bone under isoflurane anesthesia immediately
after pre-conditioning baselines were performed. The following day (conditioning day),
movement of the tumor-bearing hind limb was performed 20-24 hours into morphine infusion.
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Measure of sensory input on movement-induced BTP. To determine whether blocking
sensory input blocks movement-induced BTP, rats underwent the 3-day CPA conditioning
protocol as described above. In the morning of conditioning day, rats received saphenous saline
(350 ml) and no hind paw movement of the tumor bearing hind limb, and were then confined to
the appropriate conditioning chamber. Afternoon conditioning occurred 4 hours later. To
determine if saphenous lidocaine blocks movement-induced BTP, rats received saphenous
lidocaine (4% w/v, 350 µl) 10 min prior to the 2 min movement of the tumor bearing hind limb
and confinement within the opposite conditioning chamber. To determine whether blocking
sensory input after hind limb movement blocks movement-induced BTP, afternoon conditioning
consisted of hind limb movement for 2 min followed 10 min later by saphenous lidocaine and
confinement to the opposite conditioning chamber. All saphenous injections were performed as
previously described (Remeniuk, Sukhtankar et al. 2015). Rats were anaesthetized with a 2%
isoflurane O2 mixture. To produce an effective peripheral nerve block, lidocaine was
administered over the saphenous nerve in a single s.c. injection (4% wt/vol, 350 µL). Equivolume
saline was given as a vehicle control.

2.3.5. Radiograph Analysis of Disease Progression
Bones were rated according to a 4-point scale. 0: represented a normal, non-tumor
bearing bone with no bone remodeling; 1: represented slight signs of bone remodeling; 2:
represented diffuse bone loss or pitting without full cortical bone loss; and 3: represented clear
pitting and full cortical bone loss.
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2.3.6. Statistical Analysis
All statistical analysis was performed and all graphs were made using GraphPad Prism
6.0. Group differences in tactile sensory thresholds were analyzed across time by a two-way
analysis of variance (ANOVA). Post-hoc analysis of time-dependent changes following treatment
was performed using the Bonferroni’s multiple comparisons test wherein each time-point was
compared to pre-treatment values within each group. A probability level of 0.05 was used to
establish significance. For CPA, the effects of treatment (cancer vs control) and conditioning
chamber were analyzed by a 2-way analysis of variance (ANOVA). Sidack’s multiple comparison
tests were used for post hoc analysis of pre-conditioning (BL) vs post-conditioning values within
each treatment group. Group differences were analyzed by ANOVA using the difference scores
that were calculated as post-conditioning (test) – preconditioning (BL) time spent in the drugpaired chamber. A negative value indicates CPA whereas a positive value indicates CPP. Post-hoc
analysis was performed using Dunnett’s multiple comparison’s test. Where appropriate, analysis
was performed to determine whether the difference score was significantly different from zero
using a one-sample t-test. Group differences in intensity ratios for immunofluorescence were
determined using one-way ANOVAs followed by Dunnett’s multiple comparison’s test. F values
and degrees of freedom for all ANOVAs are presented in Table 2.2 and 2.3.
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2.4. Results
2.4.1. Tumor-induced Bone Loss, Tactile Hypersensitivity, and Impaired Limb Use
Intratibial injection of rat breast cancer cells produced bone remodeling with bone loss
apparent by D12 post-surgery in both male and female rats (Fig. 2.1A). Corresponding tactile
hypersensitivity and impaired limb use was observed in both male and female rats (Fig. 1B, C,
respectively). No overt differences in pain behaviors were observed between male and female
rats. All subsequent experiments were performed in female Fischer 344/NhSD rats.

Figure 2.1: Tumor-induced Bone Remodeling, Referred Pain and Impaired Limb Use. A.
Representative radiographs demonstrate significant bone loss in male and female rats with
fractures developing within D12 post-injection. B. Time-dependent development of tactile
hypersensitivity and C. impaired limb use, *p<0.05, **p<0.01, ***p<0.001 vs pre-surgery BL.
Graphs are mean ± SEM, n=8.
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2.4.2. Movement-induced Pain Induces CPA That Breaks Through Morphine Infusion
To determine whether movement of the tumor-bearing hind limb induces a transient
increase in pain intensity consistent with reports of BTP, rats underwent a single-trial
conditioning protocol as outlined by the flow-chart (Fig. 2.2A). Movement of the tumor bearing
hind limb significantly reduced time spent in the movement-paired chamber indicating CPA
selectively in the tumor-bearing rats (Fig. 2.2A, **p<0.01 vs sham). Sham treated control rats did
not show any difference in time spent in the conditioning chambers following movement (Fig.
2.2A; p>0.05 vs 0).
To determine whether movement induced BTP was observed in morphine treated rats,
rats underwent a single-trial conditioning protocol as outlined by the flow-chart (Fig. 2.2B).
Continuous administration of morphine across 24 hours failed to block movement-induced CPA
(Fig. 2.2B), indicating that movement-induced pain breaks through morphine previously
demonstrated to block tumor-induced ongoing pain (Remeniuk, Sukhtankar et al. 2015). Both
placebo and morphine treated tumor-bearing rats spent significantly decreased amounts of time
in the movement-paired chamber compared to sham rats (Fig. 2.2B, *p<0.05 vs sham-placebo,
***p<0.001 vs sham-morphine). The degree of CPA did not differ between the placebo and
morphine treated tumor bearing rats (p>0.05, Bonferroni t-test). Sham controls did not
demonstrate a decrease in time spent in the movement-paired chamber irrespective of placebo
or morphine treatment (Fig. 2.2B, p>0.05 vs 0).
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2.4.3. Blockade of Sensory Afferent Input from Tibia Prevents, But Does Not Reverse
Movement-induced BTP
To determine whether saphenous lidocaine induced peripheral nerve block prevented
movement-induced BTP, rats underwent a single-trial conditioning protocol as outlined by the
flow-chart (Fig. 2.3A). Pretreatment with saline did not alter movement-induced CPA in tumorbearing rats (Fig. 2.3A, *p<0.05 vs sham saline). In contrast, pretreatment with lidocaine 10 min
prior to movement of the cancer-bearing hind limb produced CPP (Fig. 2.3A, ***p<0.001 vs
sham lidocaine), likely indicating alleviation of tumor-induced ongoing pain. Sham control rats
did not alter time spent in the movement-paired chamber following saline or lidocaine
treatment 10 min prior to hind limb movement (Fig. 2.3A, p>0.05 vs 0).
To determine whether saphenous lidocaine induced peripheral nerve block following
movement blocked BTP, rats underwent a single-trial conditioning protocol as outlined by the
flow-chart (Fig. 2.3B). Blockade of afferent input from the tibia by lidocaine administration to
the saphenous nerve 10 min following hind limb movement did not reverse movement-induced
CPA (Fig. 2.3B). Cancer treated rats show equivalent decreases in time spent in the movement
treated chamber following saline or lidocaine administration 10 min following movement (Fig.
3B, **p<0.01 vs sham-saline; *p<0.05 vs sham-lidocaine). Sham rats did not demonstrate CPA to
the movement-paired chamber irrespective of saline or lidocaine treatment 10 min postmovement (Fig. 3B, p>0.05 vs 0).
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2.4.4. Spinal Capsaicin Eliminates TRPV1, SP, CGRP Immunofluorescence and IB4-SAP
Diminishes IB4 Immunofluorescence in the Spinal Cord Dorsal Horn
Immunofluorescent imaging was focused on lamina corresponding to lamina I – IV/V as
indicated in the map (Fig. 2.4A). High resolution images of lamina I-II demonstrate that DAPI
immunofluorescence (blue) does not overlap with IB4 (green Fig. 2.4B-D)) or TRPV1 (red, Fig.
2.4B); SP (red, Fig. 2.4C) or CGRP, Fig. 2.4D). A representative image demonstrating the regions
of interest used to calculate intensity ratios for immunofluorescence in lamina I (TRPV1, SP, or
CGRP; L1) and lamina 2 (IB4; L2) and the corresponding control regions (L1con, L2con) in the
deep dorsal horn (Fig. 2.4E). Representative images demonstrating co-immunofluorescent stains
for TRPV1 (red)/IB4 (green) (Fig. 2.4F); SP/IB4 (Fig. 4G); and CGRP/IB4 (Fig. 2.4H) in the spinal
dorsal horn from control treated rats demonstrate similar immunofluorescent patterns to
previous reports (Yaksh, Farb et al. 1979, Vulchanova, Olson et al. 2001, Cavanaugh, Lee et al.
2009). Immunofluorescence for TRPV1, SP and CGRP appear in the lamina I region and IB4
immunofluorescence is observed in lamina II region of the spinal cord dorsal horn.
Representative images of co-immunofluorescent stains for TRPV1 and IB4 in the spinal dorsal
horn of an IB4-SAP treated rat (Fig. 4I) demonstrate that IB4-SAP diminished IB4
immunofluorescence as reported in previous publications (Vulchanova et al., 2001).
Representative images from spinal dorsal horns of capsaicin treated rats demonstrate
elimination of terminals expressing TRPV1 (Fig. 2.4J), SP (Fig. 2.4K) and CGRP (Fig. 2.4L) without
significant alteration of IB4 immunofluorescence.
Intensity ratios of immunofluorescence confirmed that IB4-SAP significantly diminished
IB4 immunofluorescence compared to control samples (Fig. 4M, *p<0.05 vs control). IB4-SAP did
not alter immunofluorescence for TRPV1 immunofluorescence (Fig. 2.4M). TRPV1 intensity
ratios confirm that capsaicin eliminated TRPV1 immunofluorescence, with values dropping to
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96.21 ±12.22 % of the internal control ROI (Fig. 2.4N, **p<0.01 vs control). Capsaicin did not
alter the immunofluorescence of IB4 (Fig. 2.4N, p>0.05 vs control). SP intensity ratios
demonstrate that capsaicin eliminates SP values (Fig. 2.4O, **p<0.01 vs control), with mean
intensity ratio dropping to 124.71 ± 11.19 % of the control ROI, a value not different from 100%
(p>0.05 vs null hypothesis). Capsaicin did not alter IB4 immunofluorescence compared to
control treated samples (Fig. 2.4O, p>0.05 vs control). CGRP intensity ratios demonstrate that
capsaicin significantly diminishes CGRP values compared to control treated samples (Fig. 2.4P,
*p<0.05 vs control), although the values remain significantly elevated compared to 100% control
ROI (p<0.05 vs null hypothesis. IB4-SAP did not alter immunofluorescence of CGRP compared to
control treated samples (Fig. 2.4P).
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Figure 2.4. Capsaicin Eliminates TRPV1, SP and CGRP Immunofluorescent Staining and IB4-SAP
Diminishes IB4 Immunofluorescence in the Spinal Dorsal Horn.
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Figure 2.4. (continued). Capsaicin Eliminates TRPV1, SP and CGRP Immunofluorescent Staining and IB4SAP Diminishes IB4 Immunofluorescence in the Spinal Dorsal Horn. A. Spinal map from The Rat Brain in
Stereotaxic Coordinates, Fourth Edition, Paxinos and Watson (Paxinos and Watson, 1998). B. Representative
40x image inset from panel F of DAPI (blue), IB4 (green) conjugate fluorescence and TRPV1 (red)
immunofluorescence, indicating a lack of overlap between IB4, TRPV1 and DAPI signal in a control animal.
Images were collected using a single optical section. C. Representative 40x image inset from panel G. of
DAPI (blue), IB4 (green) conjugate fluorescence and SP (red) immunofluorescence, indicating a lack of
overlap between IB4 SP and DAPI signal in a control animal. D. Representative 40x image inset from panel
H. of DAPI (blue), IB4 (green) conjugate fluorescence and CGRP (red) immunofluorescence, indicating a lack
of overlap between IB4, CGRP and DAPI signal in a control animal. E. Representative image demonstrating
regions of interest (ROI) used for calculation of intensity ratios. For TRPV1, SP, and CGRP, intensity values
from an oval ROI targeting a section of lamina 1 (L1) was divided by intensity values from an oval ROI in the
deeper lamina L1 control (L1con). For IB4 immunofluorescence, a circle targeting a section of lamina 2 (L2)
was divided by L2 control (L2con). This provides a ratio of the target area of interest divided by an internal
control. F. Representative 20x image demonstrating TRPV1 (red) and IB4 (green) immunofluorescence in a
section from a control rat. G. Representative 20x image demonstrating immunofluorescence for SP (red)
and IB4 (green) in a spinal cord section from a control treated rat. H. Representative 20x image
demonstrating immunofluorescence for CGRP (red) and IB4 (green) in a spinal cord section from a control
treated rat. I. Representative image demonstrating immunofluorescence of TRPV1 (red) and reduction of
IB4 (green) immunofluorescence. J. Representative image demonstrating lack of TRPV1 (red)
immunofluorescence following treatment with capsaicin with IB4 (green) immunofluorescence remaining.
K. Representative image demonstrating lack of SP (red) immunofluorescence following treatment with
capsaicin with IB4 (green) immunofluorescence remaining. L. Representative image demonstrating absence
of CGRP (red) immunofluorescence in capsaicin treated rats with IB4 (green) immunofluorescence
remaining. M. Intensity ratios demonstrate that there is a significant reduction in IB4-binding fibers within
the spinal cord of IB4-SAP treated rats compared to controls. No significant difference was observed in
capsaicin treated rats compared to controls. All dashed lines represent ratio value (100) at which there is
equivalent mean grey values for L1/L1con or L2/L2con. All graphs represent mean +/- SEM, *p<0.05 vs
control; **p<0.01 vs control. N. Intensity ratios demonstrate that there is a significant reduction in TRPV1
immunofluorescence in capsaicin treated rats compared to controls. No difference in TRPV1 intensity ratios
were observed in IB4-SAP treated rats. O. Intensity ratios demonstrate a significant reduction in SP
immunofluorescence compared to control, no difference in SP immunofluorescence is observed in IB4-SAP
treated rats compared to controls. P. Intensity ratios demonstrate a significant reduction in CGRP
immunofluorescence in capsaicin treated rats compared to controls with no significant change in CGRP
immunofluorescence in the IB4-SAP treated rats. Scale bar indicates 100 mm.

2.4.5. Functional Blockade of IB4-binding, not TRPV1-expressing Fibers Blocks BTP
The effects of capsaicin-induced elimination of TRPV1+ fibers or IB4-SAP ablation of IB4
binding fibers on tumor-induced tactile hypersensitivity were measured as outlined by the flowchart (Fig. 2.5A). Cancer-induced tactile hypersensitivity was blocked by spinal administration of
IB4-SAP, but not spinal capsaicin (Fig. 2.5A). Cancer-treated rats that had received spinal
administration of vehicle or SAP developed tactile hypersensitivity by D12 post-cancer
implantation (Fig. 2.5A, ***p<0.001 vs BL). Tumor-bearing rats treated with spinal capsaicin
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demonstrated similar tactile hypersensitivity compared to the vehicle control (Fig. 2.5A,
***p<0.001). In contrast, rats treated with spinal IB4-SAP demonstrated tactile withdrawal
thresholds that were significantly higher than the vehicle treated rats (Fig. 2.5A, #p<0.05 vs
vehicle), and not significantly different from pre-tumor baselines (Fig. 2.5A, p>0.05 vs BL)
The effects of capsaicin-induced elimination of TRPV1+ fibers or IB4-SAP ablation of IB4
binding fibers on movement-evoked BTP was determined using a single-trial conditioning
protocol following spinal injection of capsaicin, IB4-SAP or the appropriate vehicle as outlined by
the flow-chart (Fig. 2.5B). Movement failed to induce CPA in sham-treated rats irrespective of
spinal treatment with capsaicin or IB4-SAP (Fig. 2.5B, p>0.05 vs 0). Cancer-treated rats that
received spinal administration of the appropriate intrathecal vehicle demonstrated movementinduced CPA as demonstrated by a significantly lower difference score compared to the shamtreated rats (Fig. 2.5B, *p<0.05 vs sham). Tumor-bearing rats that received spinal capsaicin
demonstrated movement-induced CPA represented by a significantly lower difference score
compared to sham-treated rats (Fig. 2.5B, **p<0.01 vs sham). Notably, the difference scores of
the spinal vehicle and spinal capsaicin treated tumor-bearing rats did not differ (p>0.05,
Bonferroni t-test). Cancer-bearing rats that received spinal IB4-SAP failed to show movementinduced CPA, demonstrated by difference scores that did not differ from sham control rats (Fig.
2.5B, p>0.05).
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Figure 2.5. Tactile Hypersensitivity and Movement-induced Breakthrough Pain is Dependent on IB4
Positive Fibers. A. Spinal administration of IB4-SAP attenuated tumor-induced tactile hypersensitivity.
Vehicle treated tumor-bearing rats demonstrated tactile hypersensitivity with paw withdrawal thresholds
significantly lower than pre-cancer implantation baselines, ***p<0.01 vs. BL. Ablation of IB4-binding fibers
by spinal administration of IB4-SAP attenuated tumor-induced tactile hypersensitivity with paw withdrawal
thresholds significantly higher compared to SAP control rats, #p<0.05 vs. SAP. Spinal ablation of TRPV1
expressing terminals in the spinal dorsal horn by spinal administration of capsaicin failed to eliminate
tumor-induced tactile hypersensitivity with paw withdrawal thresholds significantly lower than pre-cancer
baselines, ***p<0.01 vs. BL. B. Group comparison of difference scores demonstrates that movement
induced CPA in vehicle treated rats compared to sham controls, *p<0.05 vs sham. Ablation of IB4-binding
fibers blocked movement-induced CPA. In contrast, ablation of TRPV1 expressing terminals in the spinal
dorsal horn failed to block movement-induced CPA **p<0.01 vs. shams. Graphs show mean
SEM, n
(sham)= 10 capsaicin, 10 IB4-SAP; n (cancer) = 9 SAP, 8 capsaicin vehicle, 11 IB4-SAP, 10 capsaicin.
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2.4.6. Ablation of IB4 or TRPV1-expressing Fibers Did Not Alter Tumor-induced Bone
Remodeling.
Radiograph images show representative bone remodeling illustrating the rating scale
that was used to determine tumor-induced bone remodeling D13 post-surgery (Fig. 2.6A). Rats
treated with spinal capsaicin or with IB4-SAP did not demonstrate altered bone remodeling
compared to their respective vehicle controls (Fig. 2.6B).

2.5. Discussion
We have developed and characterized a novel measure of movement-evoked BTP in the
setting of morphine-controlled ongoing pain in a rat model of cancer-induced bone pain. This
measure uses the motivational aspects of pain averseness to capture a movement-triggered
transient increase in the apparent intensity of cancer-induced bone pain. When this event is
paired with a distinctive context, rats show avoidance of the chamber in a subsequent trial
producing conditioned place aversion (CPA). This approach is consistent with clinical
observations in which patients with bone metastases report transient increases in pain intensity
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that can be triggered by voluntary (e.g. switching positions) or involuntary (e.g. cough)
movement. Notably, this is relatively common in patients with skeletal metastases and can
diminish daily activity of these patients due to their desire to avoid triggering BTP, greatly
diminishing these patients’ quality of life (Mercadante 2015).

2.5.1. Reverse Translation of BT Pain
Hind limb movement prior to placement into the pairing chamber produced CPA
selectively in tumor bearing rats indicating that the movement-triggered increase in pain is
aversive and provides learning that motivates animals to avoid that chamber. Movementinduced CPA is observed in rats undergoing morphine treatment previously demonstrated to
control tumor-induced ongoing pain (Remeniuk, Sukhtankar et al. 2015). Notably, the defining
feature of BTP is that it occurs in patients on opioid medication that is controlling the persistent
background pain (Portenoy and Hagen 1989, Portenoy and Hagen 1990, Mercadante 2015).
Moderate-to-severe cancer pain is often treated with extended release opioids that engage the
mu-opioid receptor (MOR) (Paice and Ferrell 2011, Mercadante 2015). Therefore, our
observations show reverse translation from the clinic to the rat model of cancer-induced bone
pain. Opioids predominately act to modulate affective dimensions of pain by actions at opioid
receptors within the brain (Fields 2004, Navratilova, Atcherley et al. 2015). Additionally, MOR
agonists may act at receptors localized on primary afferent nociceptors and in the spinal cord
(Fields 2004, Ossipov, Dussor et al. 2010). The clinical observations and our data indicate that
movement likely engages additional nociceptive drive that is insensitive to MOR agonists at
doses that control ongoing pain.
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2.5.2. Potential Role of Peripheral and Central Sensitization
Nociceptors are likely to be sensitized as a consequence of tumor or immune-derived
factors within the intramedullary space (Mantyh 2013, Falk and Dickenson 2014, Mantyh 2014).
In addition, the ongoing pain from the tumor bearing bone can produce spinal sensitization
(Urch, Donovan-Rodriguez et al. 2003, Yanagisawa, Furue et al. 2010, Falk, Bannister et al. 2014,
Mantyh 2014). We propose that both peripheral and central sensitization amplifies nociceptive
input from movement-evoked stimulation of the tumor-bearing limb resulting in a transient
increase in pain intensity that occurs in the setting of opioids controlling the persistent
background ongoing pain. Preclinical studies demonstrated that spinal cord neurons show
enhanced responses to evoked stimuli and wide dynamic range neurons display an increase in
receptive field, hallmarks of spinal sensitization (Urch, Donovan-Rodriguez et al. 2003, Falk,
Bannister et al. 2014). These changes are observed in the setting of morphine and have been
proposed to underlie opioid resistant allodynia and BTP (Urch, Donovan-Rodriguez et al. 2005).
Such signaling likely increases the intensity of pain experienced, thereby also increasing the
affective/motivational component of the tumor-induced pain (Fields 1999). The transient
increase in pain and related unpleasantness surpasses the ability of the onboard dose of
morphine to control the pain resulting in the requirement for additional rapid onset opioids as
seen in the clinical setting, i.e., BTP.

2.5.3. Mechanistic Difference Between Initiation and Maintenance of BTP
Sensory input from the tumor-bearing bone is required for initiation of BTP. Saphenous
nerve block administered 10 min prior to movement of the tumor-bearing hind limb prevented
movement-induced BTP and induced CPP. This observation indicates that the peripheral nerve
block not only prevented the movement-triggered BT pain, but also blocked tumor-induced
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ongoing pain. Therefore, the rats experience pain relief in the lidocaine/movement paired
chamber. Thus, pain relief is the motivating factor that results in the increased time spent in the
chamber paired with nerve block and movement. This replicated our previous findings that
peripheral nerve block produces relief from tumor-induced ongoing bone pain (Remeniuk,
Sukhtankar et al. 2015). In contrast, blockade of sensory input following hind limb movement
failed to block CPA. These observations suggest that once established, blocking sensory input
from the tumor-bearing bone is no longer sufficient to reverse movement-induced BTP. We
speculate that one possible explanation is the engagement of reverberating circuits that
maintain activity within the spinal cord, or between the spinal cord and central nuclei,
independently from peripheral input. Such altered processing could account for prolonged
withdrawal responses to noxious pinprick as reported following chronic constriction injury of the
sciatic nerve (Bennett and Xie 1988). A reverberating circuit between spinal cord dorsal horn
and the dorsal reticular nucleus within the caudal medulla has been proposed to promote
enhanced response capacity of spinal neurons to noxious stimulation and implicated in acute
pain responses to noxious heat and formalin (Lima and Almeida 2002). Such reverberating
circuitry may be critical in maintaining BTP and deserves further study.

2.5.4. Separate Roles of TRPV1+ and IB4-binding Fibers in BT Pain
The observation that saphenous nerve block prevents movement-induced CPA suggests
that initiation of BTP is dependent on sensory input from the tumor-bearing bone. Our data
indicate that IB4 binding fibers mediate movement-induced breakthrough cancer pain and
referred tactile hypersensitivity, whereas TRPV1+ fibers do not. These observations are
consistent with studies demonstrating that functional blockade of TRPV1+ fibers fails to alter
responses to noxious mechanical stimulation and tactile hypersensitivity (Ossipov, Bian et al.
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1999, Cavanaugh, Lee et al. 2009, Scherrer, Imamachi et al. 2009, Okun, DeFelice et al. 2011).
Our findings are also consistent with studies demonstrating that ablation of IB4 binding fibers
blocks tactile hypersensitivity in preclinical models of inflammation, neuropathic pain and
cancer-induced orofacial pain (Stucky and Lewin 1999, Vulchanova, Olson et al. 2001, Joseph,
Chen et al. 2008, Cavanaugh, Lee et al. 2009, Ye, Dang et al. 2012). Given these data, we
propose that movement recruits TRPV1 negative nociceptive fibers resulting in an increased
pain signal that initiates an episode of BTP that is not adequately prevented by peripheral or
central actions of opioids used to control background persistent ongoing pain.
Following capsaicin, we saw reduced CGRP and complete elimination of SP
immunofluorescence and TRPV1+ fiber terminals in the spinal dorsal horn, observations
consistent with previous studies (Yaksh, Farb et al. 1979, Cavanaugh, Lee et al. 2009). IB4Saporin eliminated IB4 immunofluorescence indicating elimination of input from IB4 binding
sensory afferent fibers. The absence of sensory input by these nerve terminals within the L3
segment of the lumbar spinal cord likely eliminates much of the sensory input from the
saphenous nerve, previously demonstrated to be the primary innervation for the rat tibia
(Ivanusic 2009, Kaan, Yip et al. 2010). Previous studies have suggested a lack of IB4 binding
fibers in mouse models of cancer-induced bone pain (Jimenez-Andrade, Mantyh et al. 2010,
Castaneda-Corral, Jimenez-Andrade et al. 2011). In contrast, retrograde labeling techniques
indicate that IB4 binding fibers do innervate the intramedullary space and the periosteum of the
rat tibia (Ivanusic 2009, Kaan, Yip et al. 2010). It is unclear whether the discrepancies between
these reports are due to methodological differences or species differences. Irrespective of
whether IB4 binding fibers innervate the bone, it is likely that sensory input from tissue
surrounding the bone may also contribute to the initiation of movement-evoked BTP.
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Spinal capsaicin was demonstrated to reduce SP content within sensory fibers within
seven days (Yaksh, Farb et al. 1979). Such observations indicate that the capsaicin-induced
blockade of sensory input by TRPV1+ fibers in our studies occurred prior to tumor cell injection
and subsequent growth of tumor cells within the tibia, thereby eliminating ongoing input from
TRPV1+ nociceptive fibers throughout the experiment. Our data demonstrate that elimination of
signaling by TRPV1+ fibers is not sufficient to block movement-induced CPA or referred pain as
measured by tactile hypersensitivity in the ipsilateral hind paw. This is consistent with other
observations that long-term desensitization of TRPV1 expressing fibers by systemic
administration of the ultra-potent capsaicin analogue resiniferotoxin (RTX) blocks thermal and
ongoing pain, but fails to block development of tactile hypersensitivity in other chronic pain
models (Ossipov, Bian et al. 1999, King, Qu et al. 2011, Okun, DeFelice et al. 2011). Our
observations of hind paw tactile hypersensitivity, a measure of referred pain, and initiation of
BTP by a normally non-noxious stimulus suggest that the tumor bearing rats developed central
sensitization in the absence of input from TRPV1 expressing fibers. Previous studies have
demonstrated that development of central sensitization is dependent on input from nociceptive
afferents, presumably C-fibers (Gracely, Lynch et al. 1992, Sang, Gracely et al. 1996). It is likely
that sustained input from non-TRPV1 nociceptive fibers is sufficient to develop central
sensitization that mediates hypersensitivity to non-noxious mechanical stimulation.
Further research is warranted to examine subpopulations of sensory fibers in relation to
bone pain. As noted above, single cell RNA sequencing studies have demonstrated that there
are many potential subcategories of sensory fibers, with as many as 11 types of sensory neurons
in the mouse DRG (Usoskin, Furlan et al. 2015). Moreover, some studies have indicated overlap
of CGRP in IB4 binding neurons in species and site-specific patterns (Aoki, Ohtori et al. 2005,
Hwang, Oh et al. 2005, Price and Flores 2007). Future studies using techniques such as single cell
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capture and RNAseq of DRG cells that have been retrogradely labeled from the bone,
periosteum and perhaps the surrounding tissue are necessary to clarify potential subpopulations
of IB4 binding neurons that may mediate BT pain. Additionally, studies examining corresponding
protein expression and the relative functional contribution of observed subpopulations of fibers
innervating the bone are necessary.
Our data indicate distinctive mechanisms underlying tumor-induced ongoing and BTP.
As with all preclinical studies, future studies are required to show reproducibility of these
findings across different strains and species. This highlights the need to determine whether
therapeutic strategies currently under development block both ongoing and BTP. Notably,
advances in non-opioid therapies for ongoing pain are urgently needed to diminish reliance on
opioids irrespective of whether they effectively block BTP. Alternatively, novel compounds
targeting IB4 binding nociceptors may improve pain management for cancer pain patients and
other patient populations suffering from BTP that is inadequately treated by currently available
medications.
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CHAPTER 3
UTILIZING OPTOGENETICS TO INVESTIGATE THE ROLE OF PERIPHERAL NEURONS INVOLVED IN
CANCER-INDUCED BONE PAIN IN THE MOUSE

3.1. Introduction
3.1.1. Background of Fiber Types in Cancer-induced Bone Pain
Previous work by Patrick Mantyh and colleagues demonstrated a critical role for
peptidergic nociceptors (i.e. CGRP, SP, TRPV1 expressing) in the role of CIBP. As mentioned
previously, both through the use of IHC and a transgenic reporter mouse, work by this group
had demonstrated the presence of CGRP+ fibers in naïve bone, and pathological sprouting of
these fibers following cancer cell implantation and growth (Mach, Rogers et al. 2002, JimenezAndrade, Mantyh et al. 2010). Work by this group also demonstrated that sequestration of NGF
by a primary antibody results in diminishment of pathological sprouting of these fibers and
evoked pain behaviors (Jimenez-Andrade, Bloom et al. 2010). These findings coincide well with
observations in the mouse demonstrating a lack of non-peptidergic nociceptors (IB4-binding,
P2X3 and/or MrgD expressing) in the innervation of the bone and periosteum, leading much of
the CIBP field to believe they play little role in communicating pain in preclinical models of CIBP
in the mouse (Jimenez-Andrade, Mantyh et al. 2010). Pharmacological work using a primary
antibody to NGF and an antibody that targets the cation channel P2X3 to investigate a
comparative role for peptidergic vs non-peptidergic nociceptors was also investigated (Guedon,
Longo et al. 2016).
The role for each antibody, being to either sequester NGF as previously described in Pat
Mantyh’s work, or presumably block the ion passage pore in the P2X3 channel, allowing for a
side by side comparison in behavioral changes that these two agents may have. This was the
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first attempt to assess the role of these fibers side by side in a behavioral paradigm in CIBP. This
publication demonstrated a role for blocking the P2X3 channel in alleviating tactile
hypersensitivity that develops after tumor growth consistent with the belief that nonpeptidergic nociceptors convey mechanical nociceptive input (Cavanaugh, Lee et al. 2009).
While sequestration of NGF ameliorated tactile hypersensitivity and measures of “skeletal pain”
quantified by weight bearing away from the cancer afflicted limb, rearing, and nocifensive
behaviors typical of CIBP in preclinical models (Guedon, Longo et al. 2016). This latter
observation is likely due to the blunting of pathological sprouting of TrkA+ (and CGRP+) fibers
within the bone and the role this plays in CIBP, as work has demonstrated this treatment does
not blunt tumor growth or bone destruction.
While interesting, the most provocative piece of data shared in this body of work was
the ability for the NGF antibody to reverse off-set weight bearing, and the failure of the P2X3
antibody to do so. One interpretation of this as the authors concluded, is that blockade of P2X3
fails to alleviate pain from the bone, however, while convincingly reliable, it is still debated
whether weight bearing is effective in assessing ongoing/evoked pain from a pathological joint
or bone. Additionally, this work did not directly assess the 2 populations of fibers themselves
e.g. peptidergic vs non-peptidergic. Rather, this work investigated the function of the P2X3
channel specifically, which is primarily expressed on non-peptiderigc fibers, and added to the
body of work supporting the efficacy of NGF sequestration in reducing CIBP. This leaves the
question of whether or not the non-peptidergic fibers themselves play a role in measures of
CIBP, as blockade of one receptor population on a neuron does not necessarily silence the entire
neuron’s function. Our work (Havelin et al. 2017) in the rat implicates a role for fibers that bind
IB4 (i.e. non-peptidergic) in evoked BTP.
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However, there is the possibility that these observations are a result of a species
difference. Differences in the populations of fibers has previously been described between
species and anatomical location (DRG versus TG) by Price et al 2009, and differing innervation
patterns reported by Ivanusic 2009, and Kaan et al. 2010 in the rat vs Pat Mantyh’s work in the
mouse (Price and Flores 2007, Ivanusic 2009, Kaan, Yip et al. 2010). Classically peptidergic fibers
have been implicated in driving thermal nociception and spontaneous pain while nonpeptidergic fibers have been implicated in mechanical pain in both mouse (Cavanaugh, Lee et al.
2009, Scherrer, Imamachi et al. 2009) and rat studies (Ossipov, Bian et al. 1999, Vulchanova,
Olson et al. 2001, King, Qu et al. 2011, Havelin, Imbert et al. 2017). Therefore, we wanted to
examine whether the differential role of peptidergic and non-peptidergic fibers in the rat
translates to the mouse. The potential for analgesic targets that may exist on the nonpeptidergic population of fibers that inhibit the fiber rather than a single channel (i.e. the P2X3
channel) would be a worthwhile discovery. Further, lack of evaluation of peptidergic fibers in
alleviating ongoing or breakthrough pain in models of cancer-induced bone pain sparked our
interest in investigating the potentially differing roles these fiber populations may play in
treating cancer-induced bone pain.

3.1.2. Justification of Targeting Subpopulations of Sensory Neurons
Nav1.8 Expressing Fiber Population. Nav1.8 is a voltage gated sodium channel that
allows the conductance of sodium in a tetrodotoxin-resistant manner and is expressed on
peripheral neurons (Shields, Ahn et al. 2012). Nav1.8 has been used as a selective marker for
nociceptive neurons for at least 10-15 years, and has been implicated to be critical to
nociception in a number of publications (Akopian, Souslova et al. 1999, Nassar, Stirling et al.
2004). Interesting clinical correlates have been demonstrated, in which gain of function
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mutations in human Nav1.8 correlate with some patients that experience “painful neuropathy”
(Han, Huang et al. 2016). The generation of the Nav1.8-cre mouse by John Woods group has
allowed for the extensive use of the cre-lox system to target these nociceptive neurons for
nearly 2 decades (Nassar, Stirling et al. 2004). While the original publication determined a
critical role of the Nav1.7 channel in nociception normally expressed on Nav1.8 expressing
fibers, subsequent work has highlighted the role of the fibers that express Nav1.8. While its
utilization as a marker by crossing the cre mouse with a reporter line (cre-dependent reporter)
for purely nociceptive neurons has its limitations as demonstrated by Shields et al. 2012,
functional evaluation and involvement of Nav1.8 fibers in nociception implies their direct
involvement in transducing nociceptive stimuli (Daou, Tuttle et al. 2013, Uhelski, Bruce et al.
2017). Interestingly, while in models of neuropathic injury some reports demonstrate a down
regulation of Nav1.8 channels (Laedermann, Pertin et al. 2014) there are alternative reports that
suggest in models of CIBP Nav1.8 expression actually increases (Liu, Yang et al. 2014). Beyond
this, due to the well-characterized role of Nav1.8 fibers in transducing nociceptive input in
preclinical models of pain (Bonin, Wang et al. 2016, Daou, Beaudry et al. 2016, Uhelski, Bruce et
al. 2017), we hypothesized that transiently optogenetically silencing this population of fibers
would block ongoing pain in our model of CIBP.
MrgD Expressing Fiber Population. Our interest in MrgD expressing fibers lies not
necessarily in the function of the receptor, but the function of the cells that express MrgD.
Although the effects of activating or inhibiting MrgD are not ignored in the grand scheme of our
work. The GPCR MrgD was first reported by Dong et al. 2001 (Dong, Han et al. 2001) along with
a number of other GPCRs in the Mrg family. Unique expression patterns of the protein were
reported in sensory neurons within the DRG and TG in neonatal and adult mice, with special
attention being given to a seeming overlap of MrgD expression in nociceptors (Dong, Han et al.
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2001). Critical to its use as a cre-line, the authors demonstrated that between development and
adulthood in the mice, expression patterns of MrgD became more restricted (Dong, Han et al.
2001). Analysis of expression between preclinical species was performed by Zylka et al 2003,
who reported many of the same findings, including MrgD expression overlap with the IB4binding population of sensory neurons in the mouse, as well as overlap of expression with the
GDNF-receptor c-RET (Zylka, Dong et al. 2003). Interestingly while in the mouse the Mrg family
of GPCRs can be subdivided into the MrgA, MrgB, MrgC and MrgD families, the rat and gerbil
have a much less diverse repertoire of this family of GCPRs (Zylka, Dong et al. 2003). While
humans do have an MrgD ortholog, potentially allowing rapid translational pharmacological
work from preclinical models, humans have a set of “MrgX” genes that do not have “clear”
orthologs to rodents but closely resemble the MrgA subfamily of Mrg GPCRs, highlighting the
potential for translational work between species (Zhang, Taylor et al. 2005).
The generation of a transgenic fluorescent reporter mouse by Zylka et al. 2005,
expanded on the previous work utilizing RNA specific in-situ hybridization. Namely that
expression of MrgD appeared to be restricted to non-peptidergic sensory neurons, with distinct
lack of co-expression with markers for peptidergic sensory neurons such as CGRP and TRPV1, an
observation that may not directly translate to primates let alone humans (Zhang, Taylor et al.
2005, Zylka, Rice et al. 2005). Work by this group demonstrated that MrgD innervation is unique
to a specific layer within the skin, the stratum granulosum, as well as the stratinum gelatinosa of
the spinal cord (lamina II) within the spinal cord (Zylka, Rice et al. 2005). The authors of this
paper demonstrated that protein expression of MrgD coincided well with the RNA transcription
previously reported (Dong, Han et al. 2001). Wang and Zylka 2009, demonstrated that synaptic
terminals from MrgD afferent fibers were capable of generating excitatory postsynaptic currents
in a number of types of lamina II spinal cord neurons in a monosynaptic fashion (Wang and Zylka
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2009). In line with this work, Braz et al. 2005 investigated where this population of neurons
project into higher orders of the CNS. Finding that projections from DRG cells selectively labeled
by Nav1.8 induced expression of wheat germ agglutinin, project to interneurons in lamina II of
the spinal cord dorsal horn. Beyond this, projections from these interneurons continue on to
lamina V, and the amygdala, hypothalamus and other regions of the CNS, reportedly unique
from the projections from the peptidergic class of peripheral nociceptors (Braz, Nassar et al.
2005).
While much is still unknown about implications of activating the MrgD receptor itself
(other than inducing itch), some work has uncovered ligands capable of activating this
population of neurons in-vitro and ex-vivo (Liu, Sikand et al. 2012). Beta-alanine a small amino
acid, appears to be the endogenous ligand able to activate the MrgD receptor, as reports
suggest it has nearly a 10 fold lower EC50 to GABA, its closest competitor (Shinohara, Harada et
al. 2004). This work additionally indicated that activation of MrgD may result in the intracellular
activation of Gq and Gi classes of G-proteins, on small diameter and nociceptive cells, lending
authors to believe the possibility that activation of MrgD plays a role in regulating nociceptive
signals in the periphery, differential to that of GABA (Shinohara, Harada et al. 2004). More
diffuse investigation of MrgD expressing neurons has revealed that they have many of the
electrophysiological hallmarks of nociceptors as well. Dussor et al. 2008 revealed that these
neurons respond to extracellular ATP and can generate “long-duration action potentials” that
are TTX-resistant, and that these cells possessed calcium currents that were inhibited the MOR
agonist DAMGO, an effect blocked by naloxone. These findings led the authors to the conclusion
that MrgD expressing fibers likely respond to keratinocyte release of ATP (Dussor, Zylka et al.
2008). Due to structural and anatomical descriptions of these fibers compared to peptidergic
(CGRP expressing), they may play a unique role in transducing nociceptive stimuli from the skin
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(Dussor, Zylka et al. 2008). An interesting body of work from Rau et al. also demonstrated that
knocking out MrgD in mice resulted in decreased sensitivity to heat, mechanical sensitivity, cold,
and demonstrated in-vitro that activation of MrgD via beta-alanine results in the hyper
excitability of the neuron (Rau, McIlwrath et al. 2009).
While investigation of the cellular mechanisms of the MrgD receptor and MrgD
expressing fibers has garnered interesting findings and implications to the pain field, little work
has been published as to the role of the intact fiber in behavioral models. This may be a result of
the challenges of effectively targeting these cells in a whole living animal, or a repercussion of
the approaches used to target these cells in-vivo. MrgD, has a proposed >90% overlap in identity
with IB4-binding neurons which was classically used to characterize non-peptidergic fibers
(Cavanaugh, Lee et al. 2009). This population of neurons, much like the IB4-binding neurons, has
been shown to be critical in the transduction of mechanical nociception, while not directly being
involved in the transduction of thermal nociceptive input from the periphery (Cavanaugh, Lee et
al. 2009). This may imply a unique function for these neurons (Cavanaugh, Lee et al. 2009).
Another convincing piece of work targeting these cells in whole animals was a side by side
comparison performed by Beaudry et al. 2017, where authors demonstrated that optogenetic
activation of TRPV1 expressing neurons resulted in noxious behavior and an aversive state, but
activation of MrgD afferents was not aversive to the animals (Beaudry, Daou et al. 2017).

Preclinical evidence in the mouse suggests that MOR and DOR may be differentially
expressed on nociceptive fiber subtypes and play differing roles in alleviating modalities of pain
in the mouse (Scherrer, Imamachi et al. 2009). Given the observations by Scherrer’s group, we
tested the hypothesis that the administration of the peptidergic MOR agonist DAMGO would
alleviate ongoing pain in a model of CIBP in the mouse, whereas the peptidergic DOR agonist
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Deltorphin II would fail to do so. The basis for this hypothesis relies on previous implications of
the role of peptidergic, presumably MOR expressing nociceptive fibers, in the periphery
transducing pain from the cancer-afflicted limb (Jimenez-Andrade, Mantyh et al. 2010) and
clinical observations that MOR agonists can block persistent cancer-induced bone pain (Paice
and Ferrell 2011, Mercadante and Bruera 2016).
It was our belief that due to MOR agonists inability to treat breakthrough pain, and the
potential for differential expression of MOR and DOR on nociceptive fibers we would see a
distinct difference in MOR and DOR agonists to ameliorate ongoing versus breakthrough pain
(Havelin, Imbert et al. 2017). Here we report our utilization of both classic and novel approaches
to investigate and demonstrate the differential effects on pain behaviors these fiber populations
have in cancer-induced bone pain. Due to the lack of published work able to directly assess the
role of non-peptidergic fibers, and our success in implicating a role for non-peptiderigc fibers in
a model of BTP in the rat, we chose to use a pharmacological and optogenetic approach to
selectively and transiently silence targeted populations of nociceptive fibers. This approach
would allow us to address some of the short-comings of our work in the rat, centered mainly
around limitations associated with ablating neurons and the responsive neural adaptations that
may arise after.
Working with our collaborators at the Canadian Neurophotonic Center in Quebec, we
were able to selectively silence the fibers in the Nav1.8-cre and inducible Mrgpd

CreERT2

(MrgD-

cre) line of mice, by selectively expressing the light sensitive ArchT pump in these fibers. Initial
work utilized a selectively cre-activated Flex viral vector to activate and induce expression of the
ArchT cassette, while subsequent work utilized the ArchT transgenic mouse from Jackson labs.
By delivering light to the lumbar section of the spinal cord using methods published by Bonin et
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al. 2016, we have successfully modified nociceptive behavioral responses both in a model of
CIBP and AITC-induced nociception.
We attempted to adapt our measure of hind limb movement-induced breakthrough
pain that we previously characterized in the rat (Havelin, Imbert et al. 2017) to the mouse.
However, this proved more difficult than simply repeating the approach utilized in the rat and
instead characterized novel behavioral measures in response to hind limb movement.

3.1.3. Brief Overview of Utility of Optogenetics in the Study of Pain
The relatively recent integration of light sensitive ion channels and pumps into the field
of neuroscience research has undoubtedly been one of the largest advances in decades. The
ability to selectively activate or inhibit a neuron with spatial and temporal precision will play an
immense role in furthering our understanding of how the nervous system functions both under
“normal” circumstances and pathological ones. Additionally, the inability to resolve spatial and
temporal challenges with tools that have been widely used has limited the progress of the pain
field in locating anatomical and molecular changes in circuitry due to pathological pain. Perhaps
one day this technology can also be used to treat pathologies in the clinic. To better understand
where these tools came from and likely where they will go in the near future, it may help to give
some background into their function and history. Several excellent reviews already exist
encompassing the promising adventure and tale of optogenetics and its utilization in pain
research (Copits, Pullen et al. 2016, Xie, Wang et al. 2018). Rather, I will have a brief explanation
highlighting some key features that contribute to our utilization of this tool in studying CIBP.
The first critical piece of optogenetics was the discovery of microbial opsins, proteins
isolated from various single celled organisms that respond with varying efficiencies to different
wavelengths of light (Copits, Pullen et al. 2016). As a result of their native function, ion transport
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across a membrane in response to light, they have lent themselves to a very suitable use in
neuroscience research. Depending on the opsin, activation can result in a net increase in
positive charge within a neuron, causing it to depolarize and become activated. Two opsins used
for this are channel rhodopsin and the improved version channel rhodopsin 2 (Daou, Tuttle et al.
2013, Daou, Beaudry et al. 2016, Browne, Latremoliere et al. 2017). These 2 opsins respond to
blue light and once activated allow cations to flow into the cell causing a wave of depolarization.
With application of the correct parameters, it has been reported that this can be used to
generate single action potentials, which when translated to an in-vivo prep, are capable of
generating nocifensive behavioral responses in animal that express ChR2 under the TRPV1
promoter (Browne, Latremoliere et al. 2017).
While one major use of opsins results in the depolarization of neurons, activation of
another major classes of opsins results in a net negative charge in the neuron, resulting in
inhibition of the neuron. Two hyperpolarizing opsins exist and are widely used, the first being
halorhodospin which is activated by yellow light and allows for chloride ions to flow through the
cellular membrane. The other major opsins being archaerhodopsin (Arch) and archt-rhodospins
(ArchT) which are activated by orange to green light and actively pump protons to the exterior
of the cellular membrane. Both of these opsins net function result in the hyperpolarization of
the interior of neurons, resulting in inhibition of the neuron (Xie, Wang et al. 2018). While at
surface level both of the mechanisms of these opsins would seem to work to the same extent,
our work was directed towards the use of the ArchT opsin. This was due to the observation that
activation of halorhodospin can result in a net change in the chloride gradient within a cell,
which in turn allowed for the unintentional depolarization of a cell following exposure to GABA
(Raimondo, Kay et al. 2012). This observation was not made in work with the Arch pump
(Raimondo, Kay et al. 2012). While Arch has been implemented and used successfully to inhibit
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neuronal activity (Copits, Pullen et al. 2016, Daou, Beaudry et al. 2016, Xie, Wang et al. 2018),
our work utilized the optimized ArchT proton cassette described by Han et al. 2011. Han and
colleagues describe the ArchT pump isolated from Halorubrum strain TP009 in their work
comparing to Arch isolated from Halorubrum sodomense, as readily trafficked in mammalian
cells and a more light sensitive tool capable of inhibiting neurons. Work by our collaborators
demonstrated a unique approach for delivery of the ArchT cassette and sight of neuronal
inhibition that aided in the direction of our work, and laid feasibility for our approach in the
mouse (Bonin, Wang et al. 2016).
The next challenge of using optogenetic intervention in an in-vivo setting is the hurdle of
delivery of the opsin of choice as well as light to activate it. Several delivery methods of an opsin
cassette are widely used currently for in-vivo, each with their own advantages and challenges.
The first utilized here in this work and widely by others is through the delivery of a viral vector.
Injection of a viral vector carrying the opsin cassette of interest can either be injected locally to
allow for specific anatomical distribution of the virus or systemically to allow for widespread
expression of the vector. The use of either approach depends on the ultimate goal of the
research to be performed. If investigators wish to target a unique location in the CNS (spinal
cord or brain), viral vector can be specifically delivered to that area and expression of the light
sensitive opsin will be restricted to cell bodies and projections of those bodies. This approach
can also be used to selectively deliver an opsin to a location in the peripheral nervous system,
i.e. a specific portion of the hind paw, which allows for selective expression only in cells with
terminal endings at that location. Alternatively, systemic injection of viral vector allows for
widespread and diffuse expression of the virus, which as in our case, may be more optimal when
targeting a diffuse region of neurons, i.e. the lumbar region of the spinal cord. The inclusion of
Cre-sensitive components in viral cassette construction (loxp sites for flip-excision or stop84

cassette removal) allows for activation of viral vectors within Cre expressing cell populations of
an investigators choice. The alternative to viral delivery of an opsin is the use transgenic animals
that either selectively express an opsin under a specific promoter, or a transgenic animal that
expresses an opsin in a Cre sensitive manner. Depending on the construct of the cassette, viral
delivery of an opsin can also be used to target projections of a specific anatomical location, i.e.
cassettes that jump a single synapse can allow for selective activation of opsins in the
projections of a brain region (Gradinaru, Zhang et al. 2010). While use of transgenic animals
imbue a less complicated technical approach, investigators must rely on breeding their own
animals and ensuring genetic reliability of said colony.
Challenges of using a viral method to deliver an opsin include variables that can alter
concentration of viral vector delivery, this may result in differential delivery and expression of
opsins in tissue which may give rise to unavoidable variability in experiments. This is true of
either localized or systemic injections. Depending on the timing of delivery of the viral vector it
is possible to inadvertently induce long term changes to the immune system that may
complicate or confound results in the future. Additionally, systemic injection of viral vectors may
result in stark differences in opsin protein expression between individual animals, a complicated
variable to account for. These however can also be strengths of the approach of viral vector
delivery. Viral delivery of an opsin can allow for transfection and expression of an opsin beyond
the normal levels of a transgenic animal, allowing for activation of opsins beyond what may be
possible using a transgenic animal. This of course may result in its own confounds to the work at
hand. Viral delivery, localized or systemic, can allow for timed delivery of cre sensitive opsin
cassettes that bypass expansion of genetic activation during development, i.e. TRPV1, which
would be unavoidable in a non-inducible mouse cre line (Daou, Beaudry et al. 2016).
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Unavoidable activation of cre during a transgenic animal’s development may result in opsin
expression in undesired populations of cells in adult animals.
The last hurdle to consider when using optogenetics in an in-vivo approach is the
delivery of light to the opsin at sufficient magnitude to active the opsin. This depends heavily on
the tissue of interest, e.g. a specific brain region, specific location in the spinal cord, specific
location within the peripheral nervous system. The easiest form of light delivery is simply
exposure of tissue through lighting within the test area, or directly applying light to the tissue
with a laser (Daou, Tuttle et al. 2013). This form of light delivery lends itself to investigations
targeting fibers in the skin or perhaps the eye, essentially tissue with exposed fibers to ambient
light. Delivery of light to regions of the brain require skilled implantation of cannulas or fibers
that illuminate the region of interest without confounding “normal” behavior of the animals. A
similar approach has now been developed to target regions of the spinal cord, with the goal of
both targeting afferent terminals prior to entering the spinal cord and regions of the deeper
spinal cord (Bonin, Wang et al. 2016). Illuminating light cuffs to deliver light to the sciatic nerve
have also been used (Towne, Pertin et al. 2009, Xie, Wang et al. 2018). The use of many of these
approaches has progressed and will continue to progress as options for wireless light delivery
continue to improve. One of the major challenges originally facing wireless delivery of light to
tissues was delivering light of sufficient power to activate opsins in desired tissues, a hurdle that
appears to be progressively nearer to being jumped (Copits, Pullen et al. 2016).
Many studies have used optogenetics to investigate mechanisms driving nociception
and pain, whether targeting the central nervous system or the peripheral nervous system
(Copits, Pullen et al. 2016, Xie, Wang et al. 2018). Of interest to the work completed here, where
our goal is to use optogenetics to investigate the Nav1.8 and MrgD expressing populations of
sensory fibers, I will report findings from a few papers that performed relevant work. Not only
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to justify our approach to targeting these populations of peripheral neurons but the feasibility of
our optogenetic paradigm. Optogenetic investigation of sensory neurons expressing ChR2 under
the Nav1.8 promoter (cre-lox system) has demonstrated that many of the C-fibers that express
Nav1.8 respond to nociceptive modalities such as mechanical and thermal stimuli and these
fibers can be successfully activated by blue light (Uhelski, Bruce et al. 2017). Daou et al. 2013
has demonstrated by using blue light in mice that activation of Nav1.8 fibers results in both
behavioral and immunohistochemical hallmarks of nociceptor activation. Namely by acutely
inducing nocifensive behaviors following blue light stimulation of the hind paw, condition placed
aversion to activation of Nav1.8 fibers blocked by morphine, and c-fos staining in superficial
lamina of the spinal cord dorsal horn (Daou, Tuttle et al. 2013). Authors of this paper also
demonstrated that prolonged activation of Nav1.8 fibers using blue light resulted in central
sensitization of animals. Daou et al. 2016 demonstrated that through Arch-induced inhibition of
Nav1.8 fibers, nociceptive stimuli and inflammation induced tactile hypersensitivity could also
be blocked (Daou, Beaudry et al. 2016). Bonin et al. 2016 demonstrated light delivery of an
epidural fiber meant to target afferent terminals in the spinal cord dorsal horn could also allow
for optogenetic activation or inhibition of Nav1.8 fibers, and their associated behavioral
responses. Due to the overlap between this epidural optogenetic surgery and our own in the rat
(Havelin et al. 2017), and the ability to overcome potential adaptive/compensatory responses
with that can occur in ablative approaches, we chose to use this surgical approach to investigate
the role of these fibers in CIBP.
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3.2. Materials and Methods
3.2.1. LLC Cell Line Maintenance
The C57BL/6 mouse cell line, Lewis Lung Carcinoma (LLC) cells were purchased from
American Type Culture Collection (ATCC, CRL 1642, Manassas, VA) and were maintained in
DMEM media with L-glutamine (CellGro, Manassas, VA) with 10% fetal bovine serum (ATCC,
Manassas, VA) and 1% penicillin/streptomycin at 37°C in a 5% CO2 atmosphere. Prior to surgical
implantation, cells were washed with phosphate-buffered saline and lifted from cell culture
plates with 0.05% trypsin-EDTA (CellGro, Manassas, VA). Cells were spun at 0.7 RCF for no more
than 5 minutes and re-suspended at a concentration of 1 x 108 cells/ µL in the same DMEM
media used to culture the cells using a BioRad TC10 Automated Cell Counter (BioRad, Hercules,
CA).

3.2.2. Animal Care and Treatment
Female and male C57BL/6 mice (Charles River, Willington, MA) aged 8-12 weeks, were chosen
based on their histocompatibility with the LLC cell line. Mice were maintained on a 12-hour
light/dark cycle with food and water available ad libitum. All experiments were performed in
accordance with the policies and recommendations of the International Association for the
Study of Pain, National Institutes of Health, and the Institutional Animal Care and Use
Committee of the University of New England.

3.2.3. Transgenic Mouse Lines and Crosses
Transgenic reporter mice were purchased and maintained as homozygous lines in the
animal facilities at the University of New England. Mice were paired in harem breeding with one
male and two females. Both Nav1.8 and MrgD cre lines of mice were also maintained on a
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homozygous background. Mice heterozygous for both genes were generated by crossing the
male homozygous cre mice with homozygous floxxed-stop transgenic female mice. For example,
male Nav1.8 cre would be crossed with female tdtomato reporter mice. Mice were paired no
earlier than 6 weeks of age and allowed to continue to breed until they were roughly 8 months
of age or until they stopped producing litters. Pups were weaned at postnatal day 21 and
females and males were housed separately. Mice that underwent optic fiber implantation were
not used for experiments until they were roughly 12 weeks old to allow ease of surgical
placement of optical fibers as described later.
Nav1.8-cre. The Nav1.8-cre mouse line was generously transferred to us by Dr. Ian Meng
from the University of New England, the original origins of this mouse reported to be from John
Woods group (Nassar, Stirling et al. 2004).
MrgD-Cre-ERT2. The MrgD

creERT2

mouse line was generously transferred to us by

Wengqin Luo from the University of Pennsylvania. Characterization of this specific mouse line is
reported by (Olson, Abdus-Saboor et al. 2017). This mouse is also now commercially available
through Jackson Labs, Bar Harbor, ME, at the time of this dissertation stock number 01286.
Floxxed stop tdtomato Ai14. Experiments utilizing the fluorescent tdtomato reporter
uses the Ai14 mouse purchased from Jackson Labs, Bar Harbor, ME, at the time of this
dissertation stock number 007914. The Ai14 mouse utilizes a floxxed-STOP cassette that
requires cre activation for the functional expression of the red fluorescent protein variant
“tdtomato”.
Floxxed stop ArchT JAX Ai40D. Experiments utilizing the ArchT-eGFP transgenic mouse
use the Ai40D mouse from Jackson Labs, Bar Harbor, ME, stock number 021188. The Ai40
mouse utilizes a floxxed-STOP cassette that requires cre-activation to express the light sensitive
ArchT-eGFP fusion protein. ArchT is a functionally enhanced version of the orange-yellow light
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sensitive Arch protein which silences neurons by actively pumping protons into the extracellular
space following exposure to orange light (Han, Chow et al. 2011). ArchT was chosen as it is
reported to be more light sensitive than its predecessor, demonstrates adequate expression on
axons, a critical component to our targeted area for light delivery, and has a much faster time of
recovery from light-induced inactivity compared to other neuron inactivating light sensitive
channels such as halorhodopsin (Han, Chow et al. 2011). Functionally, pumping protons into the
extracellular space results in hyperpolarization of the transmembrane electrochemical potential,
which has demonstrated efficacy in silencing neurons.

3.2.4. Genotyping of Mouse Lines
Genotyping of samples was completed by the COBRE Behavioral core at the University
of New England. Tissue is collected from each mouse at approximately Day 21 of age
simultaneous with weaning, using surgical scissors to remove a 2mm snip of tail. Tail snips were
placed in a 1.5mL conical bottom tube and lysed by adding 50mM NaOH to the tube. Each
sample was heated to 95oC for 35 minutes, followed by the addition of 50mM HCL and 1M Tris
HCL buffer. Each sample was then spun down and stored at 4oC until processing. Animal
genotypes were confirmed using three separate protocol methods once sample preparations
were completed. Nav1.8 cre and ArchT mutant reactions were prepared using Promega GoTaq
Flexi PCR buffer, while ArchT wild type and MrgD-cre reactions were prepared with Econotaq
Plus 2x Buffer. 1 µL of DNA sample was added per reaction, into master mix of the appropriate
buffer. The conditions for each protocol varied by annealing temperature and the number of
cycles run to produce the desired product.
Nav1.8 cre/cre and Nav1.8 Wild Type must be processed as 2 separate reactions, due to
final product band sizes being approximately the same (~538 bp). Primers and conditions for
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performing Nav1.8 Cre and wild type are as follows, Nav1.8 cre common forward –
GGAATGGGATGGAGCTTCTTA, Nav1.8 cre mutant reverse – CCAATGTTGCTGGATAGTTTTTACTGC,
Nav1.8 cre wild type reverse – TTACCCGGTGTGTGCTGTAGAAAG. MrgD cre were performed as a
single reaction, with final product sizes being 550 bp for the mutant allele and 200 bp for the
wild type allele. Primers are as follows: MrgD cre mutant forward – GGATCCGCCGCATAACC,
MrgD cre wild type forward – ATACTTTTTGCCGACTTGAACTTG, MrgD cre common reverse –
TTGGGCTGCTAAGAGTGG. ArchT mutant conditions: ArchT mutant and ArchT wild type must be
processed as 2 separate reactions, due to final product band sizes for both being approximately
the same (~300 bp). Mutant reactions performed with Promega GoTaq Flexi buffer using the
following primers: ArchT mutant forward – ATTGCAGCCATTGTCTGAG, ArchT common reverse –
CCGAAAATCTGTGGGAAGTC. ArchT wild type conditions: ArchT wild type processed with
EconoTaq 2x Buffer and performed under the following conditions and primers: ArchT wild type
forward – AAGGGAGCTGCAGTGGAGTA, ArchT common reverse – CCGAAAATCTGTGGGAAGTC.
All DNA products were loaded on a 1.5% agarose gel for electrophoresis. Voltage was typically
set for 130V, for a duration of 30 minutes to separate bands. Gels were then imaged under UV
light for analysis.

3.2.5 Surgical Procedures and Manipulations
Viral Information and Transduction Protocol. Virus used for viral transfection of ArchT
was purchased from the Canadian Neurophotonics Center, QC, Canada. Viral cassette
information supplied by the Canadian Neurophotonics Center reported the vector used is
AAV2/8-CAG-Flex-ArchT-eGFP. The AAV2/8 serotype is a combination of AAV2 and AAV8
serotypes. The CAG promoter is comprised of the cytomegalovirus enhancer element, the first
exon and intron of the chicken beta-actin gene as a promoter, and the rabbit beta-globin splice
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acceptor gene which has previously been shown to induce high expression when used in AAV
vector delivery in vivo (Nitta, Kawamoto et al. 2005). “Flex” is an acronym for “flip-excision”, a
function of the endonuclease protein Cre. When loxp sites are oriented appropriately, vectors
are excised, inverted and re-inserted into the genome. In this case this vector is provided in the
anti-sense direction, upon exposure to Cre, the vector is excised and flipped to a sense direction
resulting in successful expression of the ArchT-eGFP pump and fluorescent reporter. Virus was
prepared and purchased from Canadian Neurophotonics Center, QC, CA. Titer varied minutely
between lots received. Virus was prepared in the absence of helper virus, purified from culture
medium on iodixanol gradient and resuspended in PBS 320 millimolar sodium chloride and 5%
sorbitol and 0.001% pluronic acid.
Mice received injections of 20 microliters of undiluted virus suspension at postnatal day
5. To reduce stress and potential for cannibalization of pups, the mother was removed and
lightly anesthetized with isoflurane ~1-2% prior to handling pups. After removing the mother,
gloves were rubbed in the bedding of the cage of pups in an attempt to reduce scent from the
investigator and add scent from the home cage to the gloves of the investigator. Pups were then
individually picked up and injected with 20 microliters of virus suspension from a modified
Hamilton syringe that allowed minimal waste of virus. A blunted 30-gauge needle was attached
to the luer tip of a 100 microliter syringe, this needle tip was then attached to PE10 tubing,
which was then attached to the end another 30 gauge needle tip that was gripped with a pair of
inter-locking hemostats. After injection pups were then returned to their home cage and
covered with bedding prior to the return of the mother. Pups were observed for ~2 hours prior
to being returned to the animal facility.
Cancer Implantation in Mice. Surgical implantation of the LLC cell line was consistent
with those previously described (Schwei, Honore et al. 1999, Isono, Suzuki et al. 2011). Briefly,
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mice that were 2-3 months old were anesthetized with isoflurane 2-3%. Animals had their right
hind limb area shaved and wiped with 70% ethanol followed by iodine. A small incision was
made laterally above the femur to expose underlying tissue. Going along the iliotibial band using
a pair of curved forceps, muscle was separated with blunt dissection to allow the pair of forceps
to hook over the femur and roll/displace the quadriceps over the femur exposing the distal end
of the femur, taking care to avoid ripping or damaging tissue. A small hole was then drilled
between the 2 condyles using a dental drill with a 0.6-millimeter bit. A small cannula was then
inserted into the bone marrow and attached to a 50 microliter Hamilton syringe and 2
microliters of cell suspension (1 x 108 cells/mL) was injected delivering 2 x 105 cells or cell free
media. After injection was complete the cannula was removed and the hole was then sealed
with bone wax and bone cement. The muscles displaced previously in the procedure were
returned to their original position and the incision in the skin closed with suture. Mice were then
returned to their home cages and monitored for 1-2 hours prior to being returned to the animal
facility. Mice were monitored for weight loss and any animals that lost greater than 20% of their
original body weight at any given time were removed from the study (no animals removed due
to weight loss prior to end of experiments).
Epidural Fiber Optic Manufacturing, Utilization of Laser diode system, and Quality
Assurance. Optic fibers were used and purchased as described in Bonin et al 2016, from Doric
lenses (QC, Canada). Fibers were custom made with a diffusive tip, product information,
MMF_POF_240/250-0.6_8 cm DFL. Fibers were fixed in place within a ceramic ferrule with blue
epoxy (Fiber Instrument Sales, Inc.) and allowed to dry overnight. Fibers were then cut with a
ruby dualscribe S90R (THORLABS, Newton, NJ) to measure 4.8cm in length, to allow placement
directly above the lumbar enlargement. After roughly cutting with the dualscribe implants, were
held within a polishing disc D50-FC (THORLABS, Newton, NJ) and progressively polished in a
93

figure 8 motion to ensure even polishing of the end of the fiber optic. Polishing paper
increments used were as follows: M15 silicon carbide 15 micrometers (Fiber Instrument Sales,
Inc., Oriskany, NY), diamond lapping 6 micrometer (THORLABS, Newton, NJ), 3M aluminum
oxide 3 micrometers (Fiber Instrument Sales, Inc., Oriskany, NY). Implants were then sealed in
dental cement molded to rubber caps to imitate the shape of a mouse skull and allowed to dry
overnight. Fibers were then tested for transmittance to ensure adequate transmission of light to
the end of the fiber and ensure the manufacturing process did not compromise the integrity of
the fiber. Testing of representative group of fibers is displayed in Figure 3.1, fibers with <30%
transmittance at the measured power output of the laser were not used.
After mice received surgical implantation of the fiber, animals were attached in line with
the following fiber optics for transmittance of light from the laser source to the diffusive fiber
optic. Light sources used in experiments were generated from a fiber-coupled laser diode
module – 450 and 520 nm, LDFLS_450/080_520/060 (Doric Lenses, QC, Canada). Laser diodes
were connected to a patch cord MFP_100/125/LWMJ-0.22_0cm_FC-FCA, core 100 micrometers,
NA0.22, jacket 2400 micrometers (Doric Lenses, QC, Canada). This cord was attached to a fiber
optic rotary joint, FRJ_1x1_FC-FC and fiberoptic rotary joint holder, holder FRJ_small rotary
(Doric Lenses, QC, Canada). The rotary was then connected to an optical fiber patchcord,
MFP_200/240/900-0.22_1.5m_FC-ZF2.5, core 200um, NA 0.22, jacket 900 micrometers (Doric
Lenses, QC, Canada). This was then attached to a bronze split jacket used to connect the laser
source and patch cords to the fiber optic implant attached to the mice. Depending on the
behavioral test, lasers were either manually activated by hand, setting the laser diode system to
“constant wave”, or controlled by signals from ANYMAZE software (Stoelting, Wood Dale, IL)
with TTL signals.
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Epidural Fiber Implant Surgery. Implanting the fiber optic cable to target the lumbar
enlargement of the spinal cord was performed as previously described (Bonin, Wang et al.
2016). Animals were anesthetized with 2-3% isoflurane with oxygen flow of 1 liter/minute. The
neck and top of the head of the mouse was shaved using small hair clippers and then treated
with 70% ethanol wipe and iodine. A small incision, ~3cm, was made cutting rostral to caudal
from roughly the middle of the skull (immediately rostral to lambdoid suture) down to the
middle of the neck. The skull was then rubbed with a cotton tip applicator that had been soaked
in 3% hydrogen peroxide to remove residual tissue on the skull. This aided in ensuring a dry skull
surface for later in the surgery. A set of microscissors were used to cut underlying neck muscle
along the midline of the animal taking care to not sheer tissue lateral to the midline. After an
incision of roughly 2 cm was made a cotton tip applicator was inserted into the incision and
vigorously rubbed and spun to bluntly force tissue away from the skull and to increase workable
space within the incision. Following this, tissue spreaders were inserted into the incision and
used to open the incision to a workable area. Using fine tipped forceps, a small hole was made
in the layer of tissue lying over the duramater just rostral to the C1 vertebra, taking care to
avoid puncturing the dura which was made obvious by the release of cerebrospinal fluid (CSF) if
the dura mater was punctured.
Occasionally this did happen and animals were recorded and noted as such. After blunt
dissecting a small useable hole, the end of the fiber optic implant with the diffusive tip was held
with ceramic tip forceps, 7 MZ Ceramic Tip Tweezer (Electron Microscopy Series, Hatfield, PA)
and carefully placed into the hole. After the fiber optic implant was successfully inserted using
the ceramic tip forceps, the implant was carefully and slowly threaded down the length of the
vertebral column and spinal cord to the lumbar enlargement. Noting two points of resistance,
initially as the implant passes the arch in the cervical region of the mouse’s vertebral column
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and again nearing the lumbar enlargement. These hurdles were overcome by manipulating the
mouse and gently applying force to the fiber to encourage it to terminate where necessary.
Using Loctite brand superglue (blue cap) the dental cement cap was fixed to the skull of the
mouse. The incision was then closed using suture and the animals were placed into cages and
individually housed. Animals were monitored for paralysis or complications from the surgery for
2-3 hours and then returned to the animal facility. Animals that were paralyzed were
euthanized. Prior to testing animals were attached to a laser diode light source to determine if
the implants were successfully (hit) or incorrectly placed (miss). Roughly <20% of animals
received incorrectly implanted fibers or required euthanasia due to complications of the
surgery, representative images can be found in Figure 3.1.
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Animals were allowed 5-7 days to recover prior to verification of implant as well as
experimental procedures. At least one day prior to behavioral testing animals were attached to
the laser and allowed 30 minutes to acclimate to being attached to the fiber. This was
performed prior to verification of proper placement of the implants. Proper placement was
determined by verifiable light transmitted through the back of the animal in the lumbar region
of the spinal cord, see Figure 3.1 for correct vs incorrect implant of fiber. Animals with
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incorrectly implanted fibers were used as offsite controls as the animals did not appear to find
the misplaced fiber aversive, painful or stressful.
Estimates made by Bonin et al. 2016 place light penetration to a rough maximum of
100-200 micrometers through spinal cord myelin, indicating that light penetration is limited and
likely not possible to deep lamina of the spinal cord. Cells beyond the reach of this light are also
protected which allows for specific illumination of cells shallow into the spinal cord dorsal horn.

3.2.6. Behavioral Assays and Observations
Quantification of flinching, guarding, limb use behaviors. Quantification of altered
behavior due to the development of CIBP was assessed as previously described (Honore, Rogers
et al. 2000). Mice were allowed to acclimate to a small pan empty of bedding for at least 15
minutes prior to observation of behavior. Mice were then observed for 2 minutes and the total
number of flinching bouts and time spent guarding was assessed. Some mice were also
observed via video camera set to record from underneath them in clear box, and total time
spent guarding the cancer-afflicted hind limb was measured. Limb use behavior was assessed
over a 2-minute time frame and rated by the following scale. 4, normal limb use, 3, limping with
less use of the cancer afflicted limb, 2, limping and guarding of the impaired limb, 1, partial nonuse of the hind limb, and 0, complete lack of use (dragging) of the hind limb.
Von-frey assessment of tactile hypersensitivity. Development of tactile hypersensitivity
following implantation of LLC cells in to the femur of mice was assessed using the up-down
method as previously described (Chaplan, Bach et al. 1994, Honore, Rogers et al. 2000). Mice
were allowed to acclimate to small elevated chambers with mesh flooring for 30-60 minutes
prior to testing. Testing was conducted using the calibrated von frey filaments: 2.44, 2.83, 3.22,
3.61, 4.08, 4.31, 4.56, and beginning with filament 3.61. A maximal threshold obtained from lack
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of a response from the 4.56 filament was recorded as 4 grams, and a minimal response with a
positive response from the 2.44 filament was recorded as 0.04 grams.
Quantification of rearing behaviors. Similar to previously described (Guedon, Longo et
al. 2016), mice were placed into a clear bottom plastic bin and recorded for either 5 or 30
minutes as described in each experimental paradigm. Total number of times mice placed their
full weight on their hind limbs was totaled, this simultaneously occurred when animals removed
all weight from their forepaws.
Mustard oil (AITC) induced nocifensive behaviors in animals with virally delivered ArchT.
Previous reports have demonstrated the efficacy of AITC to induce robust, but short lived
nocifensive behaviors mediated by activation of the TRPA1 channel (Eid, Crown et al. 2008,
Okun, Liu et al. 2012). Due to the overlap of TRPA1 RNA expression with Nav1.8 and MrgD RNA
expression (Figure 3.2), we chose to use this robust behavior to assess whether our optogenetic
approach could activate ArchT in Nav1.8 or MrgD fibers and block nocifensive behaviors, prior to
use in our CIBP model. Wildtype animals that did not have fiber implants were restrained and
received either an injection of 20 microliters of 30% DMSO, or 1% AITC dissolved in 30% DMSO
into the plantar surface of their hind paw. Mice with fiber optic implants were first handled and
restrained (scruffed) and attached to the brass collar to connect the laser source to the fiber
implant attached to the mouse’s head. Mice were then allowed a 15 to 30 minute habituation
period in their home cages before proceeding with testing. Most animals immediately returned
to normal mouse behavior within their home cages, i.e. grooming, sifting through bedding and
locomotion behavior. Immediately prior to injection of AITC, lasers were activated at 200mA on
continuous wave for constant delivery of light to the animal during injection and the 5 min
observation period. These mice then received either an injection of 20uL of 30% DMSO, or 1%
AITC dissolved in 30% DMSO into the plantar surface of their hind paw. Following injections of
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either vehicle or AITC animals were immediately placed into a plastic chamber with a camera set
up beneath to record time spent licking and flinching bouts for 5 minutes.

Taken from Usoskin et al. 2016

Figure 3.2. Potential Overlap in the Mrgprd (MrgD) and Trpa1 (TRPA1) Expressing Cells in the
DRG. Single Cell RNAseq demonstrating subpopulations of sensory fibers. Colored table taken
from Usoskin et al. 2015. Data mined from Linnarsson Lab website,
(http://linnarssonlab.org/drg/). Figure adapted with color scheme by Joshua Havelin for ease of
visualization.

Locomotor assay chamber assessment of behaviors. Work previously published by
Majuta et al. assessed the effects CIBP on distance travelled in animals with cancer cells
implanted into their femurs. Animals with cancer were shown to have reduced movement
simultaneous with disease progression (Majuta, Guedon et al. 2017). Behaviors were analyzed
as previously reported (Lowery, Raymond et al. 2011). Animals were placed into a 10 by 10 inch
plastic chamber (Coulbourn Instruments, Allentown, PA) and data was acquired and reported
using TruScan software (Coulbourn Instruments, Allentown, PA). Animal movements were
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tracked by a set of infrared beams at the floor level, as well as a set of infrared beams 2 inches
above to detect rearing behaviors. Total distance traveled, time spent in the center of the
chamber, at the edges of the chamber and number of center entries was recorded. Breaking the
vertical infrared beams allowed for quantification of time spent rearing and number of rears.
Distance traveled is reported in centimeters. Data was collected and summed across 1-minute
bins. Representative time course data is displayed as sum values across 5-minute bins
throughout the 30-minute experiment, and area under the curve was calculated using the
trapezoidal Riemann sum between bins.
Conditioned place preference to pain relief or aversion to hindpaw movement.

A

number of previous publications have demonstrated the efficacy of conditioning animals to pain
relief (King, Vera-Portocarrero et al. 2009, Remeniuk, Sukhtankar et al. 2015, Havelin, Imbert et
al. 2017).
Using a conditioned place preference (CPP) paradigm animals undergo a 3-day testing
procedure. The basic single trial CPP protocol occurs within a three-chambered box as
previously described (Havelin, Imbert et al. 2017). The three chambers are distinct from each
other in texture of flooring, visual cues (shades of construction paper, and black and white
stripes), and scent (pink lemonade vs vanilla chap stick), a representative image can be found in
Figure 3.3. On day 1 of testing animals are allowed to freely explore the box for 15 minutes
while their movements and time spent in each chamber are tracked and quantified by ANYMAZE
software (Stoelting, Wood Dale, IL). Time spent in each of the unique pairing chambers is
counter balanced to ensure no unintentional bias is introduced into the experiment. The
following day animals are placed into the AM chamber with exposure to a control stimulus for
30-minutes. In the case of evaluating a drug this chamber would be paired with vehicle (i.e.
saline), or hooked up to the lasers without having the laser turned on, or undergo handling with
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explicit attention to cause no movement of the hind paw. Animals are then removed and
returned to their home cages for 4 hours. Following the intermission period, animals are placed
into the PM chamber with the experimental stimulus for 30-minutes. In the case of evaluating a
drug, this chamber would be paired with drug (i.e. the MOR agonist DAMGO), or hooked up to
the lasers with the laser turned on, or a 2-minute period of movement of the hind paw. Animals
are then removed and returned to the animal facility. The following day animals are again
allowed to freely explore the CPP chambers for 15 minutes and their time in each chamber is
quantified by ANYMAZE software. Results are reported as time spent in each chamber preconditioning and post-conditioning, an increase time spent in either chamber pre vs post
considered CPP to that chamber, whereas a decrease is CPA. In addition, “different scores” are
calculated by subtracting time spent in the afternoon chamber pre-conditioning from postconditioning, a positive number indicates CPP to the pairing where as a negative value indicates
CPA, this measurement is used to compare whether treatment effects differed between groups.
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Pharmacological intervention for CPP. Mice were briefly anesthetized with isoflurane
~2% and their tails were warmed in 42 C° water. Mice were then quickly injected i.v. with either
normal saline for AM conditioning or during PM conditioning DAMGO or Deltorphin II to deliver
a dose of 3 mg/kg. Solutions were injected at 10mL/kg, eg. a 20-gram (0.02kg) mouse would
receive 0.2 mL of injection. Mice were then allowed to wake from light anesthesia before being
placed into their respective pairing chambers.
Laser activation paradigm for CPP. Mice were handled and restrained (scruffed) and
attached to the brass collar to connect the laser source to the fiber implant attached to the
mouse’s head. Mice were then allowed a 15 to 30 minute habituation period in their home
cages before proceeding with conditioning. Most animals immediately returned to normal
mouse behavior within their home cages, i.e. grooming, sifting through bedding and locomotion
behavior. Animals were then placed into their respective conditioning chambers and ANYMAZE
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software was activated. In the AM conditioning phase the lasers remained off and animals did
not receive any light to their spinal cord dorsal horn. During the PM conditioning phase
ANYMAZE software was set to deliver a continuous 200 mA pulse of green light (520nm
wavelength) to the mouse for 2 minutes, then the laser would turn off for 1 minute, and then
the laser would turn on at 200 mA output. This cycle continues for the entirety of the 30-minute
conditioning phase. After each session the animals were then removed and restrained and
detached from the brass collar and laser source and returned to their home cages.
Total distance travelled as assessed by ANYMAZE software. Animals were placed into a
clear bottom plastic bin and recorded for varying amounts of time while being tracked by
calibrated ANYMAZE software. Total distance traveled is reported in meters with this analysis.
Radiographic analysis of cancer-induced bone remodeling for inclusion/exclusion of
animals in behavioral studies. X-ray radiographs were taken at the completion of all behavioral
studies (except when the x-ray machine was not functioning). A qualitative scoring system was
used to score the level of bone remodeling induced by tumor growth similar to previously
described (Edwards, Havelin et al. 2018). Digital radiographs were taken using a
MINXRAYHF100/30 X-ray source (MinXray, Inc Northbrook, IL), at an exposure setting of 40kV,
1.5 mAs and 0.05 seconds captured on a Wireless Digital Flat Panel Detector (Model
Mars1417V-TSI, iRay Technology Co. Shanghai, China) and analyzed with Opal Software (20/20
Imaging, Konica Minolta Healthcare Wayne, NJ) at the completion of all behavioral testing. Bone
loss was rated by a blinded experimenter according to a 3-point scale. 0 = being a “normal”
bone, consistent with the contralateral leg, 1 = osteolytic or osteoblastic bone remodeling
compared to the contralateral bone, and a 2 = unicortical or bicortical bone fracture.
Representative images can be found in Figure 3.4. Animals with radiograph measurements of
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“0” that had undergone cancer cell implantation were removed from the study due to lack of
apparent cancer-induced bone remodeling.

3.2.7. Tissue Collection and Immunohistochemical Staining for Verification of MrgD-cre-ER2
mouse line
Verification of MrgD-Cre line of mice and induction protocol was determined by IHC in
DRG and spinal cord tissue using the following protocols. Mice were deeply anesthetized with
Beuthanasia-D (Henry Schein Animal Health) and underwent intracardiac perfusion through the
left ventricle with 50mL of ice cold PBS followed by 50mL of ice cold 4% PFA containing PBS, pH
7.4. The L2–L4 spinal cord segments were immediately dissected out and post fixed in 4% PFA
overnight. L2-L4 DRG were also immediately dissected and post fixed in 4% PFA overnight.
Tissue was then moved into a 30% sucrose solution at 4°C for 12–24 h for cryoprotection. Spinal
cords and DRG were embedded in optimal cutting temperature (OCT) medium (VWR) and frozen
in a 70% ethanol bath at -80°C. Spinal cord sections were cut on a cryostat (Leica) at 30 um,
whereas DRG sections were cut at 12 um, collected onto positively charged slides (Azer
Scientific), and allowed to dry before storage at -20°C.
Staining protocols used to visualize CGRP and IB4 were performed by the UNE Histology
Core. Sections were rinsed 3 times for 10 minutes with PBS containing 0.1% triton (PBSTx) to
remove OCT, then non-specific binding proteins were blocked by 30 min incubation with 5%
normal donkey serum (EMD Millipore, Billerica, MA) in 0.1% PBS-Tx for 15-60 minutes. This
blocking solution was also the antibody diluent. Primary antibodies and Alexa 647-conjugated
IB4 were incubated overnight at 4°C as follows: IB4-AF647 1:750 (1.3ug/mL, Invitrogen I32450);
rabbit anti-CGRP 1:2000 (ImmunoStar Cat# 24112 RRID:AB_572217). Sections were rinsed 3
times with PBS-Tx and incubated in the dark for 1 hour at room temperature with appropriate
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cross-adsorbed secondary antibodies: Donkey anti-rabbit Alexa Fluor 647 1:1000 (2 ug/mL,
ab150063, Abcam, Cambridge, MA). Sections were rinsed with PBS-Tx 3 times and mounted
with DAPI-containing Fluoroshield (ab104139, Abcam). Representative images were taken using
a wide field epifluorescence Leica DM2500 microscope, using either 5x or 10x objective, using
suitable filters for DAPI, GFP, tdtomato, and Alexa Fluor 647. Tissue was imaged using Leica
Application software with a Leica DFC365 FX 16-bit CCD camera, gain and exposure settings
varied between channels and tissue samples.

3.2.8. Statistical Analysis and Graphing
Data was transformed from raw data gathered either via ANYMAZE, Truscan, or by hand
to grouped data using Microsoft Excel. Data was then graphed and statistically analyzed using
Graphpad Prism software. Results from quantification of flinching, guarding, limb use behaviors
were analyzed with a 2-way ANOVA and a Tukey post hoc to compare between groups at each
time point. Results from Von-frey assessment of tactile hypersensitivity were analyzed with a 2way ANOVA and a Tukey post hoc to compare between groups at each time point. Results from
quantification of rearing behaviors were analyzed with a 2-way ANOVA and a Sidak post hoc to
compare between groups at each time point, and a Tukey post-hoc to compare within group
differences. Data from mustard oil (AITC) induced nocifensive behaviors in animals with virally
delivered ArchT were not statistically analyzed due to the small n size of the groups. Results
from LMA chamber analysis of cancer-induced change in behaviors were analyzed with a 2-way
ANOVA and a Tukey post hoc to compare between groups. Pre-conditioning versus postconditioning time spent in chamber in experiments testing conditioned place preference to pain
relief or aversion to hind paw movement were analyzed using a within subject 2-way ANOVA
with Sidak’s post hoc test comparing pre vs post conditioning values within each group.
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Difference scores between groups were analyzed with either an unpaired student T-test, or a 1way ANOVA with Uncorrected Fisher’s Least Squared Difference post hoc. Groups were
considered statistically significantly different when p values less than 0.05. Outliers were
calculated using Graphpad Prism Grubb’s Outlier test, exclusion criteria set at alpha < 0.05.
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3.3. Results
3.3.1. Classical Cancer-Induced Measures of Pain.
Consistent with previous reports, both male and female mice that underwent LLC cell
injection into the femur underwent dramatic bone remodeling and loss (Figure 3.4) that was
accompanied by the development of tactile hypersensitivity, decreased limb use and presented
with increased flinching bouts (Figure 3.5). Female and male cancer bearing animals showed
elevated flinching at Day 12 post cancer cell implantation into the femur compared to female
sham animals (p< 0.0001, n size = 12 female cancer, 11 female sham, 21 male cancer). Female
and male cancer treated animals displayed decreased levels of limb use at Day 12 post cancer
cell implantation compared to female sham animals (p< 0.0001, n size = 12 female cancer, 11
female sham, 21 male cancer). Female and male cancer animals demonstrated decreased
tactile withdrawal thresholds compared to female shams at Days 7 and 12 post cancer cell
implantation (p< 0.0001, n size = 12 female cancer, 11 female sham, 21 male cancer). In a
separate set of experiments animals were observed for changes in time spent guarding of the
cancer-afflicted hind limb and rearing activity displayed in Figure 3.6.
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A separate cohort, female mice were observed for guarding and rearing behaviors.
Consistent with previous reports at Days 11 and 12 post cancer cell implantation female animals
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that received cancer cell implantation into the femur spent more time guarding the cancer
afflicted hind limb compared to female sham controls (p< 0.05 and p<0.001, n size = 6 female
cancer, 6 female sham). Female cancer animals showed a decreased in rearing compared to
female shams at Days 11 and 12 post cancer cell implant (p < 0.05 and p < 0.0001), and cancer
treated animals showed a decrease compared to their own baseline values 11 and 12 days post
cancer cell implant (p < 0.001, p < 0.0001), sham treated animals showed a significant decrease
from their baseline values at day 12, likely due to repetitive exposure to observation chambers
(p < 0.05, n size = 8 female cancer, 8 female sham). Combined these results indicate that in our
hands this surgical intervention produces CIBP results similar to other groups (Guedon, Longo et
al. 2016).
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3.3.2. DAMGO Induced Pain Relief, and Failure or Deltorphin II to Relieve Ongoing Pain.
Administration of the peptidergic MOR agonist DAMGO at a dose of 3 mg/kg in cancer
bearing but not sham treated animals resulted in an increase in time spent in the drug paired
chamber post-conditioning, indicating a relief of ongoing pain in the cancer bearing animals
(Figure 3.7A **p < 0.01, n size = 10 sham, 12 cancer animals). A nearly significant difference
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between groups when comparing “different scores” was detected indicating a difference
between groups in response to being treated with 3 mg/kg DAMGO (Figure 3.7B, one tailed
unpaired t-test, p = 0.058, n size = 10 sham, 12 cancer animals). Neither sham nor cancer
treated animals demonstrated an increase in time spent in the 3 mg/kg Deltorphin II paired
chamber post-conditioning, indicating at this dose Deltorphin II fails to alleviate ongoing pain,
and no difference was detected between groups when comparing “different scores” in Figures
3.7C and 3.7D (no significance, n = 12 sham, 12 cancer animals).
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3.3.3. Evaluation of Tdtomato Expression in MrgD

CreER2

Mouse Line.

Visual inspection of immunohistochemical staining for CGRP and IB4 labeling of spinal
cord slices and cells within L4 DRG revealed no notable overlap of CGRP and MrgD-tdtomato
signal in either tissue as seen in Figures 3.8G and Figure 3.8H. Whereas IB4 labeling with the IB4AF647 conjugate and MrgD-tdtomato positive signals showed significant overlap in both spinal
cord slices and cell bodies of L4 DRG (Figure 3.8C and Figure 3.8D). This labeling shows that the
tamoxifen protocol used was successful in activation of cre in MrgD and IB4-binding cells, but
not CGRP positive cells. Images displayed in Figure 3.8 have been pseudo colored for ease of
consistency within this dissertation. Figure 3.8 panels, A, C, D, E, G, and H tdtomato is displayed
in green, panel B, C and D IB4-AF647 signal is blue, panel F, G and H CGRP signal from Secondary
AF647

is
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red.

3.3.4. Evaluation of Delivery and Activation of Undiluted AAV2/8 ArchT Viral Vector in MrgDtdtomato Positive Cells.
Delivery of the viral vector containing the ArchT-eGFP cassette at postnatal day 5
resulted in robust expression of ArchT-eGFP in MrgD-tdtomato positive spinal cord slices and
cells within the L4 DRG. Figure 3.9 displays a representative image of lumbar spinal cord slices
and L4 DRG where MrgD-tdomato signal overlaps robustly with virally delivered ArchT-eGFP. In
this image greater than ~70% of the cells expressing tdtomato also express ArchT-eGFP, and
signal in the spinal cord dorsal horn show robust overlap. These results were a large
improvement from previous attempts to administer a 1:10 dilution of the stock viral vector (data
not shown). In Figure 3.9 tdtomato is displayed in red, ArchT-eGFP fusion protein is visualized in
green.
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3.3.5. Fiber Optic Implant Quality Assurance and Surgical Implant Challenges.
Following hand polishing of each individual fiber optic implant, fibers were individually
tested for adequate light transmission compared to raw output from the laser patch cord. As
seen in Figure 3.1, similar output efficiencies, roughly 50-80%, were measured at 2 separate
power outputs from the laser source (30mA and 60mA) indicating no change in light emission
efficiency between the two laser power settings. Relative distribution of power efficiency
between fibers indicated consistent results from production of implants. Measured efficiencies
were also consistent with reports from collaborators at Laval University from Dr. Yves
DeKonick’s lab, where I was trained. Of note, later batches of fiber production, such as those
reported in Figure 3.12, had reduced transmission efficiency, we believe as a result of
production differences in lots of fiber optics. A representative image of challenges resulting
from implanting the fiber optic using previously described surgical procedures is displayed in
Figure 3.1. After adequate practice it was estimated that < ~20% of surgeries resulted in
incorrectly placed fiber implants, whereas paralysis of animals following surgery occurred
independent of this.

3.3.6. Successful Optogenetic Blockade of AITC Induced Nocifensive Behaviors in Nav1.8 and
MrgD Expressing Fibers.
Injection of a 1% AITC solution into the hind paw of mice induced robust licking and
flinching behaviors in wildtype mice with no fiber optic implant, as well as animals with
incorrectly implanted fiber optic implants expressing virally delivered ArchT in Nav1.8 or MrgD
expressing cells displayed in Figure 3.10. Animals expressing virally delivered ArchT in either
Nav1.8 or MrgD expressing cells with correctly placed fiber optic implants displayed a nearly
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complete blockade of nocifensive behaviors. Although not statistically analyzed this data
demonstrates that not only did our optogenetic approach to silence nociceptive fibers at the
level of the spinal cord dorsal horn prove effective, but silencing either Nav1.8 or MrgD
expressing fibers is sufficient to block AITC induced nociceptive behaviors (n = 6 wildtype vehicle
treated animals with no fiber, 8 wildtype 1% AITC treated animals with no fiber, 2 Nav1.8 virally
delivered ArchT animals with incorrectly implanted fiber optics, 2 Nav1.8 virally delivered ArchT
animals with correctly implanted fiber optics, 3 MrgD virally delivered ArchT animals with
incorrectly implanted fiber optics, 3 MrgD virally delivered ArchT animals with correctly
implanted fiber optics).
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3.3.7. ArchT Expression in Animals from Nav1.8 and MrgD cre Mouse Lines Crossed with Ai40D
ArchT Transgenic Animals.
Representative images of spinal cord dorsal horn near the lumbar section of the spinal
cord in Nav1.8 and MrgD animals crossed with the transgenic ArchT mice revealed differential
expression patterns of ArchT-eGFP displayed in Figure 3.11. Microscopic evaluation of tissue
taken from either Nav1.8-ArchT or MrgD-ArchT animals demonstrated robust eGFP expression
in expected lamina of the spinal cord dorsal horn and robust expression of eGFP in L4 DRG.
Incomplete activation of Cre in an MrgD-ArchT animal resulted in tissue found in representative
images in panels G and H. This was relatively uncommon in animals and if detected, animals
were removed from behavioral studies. DRG tissue was not used for ArchT-eGFP verification as
MrgD positive cells are likely not homogenously distributed throughout the DRG and attempting
to use IHC or staining methods to verify percent activation of IB4 to MrgD cells would have been
labor intensive and ultimately inconclusive as no arbitrary percentage of cells required to be
activated was established. Additionally, as light was being delivered to the spinal cord dorsal
horn, spinal cord tissue was more relevant to verify ArchT-eGFP expression. ArchT-eGFP is
displayed in green.
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3.3.8. ArchT Induced Silencing of Nav1.8 fibers Relieves Cancer-induced Ongoing Pain, and
ArchT Induced Silencing of MrgD Fibers in Animals with Cancer Induces CPP.
Activation of ArchT in Nav1.8-ArchT animals with cancer resulted in an increase in time
spent in the laser paired chamber post-conditioning, whereas no increase in time spent in the
laser paired chamber was observed in Nav1.8-ArchT sham treated animals displayed in Figure
3.12A (p < 0.01, n = 7 Nav1.8-ArchT sham treated animals, 9 Nav1.8-ArchT cancer treated
animals). MrgD-ArchT animals that underwent cancer implantation spent an increase in time in
the laser paired chamber post-conditioning, indicating a preference to the chamber ArchT
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induced silencing of MrgD-fibers occurred in (p < 0.01, n = 11 MrgD-ArchT cancer treated
animals). Analysis of “different scores” between the 3 groups of animals demonstrated a
significant difference between Nav1.8-ArchT sham treated animals and Nav1.8-ArchT cancer
treated and MrgD-ArchT cancer treated animals, Figure 3.12B (p < 0.05, n = 7 Nav1.8-ArchT
sham treated animals, 9 Nav1.8-ArchT cancer treated animals, 11 MrgD-ArchT cancer treated
animals). This indicates cancer treated animals that express ArchT either on Nav1.8 or MrgD
fibers showed a significant preference compared to Nav1.8-ArchT sham animals. A lack of
additional animals restricted our ability to add and compare a group of sham treated MrgDArchT animals. We conclude that silencing Nav1.8 expressing fibers induce CPP indicating
blockade of ongoing pain, and the same is likely true as a result of silencing MrgD fibers. Once
MrgD-Cre-ArchT mice are regenerated, we will rerun a replication that includes shams to 1)
provide a replication of this novel and exciting finding and 2) include the appropriate MrgD-CreArchT sham group for publication purposes.
Comparing the “difference score” in Nav1.8-ArchT animals that underwent sham
surgery or cancer surgery and MrgD-ArchT cancer treated animals with the measured fiber optic
implant efficiency does not reveal a convincing linear correlation between an animals
preference and the amount of light exposure to their spinal cord dorsal horn Figure 3.12C (R

2

values = 0.11 in Nav1.8-ArchT sham treated animals, 0.25 in Nav1.8-ArchT cancer treated
animals, and 0.06 in MrgD-ArchT cancer treated animals). This indicates that there is likely a
threshold for light-induced ArchT activation required to silence fibers resulting in CPP (on-off
scenario), rather than a linear relation between ArchT activation and pain relief. We note that
CPP may not have sufficient resolution to detect potential subtle changes in intensity of pain
relief.
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Figure 3.12. ArchT Induced Silencing of Nav1.8 Fibers Causes Relief of Ongoing Pain and ArchT Induced
Silencing of MrgD Fibers in Cancer Animals Results in CPP. In Nav1.8-ArchT animals with cancer activation
of ArchT paired with the PM chamber results in conditioned place preference, but fails to do so in sham
treated Nav1.8-ArchT animals, indicating relief of ongoing pain from the bone. MrgD-ArchT animals with
cancer also demonstrate a conditioned place preference for the PM chamber paired with ArchT activation,
however no sham animals were run limiting the interpretation of these results. A) Both Nav1.8-ArchT and
MrgD-ArchT animals with cancer demonstrated an increase in time spent with the laser paired PM
chamber, ** p < 0.01 pre vs post conditioning. A1) Scatter plots demonstrating individual animals change in
behavior following conditioning paradigm. B) Comparison of “different scores” reveals that both Nav1.8ArchT and MrgD-ArchT animals with cancer but not Nav1.8-ArchT sham treated animals developed a
change in time spent in the PM chamber. C) Linear regression analysis of “different score” compared to
measured power output of fiber optic implant reveals no correlation between power output and preference
or aversion to the PM/laser paired conditioning chamber

3.3.9. Failure to Induce CPA to Hind Paw Movement in Cancer Treated Animals, and
Alternative Behavioral Measures Affected by Hind Paw Movement.
Movement of the hind limb for 2-minutes failed to induce conditioned place aversion in
either sham or cancer treated mice, a finding that differs from our published observations in the
rat (Havelin, Imbert et al. 2017). Conditioned place aversion to hind paw movement failed in
both male and female mice that underwent cancer cell implantation in the femur Figure 3.13A
and Figure 3.13B (n = 13 sham treated male mice, 20 cancer treated male mice, 12 sham treated
female mice, 12 cancer treated female mice). In an effort to measure alternative behaviors to
conditioned place aversion, animals underwent a 2-minute hind limb movement paradigm
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followed by measurement of distance traveled and rearing behaviors, 2 measures previously
demonstrated to decrease in animals with cancer-afflicted hind limbs (Majuta, Guedon et al.
2017). Consistent with previous findings, animals with cancer travelled and reared less than
their sham counter parts Figure 3.14 (p < 0.01 and p < 0.01 respectively). No statistically
significant difference in distance travelled or rearing behavior was observed between sham
animals who did not receive 2-minute hind limb movement and those that did (p > 0.05 and p >
0.05). Animals with cancer that received movement of their cancer-afflicted hind limb travelled
less distance compared to cancer animals that did not receive hind limb movement, however no
statistical difference between groups was found in rearing behavior (p < 0.05). These results
indicate that hind limb movement in cancer treated animals but not sham treated animals
causes a decrease in movement over the 45-minute observation period (n = 5 sham treated no
movement animals, 6 sham treated hind limb movement animals, 5 cancer treated no
movement animals, 6 cancer treated hind limb movement animals).
Other behaviors that were monitored were time spent and distance travelled in the
margin and center of the LMA chambers, as well as number of center entries (Figure 3.15).
Animals with cancer spent less time in the margin, while hind limb movement in animals with
cancer decreased the distance travelled in the margin Figures 3.15A1 and Figure 3.15A (p< 0.05,
n = 5 sham no-movement, 6 sham movement, 6 cancer no-movement, 5 cancer movement and
p< 0.05, n = 5 sham no-movement, 5 sham movement, 6 cancer no-movement, 5 cancer
movement respectively). Tumor bearing animals travelled less, spent less time and entered the
center of the LMA chambers less than sham controls Figures 3.15B, 3.15B1 and Figure 3.15C
respectively (p < 0.01; n = 6 sham no-movement, 6 sham movement, 6 cancer no-movement, 5
cancer movement; p < 0.05 n = 5 sham no-movement, 5 sham movement, 6 cancer no-
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movement, 5 cancer movement; and p < 0.05 n = 5 sham no-movement, 5 sham movement, 6
cancer no-movement, 6 cancer movement, respectively).
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3.4. Discussion
We have developed a novel approach to measuring ongoing cancer-induced bone pain
and demonstrated that Nav1.8 and MrgD expressing sensory fibers play a critical role in
transducing pain in this model of CIBP in the mouse. Further, we have expanded the utility of
previously published methods to investigate the role of afferent fibers in transducing pain with
intervention to block pain signals at the level of the spinal cord dorsal horn (Bonin, Wang et al.
2016). Moreover, we adapted new measures of movement-induced pain that may serve as a
foundation for further development of a measure of BTP in the mouse by monitoring previously
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described behavioral changes that arise as a result of CIBP (Guedon, Longo et al. 2016, Majuta,
Guedon et al. 2017). We demonstrate that hind limb movement induced changes in several
behaviors, distance traveled, rearing and movement in the margin and center of an LMA
chamber, that may prove useful in developing a model of breakthrough pain in the mouse.

3.4.1. Classical Measures of CIBP.
Time course data displayed in Figures 3.5 and 3.6 demonstrate that in our hands we
have replicated previous reports within the CIBP literature. In both female and male C57BL/6
mice as tumor growth progresses within the femur, mice develop classical tactile
hypersensitivity, decreased limb use and an increase in flinching behaviors, consistent with
previous reports (Jimenez-Andrade, Bloom et al. 2010, Guedon, Longo et al. 2016, Majuta,
Guedon et al. 2017). Female mice also demonstrated classical increase in hind limb guarding
behavior and decrease in rearing, consistent with work by others (Honore, Luger et al. 2000,
Guedon, Longo et al. 2016, Majuta, Guedon et al. 2017). While these measures have been used
consistently over the past 20 years in animal models of CIBP, we wanted to expand and utilize
novel measures of pain that rely on the affective components of pain, and the ability to
condition animals to pain relief in a paradigm of conditioned place preference in mice where
previous work has focused on the rat (King, Vera-Portocarrero et al. 2009, Remeniuk,
Sukhtankar et al. 2015, Havelin, Imbert et al. 2017, Remeniuk, King et al. 2018). Additionally
transferring focus to the mouse would allow us access to use novel tools such as optogenetics to
investigate the role of ongoing afferent activity in CIBP.
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3.4.2. Efficacy of the MOR agonist DAMGO to Alleviate Ongoing CIBP.
Previous work by Scherrer et al. 2009 has demonstrated distinct overlap of the MOR
with peptidergic nociceptive afferents and the DOR with non-peptidergic afferents. This work
also demonstrated a unique delineation of pain modalities between the two nociceptive
populations, namely that peptidergic fibers respond to MOR agonists and transduce thermal
nociception and that non-peptidergic fibers respond to DOR agonists and transduce mechanical
nociception (Scherrer, Imamachi et al. 2009). These findings interest our group as we have
previously published evidence that IB4-binding nociceptors (i.e. the non-peptidergic population)
but not TRPV1 expressing (i.e. the peptidergic population) fibers plays a critical role in the
transduction of hind limb movement induced BTP, a traditionally mechanical pain experience.
However, our previous work did not investigate the role of these two fiber populations in
ongoing pain from the cancer-afflicted hind limb. The observations that these fiber populations
and receptors have overlap gave us the opportunity to attempt to evaluate the role of these
fiber types in ongoing pain in the mouse. Previously our group has demonstrated the ability for
systemic morphine to alleviate ongoing pain in a model of CIBP in the rat that mimics findings in
the clinic (Remeniuk, Sukhtankar et al. 2015). Our attempts to use systemic morphine delivery
via morphine pellets in mice led to too many complications to accurately test antinociception in
mice (data not shown). Unlike work in the rat where analgesia without hyperlocomotion or
sedation at 24 hrs post pellet implantation was observed, implantation of a single morphine
pellet (25 mg, s.c.) resulted in hyperlocomotion that persisted through the 24-hour time-point
which interfered with our ability to accurately measure behaviors (data not shown). Therefore,
we moved to a strategy implementing peptidergic opioid agonists.
We tested the hypothesis that the peptidergic MOR agonist DAMGO but not the
peptidergic DOR agonist Deltorphin II could alleviate ongoing pain in the mouse. The basis for
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this hypothesis following previous work by Patrick Mantyh demonstrating the peptidergic
population of fibers plays a critical role in transducing ongoing pain from the cancer-afflicted
limb, and the non-peptidergic fiber did not (Jimenez-Andrade, Bloom et al. 2010). In addition to
this, work in that rat ablating TRPV1 expressing (peptidergic population) fibers demonstrated
these fibers play a critical role in transducing ongoing pain (King, Qu et al. 2011). Our results
demonstrate that systemic injection and activation of the MOR with DAMGO does alleviate
ongoing pain, consistent with our hypothesis and with previous findings and clinical
observations that MOR agonists manage cancer-induced ongoing pain (Remeniuk, Sukhtankar et
al. 2015, Guedon, Longo et al. 2016, Havelin, Imbert et al. 2017). However, at a dose of 3 mg/kg
Deltorphin II failed to induce conditioned place preference in mice, again consistent with our
hypothesis and previous work (Scherrer, Imamachi et al. 2009, King, Qu et al. 2011). It is possible
that this dose of Deltorphin II was too low to effectively block ongoing pain, this dose was
chosen based on preliminary results from colleagues to reverse other pain behaviors. These
findings indirectly demonstrate a role for peptidergic nociceptors in transducing ongoing pain in
preclinical models of CIBP, and add to both preclinical and clinical evidence that MOR agonists
are capable of alleviating ongoing CIBP.

3.4.3. Efficacy of Virally Delivered ArchT to Block AITC Induced Nociceptive Behaviors.
In an attempt to verify the efficacy of our approach to target the Nav1.8 and MrgD
populations of nociceptive fibers we chose to use an acute robust model of nociception using an
injection of 1% AITC solution into the hind paw of mice. After verifying expression of virally
delivered ArchT-eGFP in both the spinal cord dorsal horn and cell bodies of the dorsal root
ganglion we sought to block nociceptive input from both populations of fibers. AITC activates
the TRPA1 channel, which is critically involved MIA induced osteoarthritic pain blocked with
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TRPA1 antagonists (Eid, Crown et al. 2008, Okun, Liu et al. 2012). Given their role in transducing
nociceptive stimuli we believed that inhibition of Nav1.8 fibers would block the nocifensive
response typically observed by activating TRPA1. Beyond this, mining the Usoskin 2016 database
revealed that Nav1.8 and MrgD RNA transcripts are present at relatively high levels in the same
cell types that express TRPA1, leading us to believe that inhibition of MrgD expressing fibers
may also block AITC induced nocifensive behaviors.
Robust nocifensive responses in wild type mice were indeed observed following hind
paw injection of 1% AITC, consistent with previous reports (Eid, Crown et al. 2008). Much to our
excitement, laser induced activation of ArchT on Nav1.8 fibers nearly completely blocked
nocifensive behaviors in mice with correctly implanted fiber optics that allowed for light delivery
to the afferent terminals within the spinal cord dorsal horn. A similar blockade of nocifensive
behaviors was observed by inhibiting MrgD afferents with ArchT, a most exciting finding indeed.
Due to the overwhelming evidence that Nav1.8 expressing fibers play a critical role in
nociceptive transduction, a recent benefit of the development of optogenetic technology, we
were not surprised to see a blockade of these behaviors in mice (Daou, Tuttle et al. 2013, Bonin,
Wang et al. 2016, Daou, Beaudry et al. 2016). However, previous to this work no published
evidence has demonstrated a transient and direct role of the MrgD fibers in transducing
nociceptive stimuli. Beyond our work in the rat implicating IB4-binding afferents in transducing
BTP, evidence for the non-peptidergic fibers in playing a role for transducing nociceptive stimuli
comes from ablating these neurons and demonstrating a critical role in transducing mechanical
stimuli and tactile hypersensitivity by Cavanuagh et al. 2009. Indeed previous studies
demonstrated that whereas optogenetic activation of TRPV1 and Nav1.8 expressing fibers
results in robust nociceptive behaviors and conditioned place aversion, activation of MrgD fibers
by channel rhodopsin resulted in paw lifting but failed to produce an aversive role (Daou, Tuttle
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et al. 2013, Bonin, Wang et al. 2016, Daou, Beaudry et al. 2016, Beaudry, Daou et al. 2017,
Uhelski, Bruce et al. 2017). Interestingly as reported by Beaudry et al. 2017, activation of TRPV1
fibers by channel rhodopsin resulted in paw withdrawal and paw licking, but not lifting, whereas
activation of MrgD fibers resulted in withdrawal and lifting but not licking. Our results indicate
that inhibition of MrgD fibers blocks afferent input that leads to licking responses, a finding that
we intend to verify by repeating this study with adequate numbers for statistical analysis. We
note that these observations may indicate that whereas direct stimulation of these afferents
does not induce a response sufficient to induce nociception or pain, inactivation of these fibers
in a state of acute pain is sufficient to produce pain relief. Nevertheless we demonstrate a
unique role for MrgD fibers in transducing AITC induced TRPA1 activated nociception, and add
evidence to the field that Nav1.8 fibers transduce a variety of nociceptive input. While
technically cumbersome, these results also demonstrate the powerful efficacy this approach to
selectively silence sensory afferents at the level of the spinal cord dorsal horn can have in the
pain field.

3.4.4. The Role of Subsets of Nociceptive Fibers in Cancer-Induced Ongoing Pain.
The stimulation paradigm was chosen based on the possibility of repetitive activation
induced exhaustion of the ArchT proton pump. There are few reported methods of relatively
long term laser exposures within behavioral paradigms investigating pain, especially with
regards to ArchT-induced CPP. Therefore, we estimated a recovery period for the ArchT proton
pump of 60 seconds. Thus we selected a 2 minute on, 1 minute off laser activation paradigm,
that would result in a total of 20 out of 30 minutes of potential inhibition of fibers.
Expanding on the use of conditioned place preference to pain relief we sought to
demonstrate the role of Nav1.8 fibers in transducing CIBP by silencing them with the light
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sensitive proton pump ArchT. We have demonstrated that ArchT-induced inhibition of Nav1.8
fibers in animals treated with cancer but not shams results in CPP to pain relief with our ArchT
activation paradigm. These results demonstrate that ongoing pain from the cancer-afflicted limb
is transduced by Nav1.8 expressing fibers. This observation is consistent with other work
demonstrating that these channels are expressed on a broad population of sensory fibers
including peptidergic and non-peptidergic fibers (Figure 3.16) which have previously been
implicated in ongoing pain and other pain behaviors in models of CIBP (Jimenez-Andrade, Bloom
et al. 2010, Bloom, Jimenez-Andrade et al. 2011, King, Qu et al. 2011). While work by Shields et
al. has demonstrated that Nav1.8 is likely not restricted to C-fibers, optogenetic activation of
Nav1.8 fibers has been demonstrated to convey nociceptive information (Daou, Tuttle et al.
2013, Daou, Beaudry et al. 2016, Uhelski, Bruce et al. 2017). We also believe this to be the first
reported evidence of optogenetically silenced Nav1.8 fibers resulting in CPP to pain relief,
demonstrating a paradigm of ArchT induced silencing of fibers that can be used in future
experiments. These results also serve as a positive control for our work in silencing MrgD
expressing fibers to measure their role in cancer-induced ongoing pain.
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Taken from Bonin et al. 2016

Figure 3.16. Demonstrable Overlap in RNAseq Data of Sensory Neurons. Single Cell
RNAseq demonstrating subpopulations of sensory fibers. Scn10A, Nav1.8 fibers; Calca,
CGRP; Mrgprd, MrgD; P2rx3, P2X3. Colored table taken from Usoskin et al. 2016. Data
mined from Linnarsson Lab website, (http://linnarssonlab.org/drg/). Figure adapted with
color scheme by Joshua Havelin for ease of visualization. Note Y-axis change between
graphs.
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Interestingly, our results also demonstrate that ArchT-induced inhibition of MrgD fibers
in animals with ongoing pain from the femur causes CPP. Initially the construction of our
experiment was based on the hypothesis that we would not see conditioned place preference in
MrgD-ArchT sham let alone cancer treated animals, and thus we needed to compare MrgDArchT cancer animals to a group we were confident that would have a positive outcome in the
study. This group was run side by side with the positive control group, Nav1.8-ArchT cancer
treated animals. Nevertheless this group of animals showed robust conditioned place
preference to the PM laser paired chamber. Prior to this a lack of evidence suggested that MrgD,
non-peptidergic, fibers would not play a role in transducing ongoing CIBP (Jimenez-Andrade,
Bloom et al. 2010, Guedon, Longo et al. 2016). Several possible explanations do exist for this
outcome. The first namely being that MrgD fibers do in fact play a role in transducing ongoing
pain from the cancer-afflicted bone. This would require as previously mentioned the inclusion of
an MrgD-ArchT sham group to demonstrate that inhibition of MrgD fibers is not inherently
rewarding for some strange reason.
Alternatively, as there is evidence that MrgD fibers play a critical role in transducing
mechanical nociception (Cavanaugh, Lee et al. 2009, Scherrer, Imamachi et al. 2009), It is
possible that inhibition of these fibers blocks the occurrence of tactile hypersensitivity that the
mice may be chronically experiencing while applying weight to the skin on their hind paws.
Many times over in CIBP models, measurements of tactile hypersensitivity from the skin of the
hind paw have been demonstrated (Honore, Luger et al. 2000, Jimenez-Andrade, Bloom et al.
2010, Guedon, Longo et al. 2016, Edwards, Havelin et al. 2018). Inhibition of this experience may
result in a rewarding affective experience to the mice, which could result in conditioned place
preference to the inhibition of MrgD fibers. However, the initial paper characterizing CPP to pain
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relief (King, Vera-Portocarrero et al. 2009) demonstrated relief of tactile hypersensitivity was
not sufficient to induce CPP, making the likelihood of this justification small.
Additionally, previous evidence by our group has implicated IB4-binding sensory
neurons (“non-peptidergic”) in being critically involved in transducing BTP following manual
manipulation of the cancer-afflicted hind limb in rats (Havelin, Imbert et al. 2017). As CIBP is a
heterogeneous and complicated pain pathology, further muddled by the fact that movement
may induce additional pain episodes as reported from the clinic, it is possible that transient
inhibition of MrgD fibers may have blocked the induction of BTP episodes caused by normal
movement of the mice throughout the PM conditioning phase. Which if in the mouse is as
painful as reported by patients in the clinic, could likely induce a drastically rewarding effect
when removed from animals with cancer. A potential method to examine this would be the use
of ambulatory movement on a rot-a-rod apparatus with a similar optogenetic stimulation
paradigm to that used in our hands, or wheel running behaviors. Work by Pat Mantyh in the
past has used the rot-a-rod apparatus to investigate the effects of ambulatory movement on
CIBP and demonstrated some interventions reverse CIBP induced deficits (Luger, Honore et al.
2001, Sabino, Ghilardi et al. 2002, Peters, Ghilardi et al. 2005). However this method has not
been established or characterized as a model of BTP in the mouse. Additionally the measures
proposed later in this body of work could be used (Figures 3.13 and 3.14).
To confirm any of these possibilities would take additional work that would require the
introduction of additional pain measures, potentially some that currently don’t exist (i.e. a
measure of BTP in the mouse).
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3.4.5. Inability to Establish CPA to Hind Paw Movement in the Mouse and Potential
Alternative Measures of Hind Paw Movement-Induced Pain.
The failure to translate hind limb movement induced conditioned place aversion in the
mouse was surprising. The robustness of aversion observed in the rat convincingly conveys that
movement of the cancer-afflicted hind limb induces an unpleasant experience in animals
(Havelin, Imbert et al. 2017). Moreover, previous work published by Patrick Mantyh has also
demonstrated that movement of the cancer-afflicted hind limb induces exacerbation of pain
measurements and neurochemical markers of nociception in the spinal cord in mice (Luger,
Honore et al. 2001, Sabino, Luger et al. 2003, Peters, Ghilardi et al. 2005). Experimenter notes
from our group during hind limb movement of the cancer-afflicted limb also demonstrate that
even in our hands mice appear to be in an exacerbated pain state, within increased limb
guarding and decreased limb use immediately following limb movement. These observations
make it is unlikely that an inter-technician variance is causing some sort of non-painful
experience during hind limb movement in our hands that did not occur in others. Another
possibility is that while rats and mice differ in some ways in their temperament, the experience
may be more stressful or anxiety inducing in the mouse compared to the rat which may impart a
detriment to the mice’s ability to learn and “remember” to avoid the hind limb movement
paired chamber on test day. This challenge would implicate that the conditioned place aversion
approach would not be feasible with mice. More likely and surmountable would be that mice
might require additional exposure to the hind limb movement paired chamber, i.e. multiple days
of pairing, however, due to the nature of the pain state the mice are in and that in order to test
this hypothesis the animals would need to be put in what may be excruciating pain more than
once with no intervention to diminish or manage this pain, ethical considerations may need to
be discussed before such an approach could be used.
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As a result of our inability to observe aversion to the hind limb movement paired
chamber, we performed an experiment to observe several other behaviors that have been
previously described to be altered as a result of tumor growth within the femur, and orofacial
cancer. Rearing behavior and total distance traveled has been reported as potential measures of
pain that decrease in animals with cancer, and orofacial pain has been demonstrated to induce
measures of anxiety in rats (Gambeta, Kopruszinski et al. 2016, Gambeta, Kopruszinski et al.
2017, Majuta, Guedon et al. 2017). These two behaviors have not, to our knowledge, been
monitored following hind limb movement of the cancer-afflicted femur with the intent to
examine changes that may present as a result of movement induced pain. We have replicated
the finding that cancer animals rear and travel less than sham treated controls, as was reported
by (Majuta, Guedon et al. 2017). Interestingly, a 2-minute movement of the hind limb did not
significantly alter either rearing or distance traveled in sham treated animals, but did decrease
both behaviors in cancer treated animals. A significant difference was observed in the amount of
distance traveled over the course of 45 minutes, where as a difference, albeit not statistically,
was observed in rearing episodes over the 45 minute observation period. We note that there is
likely a floor effect for rearing at the time-point that we tested the behaviors. Testing for these
behaviors at earlier time-points may allow for a larger, and more measureable change in
behavior.
Our intent was to monitor whether ArchT induced inhibition of Nav1.8 or MrgD fibers
could block this effect in cancer bearing animals. Due to restrictions within our animal colony
and larger animal attrition than anticipated due to the technically difficult procedure of epidural
implantation of optic fibers for the epigenetic studies, this work has not been completed. The
colony of MrgD-ArchT mice used in the previous studies will be re-established in Dr. King’s lab to
complete this work. A pharmacological intervention could be performed in a timelier manner
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than experiments requiring transgenic animals, however morphine administration in mice can
result in hyperlocomotion. We have observed this and this is well reported in the past (Lowery,
Raymond et al. 2011). The hyperlocomotion in cancer treated animals inevitably confounds the
use of “distance travelled” and rearing episodes as a measure of hind limb movement induced
suppression of this behavior that would have to be demonstrated to classify this as a measure of
BTP. It is likely that other paradigms of MOR agonist administration could be used, we have not
at this time characterized this work. Also, without a current pharmacological agent that
effectively blocks BTP, screening of compounds using this approach would have no
pharmacological positive control to compare to.

3.5. Conclusion
In conclusion, we have implemented a novel approach to investigate CIBP utilizing
cutting edge optogenetic approaches, both though viral transfection of peripheral neurons and
transgenic delivery of light sensitive proteins. Work presented here also lends evidence to a
novel role of MrgD expressing or non-peptidergic nociceptive fibers may play in transducing
CIBP. We have demonstrated and implicated Nav1.8 expressing fibers in transducing cancerinduced ongoing pain, and utilized a novel approach using optogenetically silenced peripheral
neurons to induce conditioned place preference to pain relief in the mouse. Lastly, work
presented here may allow for the development of a measure of BTP in the mouse.
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CHAPTER 4
DISCUSSION OF FINDINGS

4.1. Summary of Results
In this body of work, we put forth new and exciting data that suggests a unique role for
subpopulations of sensory neurons in mediating CIBP. While this work is not exhaustive down to
the electrophysiological level, it is the first to investigate the role for subpopulations of sensory
neurons using a paradigm of pain relief that involves the affective components of pain relief and
pain induction, rather than reflexive and evoked measures of pain. Work by myself and
colleagues have produced a model of BTP that can be evoked by manipulating the hind limb of a
cancer bearing rat, which results in the production of an aversive state that “breaks through”
onboard morphine, which can be blocked with a peripheral nerve block prior to induction of
pain. Interestingly peripheral nerve block after the induction of pain fails to block this aversive
pain state. We further demonstrate that the establishment of this pain state relies on the
involvement of IB4-binding fibers (non-peptidergic), but not TRPV1 expressing fibers
(peptidergic), an observation contrary to a number of previous theories of CIBP. Additionally,
work reported here demonstrates that in the mouse, activation of the MOR, believed to be
targeting peptidergic sensory neurons, alleviates ongoing CIBP, whereas activation of the DOR
may not. Interestingly, optogenetic induced silencing of Nav1.8 sensory fibers also relieves
ongoing pain in our mouse model of CIBP, and silencing MrgD (non-peptidergic) expressing
sensory fibers in cancer bearing animals induces conditioned place preference. This culmination
of work demonstrates and implicates a potentially unique role for the IB4-binding/MrgDexpressing/non-peptidergic populations of sensory neurons in conveying CIBP, contrary to the
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majority of published work demonstrating evidence for a lack of involvement of these fibers in
preclinical models of CIBP.

4.2. Major Findings
Classical measures of Cancer-Induced Bone Pain in the Rat and Mouse. As previously
demonstrated by others in the field, we demonstrate that implantation of the MATB3 cell line
into the tibia of rats, and the implantation of the LLC cell line into the femur of mice results in
dramatic bone degradation accompanied by behaviors associated with preclinical models of
CIBP. In both species of animals, mechanical tactile thresholds decreased as tumor growth and
bone destruction progressed, consistent with original findings in both species (Schwei, Honore
et al. 1999, Medhurst, Walker et al. 2002). Limb use in both species also decreased over time, a
finding that is consistently reported and coincides with decreased motor activity by the animals,
and decreased weight bearing to the affected hind limb, and hind limbs as a result of decreased
rearing (Medhurst, Walker et al. 2002, Remeniuk, Sukhtankar et al. 2015, Guedon, Longo et al.
2016, Majuta, Guedon et al. 2017, Remeniuk, King et al. 2018). These behaviors have been
demonstrated to coincide and likely be driven by pathological sprouting of peptidergic and
sympathetic nerve fibers in both the periosteum and marrow space within the bone.
Several papers have examined the effects of an anti-NGF primary antibody and its ability
to blunt the pathological sprouting observed in the mouse model of CIBP (Jimenez-Andrade,
Bloom et al. 2010, Mantyh, Jimenez-Andrade et al. 2010, Bloom, Jimenez-Andrade et al. 2011,
McCaffrey, Thompson et al. 2014, Guedon, Longo et al. 2016). Interestingly while this antibody
does effectively block pathological sprouting of peptidergic and sympathetic fibers, along with
the accompanying measures of pain, whether or not it blunts bone remodeling may depend on
the cell line, surgical preparation, and immune system integrity as varying reports by the same
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group have been published (Bloom, Jimenez-Andrade et al. 2011, McCaffrey, Thompson et al.
2014). These observations coincide with additional work by Patrick Mantyh and colleagues
examining models of pathological bone fracture and the nerve sprouting that accompanies
incomplete or pathological healing (Chartier, Thompson et al. 2014). Measures of spontaneous
pain as well as measures of movement in this model of bone fracture pain are also attenuated
by anti-NFG therapy, highlighting the role NGF plays in pain associated with pathological pain
from the bone (Majuta, Guedon et al. 2017, Majuta, Mitchell et al. 2018).
While not as extensively analyzed as it has been in the mouse, it appears that in similar
models of bone and joint pain, anti-NGF therapy appears to be effective in the rat, dogs, cats,
and human (Xu, Nwosu et al. 2016, Suzuki, Millecamps et al. 2018, Enomoto, Mantyh et al.
2019). Fuseya et al 2016 targeted TRPV1 expressing neurons with qx-314 in mice and
demonstrated reversal of spontaneous flinches but not scores of limb use, highlighting a
differential role of peripheral fiber types and the role they play in CIBP (Fuseya, Yamamoto et al.
2016). Interestingly, in our hands capsaicin induced ablation of TRPV1 expressing sensory
neurons (peptidergic) failed to block the development of cancer-induced mechanical tactile
hypersensitivity in the rat (Havelin, Imbert et al. 2017). This observation may be result of specie
differences, or perhaps anatomical location of the cancer-afflicted bone (femur in the mouse,
tibia in the rat). While other treatments that are effective at blocking cancer-induced bone
remodeling such as Denosumab/OPG and bisphosphonates, also appear to block classical
measures of CIBP, it is unclear as to their effects on whether blocking pathological bone
remodeling simultaneously blocks pathological sprouting. However, therapies that diminish
bone degradation in the clinic are also reported to slow development of pain (Steger and
Bartsch 2011).
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While approaches to selectively target the peptidergic population of sensory neurons
appear to be wholly efficacious in blocking the development of classical CIBP behaviors, agents
targeting the non-peptidergic population seem to have more varying effects. In the mouse,
targeting the P2X3 receptor with a primary antibody only resulted in reversal of tactile
hypersensitivity and not other measures of bone pain such as shifted weight bearing and
decreased

rearing,

indicating

potential

differential

mechanisms

mediating

tactile

hypersensitivity and other kinds of pain such as ongoing pain (Guedon, Longo et al. 2016). While
in the rat, antagonism of the P2X3 receptor resulted in a reversal of tactile hypersensitivity in 2
separate studies, and offset weight bearing (Kaan, Yip et al. 2010, Wu, Xu et al. 2012), an
observation that did not occur in the mouse (Guedon, Longo et al. 2016). In our hands, spinal
administration of IB4-saporin induced ablation of IB4-binding fibers (non-peptidergic) and
resulted in blockade of tactile hypersensitivity in the rat (Havelin, Imbert et al. 2017). The
combination of these results undeniably suggests a critical role for non-peptidergic sensory
fibers in the development and transduction of mechanical tactile hypersensitivity. To the best of
my knowledge, no alternate approaches have been attempted in the mouse in a model of CIBP,
although work investigating the effects of oral cancer pain has used an ablative approach similar
to our rat work (Ye, Bae et al. 2014).
While work presented here aligns with literature within the field, and adds interesting
new pieces that warrant further investigation, these classical measures of pain, i.e. flinching,
guarding, limb use, referred tactile hypersensitivity, weight bearing, don’t necessarily examine
our main questions regarding fiber types and their involvement in driving ongoing and
movement evoked breakthrough pain. Paramount to the justification to investigate alternative
behavioral paradigms King et al. 2009 demonstrated that alleviation of tactile hypersensitivity in
a model of neuropathic pain did not equate to alleviation of ongoing pain. That is to say,
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alleviation of tactile hypersensitivity does not mean that alleviation of ongoing pain has been
achieved, a clinical and preclinical observation (King, Vera-Portocarrero et al. 2009).
Observations such as this placed the focus and priority of our work on examining behavioral
paradigms of pain that include the affective motivation to seek out pain relief or avoid the
induction or association of pain. Namely, by using conditioned place pairing paradigms that
allow an animal to freely seek out pain relief, or avoid painful stimuli.
Role of Subsets of Peripheral Neurons in Cancer-induced Ongoing Pain. Building on our
observations that different fiber types mediate different aspects of cancer-induced bone pain
(Havelin, Imbert et al. 2017), we examined the role of MrgD vs Nav1.8 expressing fibers in
mediating ongoing pain in the mouse. Our investigation into the role that subsets of fibers play
in cancer-induced ongoing pain revealed an unsurprising role for the Nav1.8 expressing
population of fibers and a potentially unique role for MrgD expressing fibers. Previous work
used CPP to pain relief in a model of CIBP in the rat, demonstrating novel findings for
mechanisms critical to the transduction of ongoing pain. Namely that ongoing pain in the rat
requires input from peripheral neurons that innervate the tibia, which can be blocked by
peripheral nerve block with 4% lidocaine, and that the same paradigm that results in CPP to pain
relief results in release of dopamine in the Nucleus Accumbens, a hallmark of the rewarding
factor of pain relief (Remeniuk, Sukhtankar et al. 2015). In addition to this Remenuik et al. 2015
also demonstrated that whereas the NSAID diclofenac fails to alleviate ongoing pain, morphine
successfully does so. This being a direct translation from bed to bench of investigating CIBP
using CPP to pain relief. Remenuik et al. 2018 also demonstrated that the inflammatory
mediator IL-6 plays a critical role in the development and establishment of cancer-induced
ongoing pain (Remeniuk, King et al. 2018). To my knowledge these are the only two papers using
conditioned place preference to pain relief in the CIBP literature, however work investigating
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orofacial cancer pain has also demonstrated CPP to pain relief in animals with cancer (Gambeta,
Kopruszinski et al. 2017).
Work presented here solidifies the expected role that Nav1.8 expressing fibers play in
transducing ongoing CIBP. As in many other models investigating the role of Nav1.8 fibers in
models of pain we demonstrate that using a novel paradigm of Nav1.8 fiber inhibition, we can
successfully induce CPP to pain relief in mice bearing tumors in their femur. The observation
that inhibition of Nav1.8 fibers in cancer bearing but not sham animals induces CPP diminishes
the likelihood that inhibition of Nav1.8 fibers itself is rewarding, implying the likelihood that
these fibers are quiet under “normal” conditions. Silencing these fibers at the level of the spinal
cord dorsal horn in cancer-bearing animals blocks the transduction of nociceptive signals from
the periphery, similar to a peripheral nerve block which has been previously demonstrated to
induce CPP to pain relief (Remeniuk, Sukhtankar et al. 2015). This is an intuitive interpretation of
these results as it is well described and known that as a result of tumor growth and tumorinduced destruction of the bone, fibers in this tissue are constantly being bombarded with a
slew of inflammatory mediators that can directly activate and drive signals in Nav1.8 expressing
fibers (Mantyh 2014, Mantyh 2014). As the Nav1.8 fiber population includes the peptidergic
population of nociceptive neurons, which have been previously demonstrated to be critical in
transducing nociceptive stimuli, it is very likely Nav1.8 fibers are present in the bone and
periosteum and undergo changes similar to those described in the peptidergic fibers described
by others (Mach, Rogers et al. 2002, Jimenez-Andrade, Bloom et al. 2010, Bloom, JimenezAndrade et al. 2011, Castaneda-Corral, Jimenez-Andrade et al. 2011). These observations
contribute to the body of work using optogenetics to investigate the theory that Nav1.8 fibers
are critical in transducing painful stimuli from the periphery.
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Perhaps the most intriguing results included in this body of work is the demonstration
that ArchT induced silencing of MrgD expressing fibers in animals bearing tumors results in
conditioned place preference. These data indicate that blockade of MrgD expressing sensory
fibers likely blocks ongoing CIBP as no previous interventions have induced CPP in sham animals.
Additional studies are planned once the colony is re-established to verify/replicate this
observation in a study with a larger sample size and include MrgD sham controls as the initial
study only included Nav1.8 sham controls. As mentioned previously, only correlative evidence
exists using IHC methods staining for P2X3, staining with fluorescent IB4-conjugates, and
transgenic reporter animals that demonstrates a lack of the presence of these fibers in the naïve
and cancer-afflicted femur (Mach, Rogers et al. 2002, Jimenez-Andrade, Mantyh et al. 2010).
Additionally, blockade or antagonism of P2X3 with antibody or antagonist has been
demonstrated to play a role in measures of CIBP such as tactile hypersensitivity. Notably, these
measures do not necessarily measure ongoing pain (Kaan, Yip et al. 2010, Wu, Xu et al. 2012,
Guedon, Longo et al. 2016).
In addition, blocking a single channel on a fiber differs from blocking the activity of the
entire neuron as we do by stimulating ArchT in the MrgD expressing neurons. Therefore, this
may account for differential effects observed between our studies and those selectively blocking
the P2X3 channel. As such, whether MrgD fibers play a role in ongoing pain was an open
question. Our work indicates that blocking MrgD fibers blocks ongoing pain both in
acute/transient pain states as indicated by our AITC findings and likely in CIBP. We note that
others have demonstrated that driving MrgD fibers fails to induce pain-like behaviors indicating
that driving these fibers alone may not be sufficient to induce pain (Beaudry, Daou et al. 2017).
One limitation of previous imaging studies examining whether MrgD expressing or IB4-binding
fibers innervate the bone is that identification, imaging and the treatment of decalcified tissue
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as well as the periosteum can cause loss of antigen and general abuse to the tissue, resulting in
a very challenging endeavor, and potentially leading to a false negative result (Mach, Rogers et
al. 2002, Akkiraju, Bonor et al. 2016). These reservations of previous work lend some in the field
to believe there may yet be a subpopulation of non-peptidergic fibers that does exist in the
bone but has not been discovered or reported.
There are alternative explanations that would explain CPP to inhibition of MrgD fibers in
tumor bearing animals. Due to the rapid nature of how quickly optogenetic tools can inhibit
neurons, and how quickly this electrochemical effect wears off, it is unlikely that ArchT
mediated inhibition of MrgD fibers results in a proteomic or genetic shift in cellular activity that
could produce CPP. This begins the conundrum of interpreting and discussing these results if, as
the field currently reports, MrgD fibers do not innervate the cancer afflicted femur or
periosteum. The question becomes how does inhibiting this class of fibers that do not innervate
the site of ongoing tumor pathology, result in a positive affective condition for the animals? I
propose that the pain signal maintaining and generating ongoing pain originates from fibers
either in the bone or the periosteum surrounding the bone, rather than a secondary site such as
the skin. This does leave the possibility that sensitization of fibers in surrounding or anatomically
relevant tissue can occur (i.e. peripheral and central sensitization) which may result in
pathological pain originating from fibers other than those in the bone.
One attractive hypothesis is that if indeed MrgD expressing fibers do not innervate the
bone or periosteum, perhaps activation of nociceptive fibers that do innervate the bone in one
way or another lead to the generation of an antidromic signal from the spinal cord that leads to
the sensitization of MrgD expressing fibers. Ferrari et al. 2015, elegantly describes just such a
situation where hyperalgesic priming induced at the level of the spinal cord generates an
antidromic signal, potentially CPEB mRNA, that induced hyperalgesia in peripheral sensory
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fibers, and may be unique to the non-peptidergic population of nociceptors (Ferrari, Araldi et al.
2015). Origin of this signal is likely beyond the scope of this body of work, but may result as a
cause of cancer-induced hypertrophy of astrocytes within the spinal cord as reported by others
(Sabino, Luger et al. 2003). Interestingly in a side by side comparison of the effects of different
cancer cell lines, out of the sarcoma, melanoma, and colon tumors compared, melanoma cells
didn’t induce drastic bone degradation, did not result in ambulatory movement induced pain,
and did not induce astrocyte hypertrophy in the spinal cord (Sabino, Luger et al. 2003).
Potentially indicating a necessary role of astrocyte hypertrophy in driving measures of ongoing
and ambulatory movement-induced pain. Interestingly, recent work using optogenetic
activation of astrocytes in the spinal cord, believed to induce release of ATP (an activator of the
P2X3 receptor found on non-peptidergic fibers) has been shown to induce measures of
nociception from the hind paw (Nam, Kim et al. 2016). Perhaps astrocytes within the spinal cord
are producing a signal that causes changes in the MrgD expressing population of neurons in an
antidromic fashion. To date no one has reported whether or not the induction of hyperalgesic
priming results in a prolonged ongoing pain state that can be assessed by using CPP to pain
relief. However, work by Okun et al. 2011 has demonstrated that while mechanical
hypersensivity persists, the ongoing pain from CFA injection into the hind paw does diminish,
and previous work has demonstrated that CFA can induce hyperalgesic priming in the periphery.
This observation does not entirely exclude the possibility that astrocytes are inducing
some form of sensitization that results in hyperalgesia, or some form of activity that leads to an
ongoing pain signal from the MrgD expressing neurons. Not only are mechanisms of induction
from the periphery different than signals from the spinal cord, cancer-induced activation of
nociceptors is a chronic and increasingly intense stimulus. If this is driving pathology capable of
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causing sensitization, it is likely different in effect compared to a single priming stimulus, not to
mention different in nature to the second hyperalgesia precipitating stimulus.

4.3. Limitations and Lingering Questions
Role of TRPV1 and IB4-binding neurons in Ongoing Pain in the Rat. While the objective
of our work in the rat was to establish a model of BTP and investigate primary nociceptor
populations in said model, it would have been exciting to examine whether or not ablation of
TRPV1 or IB4-binding fibers had a differential effect on ongoing pain. Based on the literature at
the time, with the overwhelmingly demonstrated role for peptidergic fibers in classic measures
of CIBP pain we hypothesized that ablation of TRPV1 expressing fibers would eliminate ongoing
pain, whereas ablation of IB4-binding fibers would not. With the addition of our paper, Havelin
et al. 2017, and the work provided here in the mouse, it is possible we would have observed
something different. One limitation to consider during this approach is that in the rat, the
classical “peptidergic” and “non-peptidergic” populations of nociceptive fibers have been
demonstrated to be more overlapping than what is observed in the mouse, and in the rat small
numbers of fibers both bind IB4 and express markers of peptidergic fibers (Price and Flores
2007). This can confound the translatability of results between the mouse and rat, where the
ablation of IB4-binding fibers (non-peptidergic) actually results in ablation of some peptidergic
fibers, and vice versa. While the minutia of this does not ultimately change the results of
ablating “all” fibers of one category or the other, it could hinder steps towards isolating these
populations and searching for targets for pharmacological compounds. Second, the approach of
ablating fibers can inevitably lead to the development of compensatory effects of the nervous
system. Whether this be fiber populations growing into areas they were previously restricted
from, or perhaps compensatory signaling where fiber terminals once were, not to mention the
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potential for altered signaling properties as a result of degenerated neurons both in the spinal
cord and in the dorsal root ganglion.
Definitive Role of MrgD Expressing Fibers in Ongoing Pain in the Mouse. While inhibition
of Nav1.8 fibers in the sham group did not result in CPP, it is worth examining the effects of
inhibiting just the MrgD population in naïve or sham treated animals. Inhibition of Nav1.8 fibers
likely results in the simultaneous inhibition of both the peptidergic and non-peptidergic fibers,
which has been demonstrated here to be neither inherently averse nor rewarding. However it is
beyond this body of work to hypothesize the differences that may occur during simultaneous
inhibition of both, or inhibition of singular populations, this contributes to the necessity to test
the effects of independent inhibition of the MrgD population.
It would also be very interesting to utilize the recently published CGRP-cre mouse that
would allow for inhibition of the peptidergic population in our approach (Cowie, Moehring et al.
2018). Based solely on the literature surrounding CIBP, I hypothesize we would also see CPP to
pain relief by inhibiting the peptidgeric population of fibers. If this were to end up being true,
many, many grants could be written proposing ideas to investigate signaling at the level of the
spinal cord and DRG examining converging or diverging roles for these populations.
Steps to Investigate Rearing and Movement as Measures of BTP in the Mouse and
Utilizing Optogenetics to Tease out Fibers’ Roles in BTP. We provide here at least 2 measures of
behaviors that are altered in cancer bearing animals that are not in sham animals, and several
others that may reflect anxiety behaviors in cancer-bearing mice. There are many more
parameters and behaviors that can be observed and measured using locomotor chambers. The
telltale examination to prove that rearing and distance traveled may be used as measures of BTP
would be to demonstrate that hind limb movement induced decrease in behaviors persists while
a MOR agonist is onboard. We did in fact try this using 25mg morphine pellets, however 24
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hours post morphine pellet implantation our wildtype mice still exhibited stereotypical signs of
high dose MOR agonists, i.e. straub tail, hyperlocomotion and circling patterns. Specifically,
hyperlocomotion and circling patterned behavior resulted in an inability to use distance
travelled or rearing as a measure of behavior, the mice treated with morphine demonstrated an
immense increase in movement, and in addition to this they spent very little time rearing.
We also began to investigate whether or not inhibition of Nav1.8 or MrgD fibers blocked
hind limb movement decreases in distance travelled and rearing, however, we met several
technical challenges that stopped these results from being completed and included in this body
of work. The approach we took while doing this was by inhibiting either population of neurons
for 2 minutes prior to hind limb movement, the 2 minutes during hind limb movement and then
were placed into a chamber with laser activation of 2 minutes ON and 1 minute OFF for the 30minute duration of testing. The first challenge in doing this is restraining the animal while it has
a laser cord attached to its head. This occasionally resulted in abrupt disruption of the fiber
implant rendering it useless, blocking our ability to successfully expose neuron populations to
our 520nm laser, and inhibiting them. In the animals we did successfully expose to our laser
paradigm we did not see a reversal of behaviors. This could be the result of any number of
things. A few thoughts and examples I have had are that pre-exposure to the laser may not have
been long enough to inhibit or outcompete signals being generated in the periphery, or that
unavoidable complications persist with our approach to having the mice attached to the laser
source. The implementation of wireless optogenetics may allow for a path around some of these
potential complications.
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4.4. Future Directions
Complexities of the fiber implant surgery, timing of CIBP with the health of the mice,
and mouse colony challenges stopped us from investigating whether transient inhibition of
MrgD fibers blocks tactile hypersensitivity. It will be interesting to investigate this when the
MrgD-ArchT colony of mice is reestablished. If reversal of tactile hypersensitivity is observed it
would emphasize a role of the MrgD (non-peptidergic) fibers in transducing mechanical modality
of nociception.
Investigating GABAergic signaling in the lumbar spinal cord in BTP. Current work in the
laboratory is investigating the role for GABAergic signaling in the lumbar spinal cord both
utilizing pharmacological and optogenetic interventions. This direction follows the observation
that lidocaine before hind limb movement blocks BTP while, lidocaine post hind limb movement
fails to do so. This dichotomy raises interesting questions about what may be occurring at the
level of the spinal cord or supraspinal in terms of maintaining the experience of BTP. It would
also be interesting to investigate the role the rACC or RVM may be playing in maintaining the
unpleasant affective component of hind limb induced BTP.

Immunohistochemical Analysis of Tissues. Current work in the lab is investigating of the effects
cancer-induced bone remodeling and pain has on peripheral nerves in the bone and periosteum,
as well as sensory nerve terminals in the spinal cord dorsal horn. We are currently performing a
number of comparisons between naïve, sham treated and cancer treated animals.
The first investigation we are performing is to identify whether Nav1.8 or MrgD fibers
are undergoing sprouting in the bone or periosteum. Although several publications have already
investigated fiber sprouting in the bone, we have collected bones from animals that expressed
tdtomato in either Nav1.8 expressing or MrgD expressing cells, with the goal of identifying their
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location in the bone, and what changes they may undergo during cancer. We expect to see
pathological sprouting of Nav1.8 fibers in animals that have tumor growth within their bones,
while observing relatively normal morphology of fiber endings in naïve and sham treated
animals. This would replicate previous work by Pat Mantyh as the Nav1.8 fibers should contain
peptidergic fibers that have been extensively demonstrated to undergo pathological growth in
the presence of cancer. Given our results that demonstrated CPP to inhibition of MrgD fibers,
we aren’t sure if we will see MrgD-tdtomato fibers undergo pathological sprouting into the
bone. Presumably based on the literature, there will be no MrgD-tdtomato fibers in the bone or
periosteum of naïve or sham animals. Despite results published in the mouse, there is always
the slight possibility that different cancer lines and different strains of mice respond differently
to this procedure. Most of the previous work in mice has been with immunocompromised mice,
C3H mice or BalbC strains of mice, and different cell lines than the LLC line we used.
Secondly we are investigating the correlation between ATF3 expression and fiber
subtypes in L2 and L4 DRG in naïve, sham and cancer treated animals. Previous reports by Peters
et al. 2005 and King et. Al 2007 demonstrated increased ATF3 expression in cancer bearing
animals to differing degrees. We would like to understand if ATF3 expression occurs to a higher
degree in Nav1.8+ cells than Nav1.8- negative cells, or if ATF3 is induced evenly amongst
different cell types. If ATF3 is selectively, or at least correlated to be expressed more so in
Nav1.8 cells, it might mean that nerve injury may be driving some degree of neuropathic pain in
this model. We ask the same question in MrgD expressing cells. ATF3 expression in MrgDtdtomato+ cells may mean that cancer-induced bone remodeling or pain is somehow causing
nerve damage to this cell population that has classically been demonstrated to innervate the
skin.
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4.5 Concluding Remarks
In conclusion, this body of work contains novel implications of the role of subpopulations of
sensory neurons contributing to cancer-induced bone pain. Additionally this body of work
contributes to the body of work emphasizing the heterogeneity, and therefore difficulty of
uncovering critical mechanisms driving cancer-induced bone pain. Work here also supports the
differential roles of subpopulations of sensory fibers, and demonstrates a unique role for the
non-peptidergic, specifically MrgD expressing, fibers in transducing cancer-induced bone pain.
Future work involving the study of cancer-induced bone pain should not discount and continue
to study the potentially critical role that MrgD expressing fibers may be playing in cancerinduced bone pain, as work in the field has and likely currently is being done. It is my hope that
these novel findings contribute to the future work and discovery of more optimal treatments for
those who are unfortunate enough to suffer from cancer pain, and cancer-induced bone pain.
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